Imidazole-containing inhibitors of ALK2 kinase
Patent Information
- Application Number
- ZA202000217
- Authority / Receiving Office
- ZA · ZA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-06-15
- Filing Date
- 2020-01-13
- Publication Date
- 2026-10-28
- Estimated Expiration
- 2038-06-14
AI Technical Summary
Current treatments for Fibrodysplasia Ossificans Progressiva (FOP) and related disorders lack effective inhibitors for the ALK2 kinase, which are crucial for regulating BMP signaling and preventing excessive bone formation.
Development of imidazole-containing compounds that specifically inhibit the ALK2 kinase, offering therapeutic potential for treating FOP and other conditions by modulating kinase activity.
These compounds effectively inhibit ALK2 kinase, providing a therapeutic approach to manage FOP and potentially treat cancer, including glioma, by reducing inappropriate kinase activation.
Abstract
Description
[0001] IMIDAZOLE-CONTAINING INHIBITORS OFALK2 KINASE
[0002] RELATED APPLICATION
[0003] This application claims the benefit of priority to U.S. Provisional Patent Application serial number 62 / 520,150, filed June 15, 2017.
[0004] BACKGROUND OF THE INVENTION
[0005] A single mutation (R206H) within the kinase domain of one (ACVR1 / ALK2) of the four human bone morphogenetic protein (BMP) receptors has been linked to a catastrophic disorder of secondary (heterotopic) bone formation. As a result of the mutation, all children presenting with features of classic Fibrodysplasia Ossificans Progressiva (FOP) eventually become encased in, and their movement blocked by, a second heterotopic skeleton. The disorder has long been associated with dysregulation of BMP signaling in soft tissues (skeletal muscle, tendon, ligament, fascia) that were transformed into ribbons, sheets and plates of heterotopic bone via an endochondral process. In addition to the common R206H mutation linked to the classic form of FOP, other dysregulating mutations have been identified in ACVR1 / ALK2 that lead to atypical and variant forms of FOP. Further, compounds effective in regulating BMP signaling based on their ability to inhibit ALK2 have been shown also to inhibit kinases from multiple signaling pathways.
[0006] Thus, there remains a need for additional compounds that inhibit the ALK2 kinase which will be suitable for various important therapeutic applications.
[0007] SUMMARY OF THE INVENTION
[0008] In certain aspects, the invention rovides a compound of formula (I) or formula (II):
[0009]
[0010] or a pharmaceutically acceptable salt thereof;
[0011] wherein: A is a fused optionally substituted aromatic ring, heteroaromatic ring, partially unsaturated cycloalkyl ring, or partially unsaturated heterocycloalkyl ring;
[0012] W is C or N;
[0013] Rarepresents H or alkyl;
[0014] R1represents heteroarylene;
[0015] Rlarepresents H or optionally substituted -C(0)alkyl, -C(0)0(alkyl), -C(0)(heterocyclyl), - C(0)(aryl), -C(0)(heteroaryl), -C(0) RxRy, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
[0016] J represents H, halo, -OR2, - R2R3, -C(0) R2R3, -C(0)0(alkyl), -C(0)OH, aryl, or
[0017] heteroaryl, wherein aryl or heteroaryl is optionally substituted by one or more occurrences of R2a;
[0018] R2represents optionally substituted alkyl, aralkyl, heteroaralkyl, cycloalkyl, heterocycloalkyl,
[0019] (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, or hydroxyalkyl;
[0020] R3represents H or alkyl; or
[0021] R2and R3, taken together, form a heterocycloalkyl ring, optionally substituted by one or more occurrences of R2a;
[0022] R2a, independently for each occurrence, represents halo, hydroxyl, -C(0)H, oxo, - H2, - C(0) H2, -C(0)OH, -C(0)R5, -C(0)OR5, -C(0) H(R5), or optionally substituted alkyl, alkoxyl, hydroxyalkyl, heteroaryl, aryl, or -N(alkyl)2;
[0023] or any two germinal or vicinal occurrences of R2a, taken together, may form a spiro or fused cycloalkyl ring;
[0024] R5, independently for each occurrence, represents optionally substituted alkyl, aralkyl, aryl, heteroaralkyl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, or
[0025] (heterocycloalkyl)alkyl; and
[0026] Rxand Ryeach independently represent H, alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, or hydroxyalkyl.
[0027] In further aspects, the invention provides a compound of formula (III) or formula
[0028] (IV):
[0029] (III)
[0030] or a pharmaceutically acceptable salt thereof;
[0031] wherein:
[0032] A is a fused optionally substituted aromatic ring, heteroaromatic ring, partially unsaturated cycloalkyl ring, or partially unsaturated heterocycloalkyl ring;
[0033] W is C or N;
[0034] B is CH or N;
[0035] D is CH or N;
[0036] provided that when B is CH, then D is N; or when D is CH, then B is N;
[0037] Rarepresents H or alkyl;
[0038] R1represents heteroarylene;
[0039] Rlarepresents H or optionally substituted -C(0)alkyl, -C(0)aryl, -C(0)heteroaryl, -
[0040] C(0)0(alkyl), -C(0)(heterocyclyl), -C(0) RxRy, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
[0041] J represents H, halo, -OR2, - R2R3, -C(0) R2R3, -C(0)0(alkyl), -C(0)OH, aryl, or
[0042] heteroaryl, wherein aryl or heteroaryl is optionally substituted by one or more occurrences of R2a;
[0043] R2represents optionally substituted alkyl, aralkyl, heteroaralkyl, cycloalkyl, heterocycloalkyl,
[0044] (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, or hydroxyalkyl;
[0045] R3represents H or alkyl; or
[0046] R2and R3, taken together, form a heterocycloalkyl ring, optionally substituted by one or more occurrences of R2a;
[0047] R2a, independently for each occurrence, represents halo, hydroxyl, -C(0)H, oxo, - H2, - C(0) H2, -C(0)OH, -C(0)R5, -C(0)OR5, -C(0) H(R5), or optionally substituted alkyl, alkoxyl, hydroxyalkyl, heteroaryl, aryl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, or -N(alkyl)2;
[0048] or any two germinal or vicinal occurrences of R2a, taken together, may form a spiro or fused cycloalkyl ring; R5, independently for each occurrence, represents optionally substituted alkyl, aralkyl, aryl, heteroaralkyl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, or
[0049] (heterocycloalkyl)alkyl; and
[0050] Rxand Ryeach independently represent H, alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, or hydroxy alkyl.
[0051] In still further aspects, the invention provides a compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
[0052]
[0053] In certain aspects, the invention provides a pharmaceutical composition, comprising a compound of the invention, or a pharmaceutically acceptable salt thereof; and a
[0054] pharmaceutically acceptable excipient.
[0055] In certain aspects, the invention provides methods of inhibiting ALK2 kinase, comprising administering to a subject in need thereof an effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
[0056] The present invention also provides methods of treating fibrodysplasia ossificans progressiva, comprising administering to a subject in need thereof an effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
[0057] In further aspects, the invention provides methods of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. In certain embodiments, the cancer is a glioma.
[0058] DETAILED DESCRIPTION
[0059] Provided herein are compounds of formulae (I), (II), (III), and (IV), and
[0060] pharmaceutically acceptable salts thereof, that are useful for inhibiting ALK2 kinase, and useful in the treatment or prevention of a disease or condition that would benefit from inhibition of ALK2 kinase. For example, the disclosed inhibitors of ALK2 kinase are useful in therapeutic methods and compositions suitable for use in treating cancer or fibrodysplasia ossificans progressiva.
[0061] Definitions
[0062] The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
[0063] The term "heteroatom" is art-recognized and refers to an atom of any element other than carbon or hydrogen. Illustrative heteroatoms include boron, nitrogen, oxygen, phosphorus, sulfur and selenium, and alternatively oxygen, nitrogen or sulfur.
[0064] The term "alkyl" as used herein is a term of art and refers to saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In certain embodiments, a straight-chain or branched-chain alkyl has about 30 or fewer carbon atoms in its backbone (e.g., C1-C30 for straight chain, C3-C30 for branched chain), and alternatively, about 20 or fewer, or 10 or fewer. In certain embodiments, the term "alkyl" refers to a C1-C10 alkyl group. In certain embodiments, the term "alkyl" refers to a Ci-C6alkyl group, for example a Ci-C6straight-chain alkyl group. In certain embodiments, the term "alkyl" refers to a C3-C12 branched-chain alkyl group. In certain embodiments, the term "alkyl" refers to a C3-C8 branched-chain alkyl group. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso- butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl.
[0065] The term "cycloalkyl" means mono- or bicyclic or bridged saturated carbocyclic rings, each having from 3 to 12 carbon atoms. Certain cycloalkyls have from 5-12 carbon atoms in their ring structure, and may have 6-10 carbons in the ring structure. Preferably, cycloalkyl is (C3-C7)cycloalkyl, which represents a monocyclic saturated carbocyclic ring, having from 3 to 7 carbon atoms. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Bicyclic cycloalkyl ring systems include bridged monocyclic rings and fused bicyclic rings. Bridged monocyclic rings contain a monocyclic cycloalkyl ring where two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge of between one and three additional carbon atoms {i.e., a bridging group of the form -(CH2)w-, where w is 1, 2, or 3). Representative examples of bicyclic ring systems include, but are not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane. Fused bicyclic cycloalkyl ring systems contain a monocyclic cycloalkyl ring fused to either a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocyclyl, or a monocyclic heteroaryl. The bridged or fused bicyclic cycloalkyl is attached to the parent molecular moiety through any carbon atom contained within the monocyclic cycloalkyl ring. Cycloalkyl groups are optionally substituted. In certain embodiments, the fused bicyclic cycloalkyl is a 5 or 6 membered monocyclic cycloalkyl ring fused to either a phenyl ring, a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, a 5 or 6 membered monocyclic heterocyclyl, or a 5 or 6 membered monocyclic heteroaryl, wherein the fused bicyclic cycloalkyl is optionally substituted.
[0066] The term "(cycloalkyl)alkyl" as used herein refers to an alkyl group substituted with one or more cycloalkyl groups. An example of (cycloalkyl)alkyl is cyclohexylmethyl group.
[0067] The term "heterocycloalkyl" as used herein refers to a radical of a non-aromatic ring system, including, but not limited to, monocyclic, bicyclic, and tricyclic rings, which can be completely saturated or which can contain one or more units of unsaturation, for the avoidance of doubt, the degree of unsaturation does not result in an aromatic ring system, and having 3 to 12 atoms including at least one heteroatom, such as nitrogen, oxygen, or sulfur. For purposes of exemplification, which should not be construed as limiting the scope of this invention, the following are examples of heterocyclic rings: aziridinyl, azirinyl, oxiranyl, thiiranyl, thiirenyl, di oxiranyl, diazirinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3- dithiolanyl, 1,3-dithianyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, azetyl, oxetanyl, oxetyl, thietanyl, thietyl, diazetidinyl, dioxetanyl, dioxetenyl, dithietanyl, dithietyl, dioxalanyl, oxazolyl, thiazolyl, triazinyl, isothiazolyl, isoxazolyl, azepines, azetidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, oxopiperidinyl, oxopyrrolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, quinuclidinyl, thiomorpholinyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiomorpholinyl, 1, 1-dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, and trithianyl. A heterocycloalkyl group is optionally substituted by one or more substituents as described below.
[0068] The term "(heterocycloalkyl)alkyl" as used herein refers to an alkyl group substituted with one or more heterocycloalkyl (i.e., heterocyclyl) groups.
[0069] The term "alkenyl" as used herein means a straight or branched chain hydrocarbon radical containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5- hexenyl, 2-heptenyl, 2-methyl-l-heptenyl, and 3-decenyl. The unsaturated bond(s) of the alkenyl group can be located anywhere in the moiety and can have either the (Z) or the (E) configuration about the double bond(s).
[0070] The term "alkynyl" as used herein means a straight or branched chain hydrocarbon radical containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1- propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.
[0071] The term "alkylene" is art-recognized, and as used herein pertains to a diradical obtained by removing two hydrogen atoms of an alkyl group, as defined above. In one embodiment an alkylene refers to a disubstituted alkane, i.e., an alkane substituted at two positions with substituents such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, fluoroalkyl (such as trifluromethyl), cyano, or the like. That is, in one embodiment, a "substituted alkyl" is an "alkylene".
[0072] The term "amino" is a term of art and as used herein refers to both unsubstituted and substituted amines, e.g., a moiety that may be represented by the general formulas:
[0073]
[0074] wherein Ra, Rb, and Rc each independently represent a hydrogen, an alkyl, an
[0075] alkenyl, -(CH2)x-Rd, or Ra and Rb, taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; Rd represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocyclyl or a polycyclyl; and x is zero or an integer in the range of 1 to 8. In certain embodiments, only one of Raor Rb may be a carbonyl, e.g., Ra, Rb, and the nitrogen together do not form an imide. In other embodiments, Raand Rb (and optionally Rc) each independently represent a hydrogen, an alkyl, an alkenyl, or -(CH2)x-Rd. In certain embodiments, the term "amino" refers to - H2.
[0076] In certain embodiments, the term "alkylamino" refers to - H(alkyl).
[0077] In certain embodiments, the term "dialkylamino" refers to -N(alkyl)2. The term "amido", as used herein, means - HC(=0)-, wherein the amido group is bound to the parent molecular moiety through the nitrogen. Examples of amido include alkylamido such as CH3C(=0)N(H)- and CH3CH2C(=0)N(H)-.
[0078] The term "acyl" is a term of art and as used herein refers to any group or radical of the form RCO- where R is any organic group, e.g., alkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl. Representative acyl groups include acetyl, benzoyl, and malonyl.
[0079] The term "aminoalkyl" as used herein refers to an alkyl group substituted with one or more one amino groups. In one embodiment, the term "aminoalkyl" refers to an
[0080] aminomethyl group.
[0081] The term "aminoacyl" is a term of art and as used herein refers to an acyl group substituted with one or more amino groups.
[0082] The term "aminothionyl" as used herein refers to an analog of an aminoacyl in which the O of RC(O)- has been replaced by sulfur, hence is of the form RC(S)-.
[0083] The term "phosphoryl" is a term of art and as used herein may in general be represented by the formula:
[0084] Q50
[0085] II
[0086] p
[0087] OR 59
[0088] wherein Q50 represents S or O, and R59 represents hydrogen, a lower alkyl or an aryl; for example, -P(0)(OMe)- or -P(0)(OH)2. When used to substitute, e.g., an alkyl, the phosphoryl group of the phosphorylalkyl may be represented by the general formulas:
[0089] Q50 Q50 Q51— p o Q51— P— OR59
[0090] OR59 OR59
[0091] wherein Q50 and R59, each independently, are defined above, and Q51 represents O, S or N; for example, -0-P(0)(OH)OMe or - H-P(0)(OH)2. When Q50 is S, the phosphoryl moiety is a "phosphorothioate."
[0092] The term "aminophosphoryl" as used herein refers to a phosphoryl group substituted with at least one amino group, as defined herein; for example, -P(0)(OH) Me2.
[0093] The term "azide" or "azido", as used herein, means an -N3group.
[0094] The term "carbonyl" as used herein refers to -C(=0)-.
[0095] The term "thiocarbonyl" as used herein refers to -C(=S)-. The term "alkylphosphoryl" as used herein refers to a phosphoryl group substituted with at least one alkyl group, as defined herein; for example, -P(0)(OH)Me.
[0096] The term "alkylthio" as used herein refers to alkyl-S-. The term "(alkylthio)alkyl" refers to an alkyl group substituted by an alkylthio group.
[0097] The term "carboxy", as used herein, means a -CO2H group.
[0098] The term "aryl" is a term of art and as used herein refers to includes monocyclic, bicyclic and polycyclic aromatic hydrocarbon groups, for example, benzene, naphthalene, anthracene, and pyrene. Typically, an aryl group contains from 6-10 carbon ring atoms (i.e., (C6-Cio)aryl). The aromatic ring may be substituted at one or more ring positions with one or more substituents, such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, fluoroalkyl (such as trifluromethyl), cyano, or the like. The term "aryl" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is an aromatic hydrocarbon, e.g., the other cyclic rings may be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyl s. In certain embodiments, the term "aryl" refers to a phenyl group.
[0099] The term "arylene" means a diradical obtained by removing two hydrogen atoms of an aryl group, as defined above. In certain embodiments an arylene refers to a disubstituted arene, i.e., an arene substituted at two positions with substituents such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, fluoroalkyl (such as trifluoromethyl), cyano, or the like. That is, in certain embodiments, a "substituted aryl" is an "arylene".
[0100] The term "heteroaryl" is a term of art and as used herein refers to a monocyclic, bicyclic, and polycyclic aromatic group having 3 to 12 total atoms including one or more heteroatoms such as nitrogen, oxygen, or sulfur in the ring structure. Exemplary heteroaryl groups include azaindolyl, benzo(b)thienyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl, benzoxadiazolyl, furanyl, imidazolyl, imidazopyridinyl, indolyl, indolinyl, indazolyl, isoindolinyl, isoxazolyl, isothiazolyl, isoquinolinyl, oxadiazolyl, oxazolyl, purinyl, pyranyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-d]pyrimidinyl, quinolinyl, quinazolinyl, triazolyl, thiazolyl, thiophenyl, tetrahydroindolyl, tetrazolyl, thiadiazolyl, thienyl, thiomorpholinyl, triazolyl or tropanyl, and the like. The "heteroaryl" may be substituted at one or more ring positions with one or more substituents such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydiyl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, fluoroalkyl (such as trifluromethyl), cyano, or the like. The term "heteroaryl" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is an aromatic group having one or more heteroatoms in the ring structure, e.g., the other cyclic rings may be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyl s.
[0101] The term "heteroarylene" means a diradical obtained by removing two hydrogen atoms of a heteroaryl group, as defined above. In certain embodiments an heteroarylene refers to a disubstituted heteroarene, i.e., a heteroarene substituted at two positions with substituents such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydiyl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, fluoroalkyl (such as trifluoromethyl), cyano, or the like. That is, in certain embodiments, a "substituted heteroaryl" is an "heteroarylene".
[0102] The term "aralkyl" or "arylalkyl" is a term of art and as used herein refers to an alkyl group substituted with an aryl group, wherein the moiety is appended to the parent molecule through the alkyl group.
[0103] The term "heteroaralkyl" or "heteroarylalkyl" is a term of art and as used herein refers to an alkyl group substituted with a heteroaryl group, appended to the parent molecular moiety through the alkyl group.
[0104] The term "alkoxy" as used herein means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.
[0105] The term "alkoxyalkyl" refers to an alkyl group substituted by an alkoxy group.
[0106] The term "alkoxycarbonyl" means an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, represented by -C(=0)-, as defined herein. Representative examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl.
[0107] The term "alkylcarbonyl", as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
[0108] Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl- 1-oxopropyl, 1-oxobutyl, and 1-oxopentyl.
[0109] The term "arylcarbonyl", as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
[0110] Representative examples of arylcarbonyl include, but are not limited to, benzoyl and (2- pyridinyl)carbonyl.
[0111] The term "alkylcarbonyloxy" and "arylcarbonyloxy", as used herein, means an alkylcarbonyl or arylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, and tert-butylcarbonyloxy. Representative examples of arylcarbonyloxy include, but are not limited to phenyl carbonyloxy.
[0112] The term "alkenoxy" or "alkenoxyl" means an alkenyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkenoxyl include, but are not limited to, 2-propen-l-oxyl (i.e., CH2=CH-CH2-0-) and vinyloxy (i.e., CH2=CH-0-).
[0113] The term "aryloxy" as used herein means an aryl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
[0114] The term "heteroaryloxy" as used herein means a heteroaryl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
[0115] The term "carbocyclyl" as used herein means a monocyclic or multicyclic (e.g., bicyclic, tricyclic, etc.) hydrocarbon radical containing from 3 to 12 carbon atoms that is completely saturated or has one or more unsaturated bonds, and for the avoidance of doubt, the degree of unsaturation does not result in an aromatic ring system (e.g., phenyl).
[0116] Examples of carbocyclyl groups include 1-cyclopropyl, 1-cyclobutyl, 2-cyclopentyl, 1- cyclopentenyl, 3-cyclohexyl, 1-cyclohexenyl and 2-cyclopentenylmethyl.
[0117] The term "cyano" is a term of art and as used herein refers to -CN.
[0118] The term "halo" is a term of art and as used herein refers to -F, -CI, -Br, or -I.
[0119] The term "haloalkyl" as used herein refers to an alkyl group, as defined herein, wherein some or all of the hydrogens are replaced with halogen atoms.
[0120] The term "hydroxy" is a term of art and as used herein refers to -OH. The term "hydroxyalkyl", as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of hydroxyalkyl include, but are not limited to,
[0121] hydroxymethyl, 2-hydroxy ethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and 2-ethyl-4- hydroxyheptyl.
[0122] The term "silyl", as used herein, includes hydrocarbyl derivatives of the silyl (H3S1-) group (i.e., (hydrocarbyl)3Si-), wherein a hydrocarbyl groups are univalent groups formed by removing a hydrogen atom from a hydrocarbon, e.g., ethyl, phenyl. The hydrocarbyl groups can be combinations of differing groups which can be varied in order to provide a number of silyl groups, such as trimethyl silyl (TMS), tert-butyldiphenylsilyl (TBDPS), tert- butyldimethylsilyl (TBS / TBDMS), triisopropyl silyl (TIPS), and [2- (trimethylsilyl)ethoxy]methyl (SEM).
[0123] The term "silyloxy", as used herein, means a silyl group, as defined herein, is appended to the parent molecule through an oxygen atom.
[0124] Certain compounds contained in compositions of the present invention may exist in particular geometric or stereoisomeric forms. In addition, compounds of the present invention may also be optically active. The present invention contemplates all such compounds, including cis- and trans-isomers, (R)- and (^-enantiomers, diastereoisomers, (D)-isomers, (L)-isomers, the racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
[0125] If, for instance, a particular enantiomer of compound of the present invention is desired, it may be prepared by asymmetric synthesis, or by derivation with a chiral auxiliary, where the resulting diastereomeric mixture is separated and the auxiliary group cleaved to provide the pure desired enantiomers. Alternatively, where the molecule contains a basic functional group, such as amino, or an acidic functional group, such as carboxyl,
[0126] diastereomeric salts are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means well known in the art, and subsequent recovery of the pure enantiomers.
[0127] It will be understood that "substitution" or "substituted with" includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, fragmentation, decomposition, cyclization, elimination, or other reaction.
[0128] The term "substituted" is also contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, those described herein above. The permissible substituents may be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and / or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. This invention is not intended to be limited in any manner by the permissible substituents of organic compounds.
[0129] In certain embodiments, the optional substituents can include, for example, halogen, haloalkyl, hydroxyl, carbonyl (such as carboxyi, alkoxycarbonyi, formy!, or acyl), thiocarbonyl (such as thioester, thioacetate, or thioforniate), alkoxyl, alkeiiyioxy, alkvnyloxy, phosphor}'!, phosphate, phosphonate, phosphinate, amino (including aikyi- and
[0130] dialkylamino), ami do, amidine, inline, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamide, sulfonyl, silyl, silyloxy, heterocycloalkyl, cycloalkyl, alkyl, alkenyl, alkynyl, aryi, heteroary!, araikyl, or heteroaralkyl group.
[0131] The phrase "protecting group", as used herein, means temporary substituents which protect a potentially reactive functional group from undesired chemical transformations. Examples of such protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively. The field of protecting group chemistry has been reviewed (Greene, T.W.; Wuts, P.G.M. Protective Groups in Organic Synthesis, 2nded.; Wiley: New York, 1991). Protected forms of the inventive compounds are included within the scope of this invention.
[0132] For purposes of the invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 67th Ed., 1986-87, inside cover.
[0133] Other chemistry terms herein are used according to conventional usage in the art, as exemplified by The McGraw-Hill Dictionary of Chemical Terms (ed. Parker, S., 1985), McGraw-Hill, San Francisco, incorporated herein by reference). Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The term "pharmaceutically acceptable salt" as used herein includes salts derived from inorganic or organic acids including, for example, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, phosphoric, formic, acetic, lactic, maleic, fumaric, succinic, tartaric, glycolic, salicylic, citric, methanesulfonic, benzenesulfonic, benzoic, malonic, trifluoroacetic, trichloroacetic, naphthalene-2-sulfonic, and other acids. Pharmaceutically acceptable salt forms can include forms wherein the ratio of molecules comprising the salt is not 1 : 1. For example, the salt may comprise more than one inorganic or organic acid molecule per molecule of base, such as two hydrochloric acid molecules per molecule of compound of Formula I, II, III, or IV. As another example, the salt may comprise less than one inorganic or organic acid molecule per molecule of base, such as two molecules of compound of Formula I, II, III, or IV per molecule of tartaric acid.
[0134] The terms "carrier" and "pharmaceutically acceptable carrier" as used herein refer to a diluent, adjuvant, excipient, or vehicle with which a compound is administered or formulated for administration. Non-limiting examples of such pharmaceutically acceptable carriers include liquids, such as water, saline, and oils; and solids, such as gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating, flavoring, and coloring agents may be used. Other examples of suitable pharmaceutical carriers are described in Remington 's Pharmaceutical Sciences by E.W. Martin, herein incorporated by reference in its entirety.
[0135] The term "treat" as used herein means prevent, halt or slow the progression of, or eliminate a disease or condition in a subject. In one embodiment "treat" means halt or slow the progression of, or eliminate a disease or condition in a subject. In one embodiment, "treat" means reduce at least one objective manifestation of a disease or condition in a subject.
[0136] The term "effective amount" as used herein refers to an amount that is sufficient to bring about a desired biological effect.
[0137] The term "therapeutically effective amount" as used herein refers to an amount that is sufficient to bring about a desired therapeutic effect.
[0138] The term "inhibit" as used herein means decrease by an objectively measurable amount or extent. In various embodiments "inhibit" means decrease by at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 95 percent compared to relevant control. In one embodiment "inhibit" means decrease 100 percent, i.e., halt or eliminate. The term "subject" as used herein refers to a mammal. In various embodiments, a subject is a mouse, rat, rabbit, cat, dog, pig, sheep, horse, cow, or non-human primate. In one embodiment, a subject is a human.
[0139] Compounds
[0140] The present invention provides a com ound of Formula (I) or (II):
[0141] ;
[0142] or a pharmaceutically acceptable salt thereof;
[0143] wherein:
[0144] A is a fused optionally substituted aromatic ring, heteroaromatic ring, partially unsaturated cycloalkyl ring, or partially unsaturated heterocycloalkyl ring;
[0145] W is C or N;
[0146] Rarepresents H or alkyl;
[0147] R1represents heteroarylene;
[0148] Rlarepresents H or optionally substituted -C(0)alkyl, -C(0)aryl, -C(0)heteroaryl, -
[0149] C(0)0(alkyl), -C(0)(heterocyclyl), -C(0) R¾y, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
[0150] J represents H, halo, -OR2, - R2R3, -C(0) R2R3, -C(0)0(alkyl), -C(0)OH, aryl, or
[0151] heteroaryl, wherein aryl or heteroaryl is optionally substituted by one or more occurrences of R2a;
[0152] R2represents optionally substituted alkyl, aralkyl, heteroaralkyl, cycloalkyl, heterocycloalkyl,
[0153] (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, or hydroxyalkyl;
[0154] R3represents H or alkyl; or
[0155] R2and R3, taken together, form a heterocycloalkyl ring, optionally substituted by one or more occurrences of R2a;
[0156] R2a, independently for each occurrence, represents halo, hydroxyl, -C(0)H, oxo, - H2, - C(0) H2, -C(0)OH, -C(0)R5, -C(0)OR5, -C(0) H(R5), or optionally substituted alkyl, alkoxyl, hydroxyalkyl, heteroaryl, aryl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, or -N(alkyl)2;
[0157] or any two germinal or vicinal occurrences of R2a, taken together, may form a spiro or fused cycloalkyl ring;
[0158] R5, independently for each occurrence, represents optionally substituted alkyl, aralkyl, aryl, heteroaralkyl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, or
[0159] (heterocycloalkyl)alkyl; and
[0160] Rxand Ryeach independently represent H, alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, or
[0161] hydroxyalkyl.
[0162] In certain embodiments, the compound of the invention is represented by formula (la) or formula (Ha):
[0163]
[0164] wherein: valence permitting, Q, T, U, and V each independently represent CH, CH2, N, H, O, or S02, wherein any hydrogen of a CH, CH2, or NH group is optionally replaced by an occurrence of R4;
[0165] R4, independently for each occurrence, represents halo, cyano, or optionally substituted alkyl, alkenyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkenyl, (heterocycloalkyl)alkyl, cycloalkyl, (cycloalkyl)alkyl, halocycloalkyl, hydroxycycloalkyl, aminocycloalkyl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, -CH2C(0)NH2, -C(0)R5, - C(0)OR5, or -S(0)2R5; m is an integer from 0-4, as permitted by valence. In certain embodiments, the compound of the invention is represented by formula (lb) or formula (lib):
[0166]
[0167] wherein Q represents CH or N; and V represents CH or N. In certain embodiments, Q is N and V is CH. In alternative embodiments, Q is CH and V is N.
[0168] In certain embodiments, the compound of the invention is represented by formula (Ic) or formula (He):
[0169] (lie).
[0170] In certain embodiments, the compound of the invention is represented by formula (Id) or formula (lid):
[0171]
[0172] (lid); wherein T represents CH2, NH, O, or SO2; and U represents CH2, NH, O, or SO2. In certain embodiments, T is NH; and U is CH2. In other embodiments, T is CH2 and U is NH.
[0173] In certain embodiments, the compound of the invention is represented by formula (Ie) or formula (He):
[0174]
[0175] In any one of formulae (la), (Ila), (lb), (lib), (Ic), (lie), (Id), (lid), (Ie), and (He), in certain embodiments, m is 0 or 1.
[0176] In certain embodiments, the compound of the invention is represented by formula (Ij) or 05):
[0177]
[0178] (iij); wherein: W is C or N; valence permitting, X, Y, and Z each independently represent CH, CH2, CO, N, NH, O, S, or SO2, wherein any hydrogen of a CH, CH2, or NH group is optionally replaced by an occurrence of R4;
[0179] R4, independently for each occurrence, represents cyano, halo, or optionally substituted alkyl, alkenyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkenyl, (heterocycloalkyl)alkyl, cycloalkyl, (cycloalkyl)alkyl, halocycloalkyl, hydroxycycloalkyl, aminocycloalkyl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, -CH2C(0)NH2, -C(0)R5, - C(0)OR5, or -S(0)2R5; n is an integer from 0-4, as permitted by valence.
[0180] In certain embodiments, R4, independently for each occurrence, represents halo, or optionally substituted alkyl, alkenyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkenyl,
[0181] (heterocycloalkyl)alkyl, cycloalkyl, (cycloalkyl)alkyl, -CH2C(0)NH2, -C(0)R5, -C(0)OR5, or -S(0)2R5.
[0182] In certain embodiments, R4, independently for each occurrence, represents halocycloalkyl, hydroxycycloalkyl, aminocycloalkyl, aryloxy, heteroaryloxy, arylalkyloxy, or heteroaryl alkyl oxy .
[0183] In certain embodiments, one of X, Y, or Z is NR4.
[0184] In certain such embodiments, R4is selected from the group consisting of:
[0185]
[0186] In certain embodiments, the compound of the invention is represented by formula (Ik) or (Ilk):
[0187] wherein X, Y, and Z each independently represent CH, N, NH, O, S, or SO2.
[0188] In certain embodiments, the compound of the invention is represented by formula (Ik') or (Ilk'):
[0189] (Ilk').
[0190] Alternatively, in certain embodiments, the compound of the invention is represented by formula (Ik") or (Ilk"):
[0191] wherein at least one of X and Z is selected from the group consisting of O, N, NH, and S.
[0192] In certain embodiments of the compounds of formula (Ik") and (Ilk"), one of X and Z is selected from the group consisting of O, NH, and S; and the other of X and Z is CH. For example, X may be selected from the group consisting of O, NH, and S. Alternatively, Z may be selected from the group consisting of O, NH, and S.
[0193] In other embodiments of the compounds of formula (Ik") and (Ilk"), each of X and Z are selected from the group consisting of O, N, NH, and S. For example, one of X and Z may be N and the other of X and Z may be NH.
[0194] In certain embodiments, the compound of the invention is represented by formula (In) or (Iln):
[0195]
[0196] wherein each of Y and Z are selected from the group consisting of O, N, H, and S.
[0197] In certain such embodiments, Y is N and Z is NH.
[0198] In certain embodiments, the compound of the invention is represented by formula (Im) or (Ilm):
[0199] wherein X, Y, and Z each independently represent CH2, CO, NH, O, S, or SO2.
[0200] In certain embodiments of the compounds of formula (Im) or (Ilm), each of X, Y, and Z is CH2. In alternative embodiments, one of X, Y, and Z is N or O.
[0201] In any one of formulae (Ij), (IIj), (Ik), (Ilk), (Ik'), (Ilk'), (Ik"), (Ilk"), (Im), and (Ilm), in certain embodiments, n is 0 or 1.
[0202] In any of the foregoing embodiments, R4, if present, may be selected from the group consisting of optionally substituted alkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, and (heterocycloalkyl)alkyl.
[0203] In any of the foregoing embodiments, Ramay be H.
[0204] In certain embodiments, R1is a nitrogen-containing heteroarylene, such as a 5- membered nitrogen-containing heteroarylene. In ments, R1is imidazolene.
[0205] In some embodiments, -R^R13represents
[0206] In certain embodiments, Rlais H. Alternatively, R may be optionally substituted phenyl. Specifically, R may be phenyl, substituted by one or more occurrences of halo, hydroxyl, cyano, -C(0) H2, hydroxyalkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, -C(0)alkyl, -C(0)0-alkyl, heterocycloalkyl, -C(0) H(alkyl), -C(0)N(alkyl)2, -C(0)heterocycloalkyl, -C(0)(prolinol), - C(0) H((cycloalkyl)alkyl), or -C(0)NH(cycloalkyl). In certain embodiments, Rlais phenyl, substituted by two or more occurrences of alkoxy. Preferably, Rlais 3,4,5-trimethoxyphenyl.
[0207] In certain embodiments, Rlais substituted phenyl, wherein two adjacent substituents on the phenyl, taken together with the intervening atoms, form an optionally substituted cycloalkyl or heterocycloalkyl ring. For example, Rlamay be phenyl, wherein two adjacent substituents form a fused optionally substituted heterocyclic ring such as 1,4-dioxane or 1,3- dioxolane.
[0208] In certain embodiments, Rlais optionally substituted heteroaryl, such as quinoline. In certain embodiments, J is aryl, optionally substituted by one or more occurrences of R
[0209] In alternative embodiments, J is - R2R3.
[0210] In certain such embodiments, R2and R3, taken together, form a heterocycloalkyl ring, for example, a pyrrolidine ring, optionally substituted by one or more occurrences of R2a.
[0211] In certain such embodiments, R2a, independently for each occurrence, may represent - C(0) H2, -C(0)R5, hydroxyalkyl, heteroaryl, or aryl; preferably -C(0) H2, or hydroxyalkyl.
[0212] In certain embodiments, A represents a fused optionally substituted cycloalkyl ring, such as an optionally substituted cyclohexane or cycloheptane ring.
[0213] In certain embodiments, A represents a fused optionally substituted heterocycloalkyl ring, such as an optionally substituted tetrahydrofuran or pyrrolidine ring.
[0214] In certain embodiments, the compound of the invention is selected from the group consisting of the compounds depicted in the following tables, or a pharmaceutically acceptable salt thereof:
[0215]
[0216]
[0217] -24 -
[0218]
[0219]
[0220]
[0221] -41 -
[0222]
[0223]
[0224]
[0225]
[0226]
[0227] - 52 -
[0228]
[0229] - 53 -
[0230]
[0231] - 56 -
[0232]
[0233] In further aspects, the invention provides a compound represented by formula (III) or formula (IV):
[0234] or a pharmaceutically acceptable salt thereof;
[0235] wherein:
[0236] A is a fused optionally substituted aromatic ring, heteroaromatic ring, partially unsaturated cycloalkyl ring, or partially unsaturated heterocycloalkyl ring;
[0237] W is C or N;
[0238] B is CH or N;
[0239] D is CH or N;
[0240] provided that when B is CH, then D is N; or when D is CH, then B is N;
[0241] Rarepresents H or alkyl;
[0242] R1represents heteroarylene;
[0243] Rlarepresents H or optionally substituted -C(0)alkyl, -C(0)aryl, -C(0)heteroaryl, -
[0244] C(0)0(alkyl), -C(0)(heterocyclyl), -C(0) R¾y, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; J represents H, halo, -OR2, - R2R3, -C(0) R2R3, -C(0)0(alkyl), -C(0)OH, aryl, or heteroaryl, wherein aryl or heteroaryl is optionally substituted by one or more occurrences of R2a;
[0245] R2represents optionally substituted alkyl, aralkyl, heteroaralkyl, cycloalkyl, heterocycloalkyl,
[0246] (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, or hydroxyalkyl;
[0247] R3represents H or alkyl; or
[0248] R2and R3, taken together, form a heterocycloalkyl ring, optionally substituted by one or more occurrences of R2a;
[0249] R2a, independently for each occurrence, represents halo, hydroxyl, -C(0)H, oxo, - H2, - C(0) H2, -C(0)OH, -C(0)R5, -C(0)OR5, -C(0) H(R5), or optionally substituted alkyl, alkoxyl, hydroxyalkyl, heteroaryl, aryl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, or -N(alkyl)2;
[0250] or any two germinal or vicinal occurrences of R2a, taken together, may form a spiro or fused cycloalkyl ring;
[0251] R5, independently for each occurrence, represents optionally substituted alkyl, aralkyl, aryl, heteroaralkyl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, or
[0252] (heterocycloalkyl)alkyl; and
[0253] Rxand Ryeach independently represent H, alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, or
[0254] hydroxyalkyl.
[0255] In certain embodiments, the compound is represented by formula (Ilia) or formula
[0256] (IVa):
[0257] (IVa); wherein: valence permitting, Q, T, U, and V each independently represent CH, CH2, N, H, O, or SO2, wherein any hydrogen of a CH, CH2, or NH group is optionally replaced by an occurrence of R4;
[0258] R4, independently for each occurrence, represents halo, cyano, or optionally substituted alkyl, alkenyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkenyl, (heterocycloalkyl)alkyl, cycloalkyl, (cycloalkyl)alkyl, halocycloalkyl, hydroxycycloalkyl, aminocycloalkyl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, -CH2C(0)NH2, -C(0)R5, - C(0)OR5, or -S(0)2R5; m is an integer from 0-4, as permitted by valence.
[0259] In certain embodiments, the compound is represented by formula (Illb) or formula
[0260] (IVb):
[0261]
[0262] J
[0263] R1
[0264] ^R1a(IVb); wherein Q represents CH or N; and V represents CH or N. In certain embodiments, Q is N and V is CH. In alternative embodiments, Q is CH and V is N.
[0265] In certain embodiments, the compound is represented by formula (IIIc) or formula
[0266] (IVc):
[0267] (IVc).
[0268] In certain embodiments, the compound is represented by formula (Hid) or formula
[0269] wherein T represents CH2, NH, O, or SO2; and U represents CH2, NH, O, or SO2. In certain embodiments, T is NH; and U is CH2. In other embodiments, T is CH2 and U is NH.
[0270] In certain embodiments, the compound is represented by formula (Hie) or formula
[0271] (IVe):
[0272] .
[0273] In any one of formulae (Ilia), (IVa), (Illb), (IVb), (IIIc), (IVc), (Hid), (IVd), (Ille), and (IVe), in certain embodiments, m is 0 or 1.
[0274] In certain embodiments, the compound is represented by formula (Illj) or formula
[0275] (IVj):
[0276] wherein: W is C or N; valence permitting, X, Y, and Z each independently represent CH, CH2, CO, N, NH, O, S, or SO2, wherein any hydrogen of a CH, CH2, or NH group is optionally replaced by an occurrence of R4;
[0277] R4, independently for each occurrence, represents halo, cyano, or optionally substituted alkyl, alkenyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkenyl, (heterocycloalkyl)alkyl, cycloalkyl, (cycloalkyl)alkyl, halocycloalkyl, hydroxycycloalkyl, aminocycloalkyl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, -CH2C(0)NH2, -C(0)R5, - C(0)OR5, or -S(0)2R5; n is an integer from 0-4, as permitted by valence.
[0278] In certain embodiments, R4, independently for each occurrence, represents halo, or optionally substituted alkyl, alkenyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkenyl,
[0279] (heterocycloalkyl)alkyl, cycloalkyl, (cycloalkyl)alkyl, -CH2C(0)NH2, -C(0)R5, -C(0)OR5, or -S(0)2R5.
[0280] In certain embodiments, R4, independently for each occurrence, represents halocycloalkyl, hydroxycycloalkyl, aminocycloalkyl, aryloxy, heteroaryloxy, arylalkyloxy, or heteroaryl alkyl oxy .
[0281] In certain embodiments, one of X, Y, or Z is NR4.
[0282] In certain such embodiments, R4is selected from the group consisting of:
[0283]
[0284] In certain embodiments, the compound is represented by formula (Illk) or (IVk):
[0285] wherein X, Y, and Z each independently represent CH, N, NH, O, S, or SO2.
[0286] In further embodiments, the compound is represented by formula (Illk') or (IVk'):
[0287]
[0288] In certain embodiments, the compound is represented by formula (Illk") or (IVk"):
[0289] wherein at least one of X and Z is selected from the group consisting of O, N, NH, and S.
[0290] In certain embodiments of the compounds of formula (Illk") and (IVk"), one of X and Z is selected from the group consisting of O, NH, and S; and the other of X and Z is CH. For example, X may be selected from the group consisting of O, NH, and S. Alternatively, Z may be selected from the group consisting of O, NH, and S.
[0291] In further embodiments of the compounds of formula (Illk") and (IVk"), each of X and Z are selected from the group consisting of O, N, NH, and S. For example, one of X and Z is N and the other of X and Z is NH.
[0292] In certain embodiments, the compound of the invention is represented by wherein the compound is represented by formula (Illn) or (IVn):
[0293]
[0294] wherein each of Y and Z are selected from the group consisting of O, N, NH, and S. In certain embodiments, Y is N and Z is NH.
[0295] In certain embodiments, the compound of the invention is represented by formula
[0296] (Illm) or (IVm):
[0297] wherein X, Y, and Z each independently represent CH2, CO, NH, O, S, or SO2.
[0298] In certain embodiments of the compounds of formula (Illm) or (IVm), each of X, Y, and Z is CH2. In alternative embodiments, one of X, Y, and Z is N or O.
[0299] In any one of formulae (Illj), (IVj), (Illk), (IVk), (Illk'), (IVk'), (IHk"), (IVk"), (Illm), and (IVm), in certain embodiments, n is 0 or 1.
[0300] In any of the foregoing embodiments, R4, if present, may be selected from the group consisting of optionally substituted alkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, and (heterocycloalkyl)alkyl.
[0301] In any of the foregoing embodiments, Ramay be H.
[0302] In certain embodiments, R1is a nitrogen-containing heteroarylene, such as a 5- membered nitrogen-containing heteroarylene. In certain embodiments, R1is imidazolene.
[0303] In some embodiments,
[0304] In certain embodiments, Rlais H. Alternatively, R may be optionally substituted phenyl. Specifically, R may be phenyl, substituted by one or more occurrences of halo, hydroxyl, cyano, -C(0) H2, hydroxlalkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, -C(0)alkyl, -C(0)0-alkyl, heterocycloalkyl, -C(0) H(alkyl), -C(0)N(alkyl)2, -C(0)heterocycloalkyl, -C(0)(prolinol), - C(0) H((cycloalkyl)alkyl), or -C(0)NH(cycloalkyl). In certain embodiments, Rlais phenyl, substituted by two or more occurrences of alkoxy. Preferably, Rlais 3,4,5-trimethoxyphenyl.
[0305] In certain embodiments, Rlais substituted phenyl, wherein two adjacent substituents on the phenyl, taken together with the intervening atoms, form an optionally substituted cycloalkyl or heterocycloalkyl ring. For example, Rlamay be phenyl, wherein two adjacent substituents form a fused optionally substituted heterocyclic ring such as 1,4-dioxane or 1,3- dioxolane.
[0306] In certain embodiments, Rlais optionally substituted heteroaryl, such as quinoline. In certain embodiments, J is aryl, optionally substituted by one or more occurrences of R2a.
[0307] In alternative embodiments, J is - R2R3.
[0308] In certain such embodiments, R2and R3, taken together, form a heterocycloalkyl ring, for example, a pyrrolidine ring, optionally substituted by one or more occurrences of R2a.
[0309] In certain such embodiments, R2a, independently for each occurrence, may represent - C(0) H2, -C(0)R5, hydroxyalkyl, heteroaryl, or aryl; preferably -C(0) H2, or hydroxyalkyl.
[0310] In certain embodiments, the compound of the invention is selected from the group consisting of the compounds depicted in the following table:
[0311]
[0312] Pharmaceutical Compositions
[0313] The invention provides pharmaceutical compositions, each comprising one or more compounds of the invention, or pharmaceutically acceptable salts thereof, and a
[0314] pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical
[0315] composition comprises a compound of the invention and a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition comprises a plurality of compounds of the invention, or pharmaceutically acceptable salts thereof, and a
[0316] pharmaceutically acceptable carrier.
[0317] In certain embodiments, a pharmaceutical composition of the invention further comprises at least one additional pharmaceutically active agent other than a compound of the invention. The at least one additional pharmaceutically active agent can be an agent useful in the treatment of a disease or condition that would be benefitted by inhibition of ALK2 kinase.
[0318] Pharmaceutical compositions of the invention can be prepared by combining one or more compounds of the invention, or pharmaceutically acceptable salts thereof, with a pharmaceutically acceptable carrier and, optionally, one or more additional pharmaceutically active agents.
[0319] Methods of Use
[0320] The present invention provides compounds, and pharmaceutically acceptable salts thereof, that are useful for treating or preventing a disease or condition whose treatment would benefit from ALK2 kinase inhibition.
[0321] In certain aspects, the invention provides a method of inhibiting ALK2 kinase, comprising administering to a subject in need thereof an effective amount of a compound of the invention (e.g., a compound of formula (I), (II), (III), or (IV)), or a pharmaceutically acceptable salt thereof.
[0322] In certain aspects, the invention provides a compound of the invention, or a pharmaceutically acceptable salt thereof, for use as a medicament.
[0323] In certain aspects, the invention provides methods of treating fibrodysplasia ossificans progressive, comprising the step of administering to a subject in need thereof a
[0324] therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
[0325] The present invention also provides a method of treating cancer, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
[0326] In certain embodiments, the cancer comprises tumors of the central nervous system, breast cancer, prostate cancer, skin cancer (including basal cell carcinoma cell carcinoma, squamous cell carcinoma and melanoma), cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, glioma, pancreatic cancer, stomach cancer, liver cancer, colon cancer, renal cancer, bladder cancer, oesophageal cancer, cancer of the larynx, cancer of the parotid, cancer of the biliary tract, rectal cancer, endometrial cancer, adenocarcinomas, small cell carcinomas, neuroblastomas,
[0327] mesotheliomas, adrenocortical carcinomas, epithelial carcinomas, desmoid tumors, desmoplastic small round cell tumors, endocrine tumors, Ewing sarcoma family tumors, germ cell tumors, hepatoblastomas, hepatocellular carcinomas, non-rhabdomyosarcoma, soft tissue sarcomas, osteosarcomas, peripheral primitive neuroectodermal tumors, retinoblastomas, rhabdomyosarcomas, and Wilms tumors.
[0328] In certain embodiments, the cancer is a glioma, such as diffuse intrinsic pontine glioma.
[0329] The compounds of the invention are useful in treating any disease or condition whose treatment would benefit from ALK2 kinase inhibition, meaning that in such disease or condition it would be desirable to reduce ALK2 kinase activity. For example, it may be desirable to reduce ALK2 kinase activity in the setting of inappropriate activation or hyperactivation of ALK2 kinase.
[0330] Formulations, Routes of Administration, and Dosing
[0331] The compounds of the invention, and pharmaceutically acceptable salts thereof, can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient, in a variety of forms adapted to the chosen route of administration, e.g., orally or parenterally, by intravenous, intraperitoneal, intramuscular, topical, or subcutaneous routes. Additional routes of administration are also contemplated by the invention.
[0332] Thus, the present compounds or pharmaceutically acceptable salts thereof may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet. For oral therapeutic administration, the active compound (i.e., a compound of the invention or a pharmaceutically acceptable salt thereof) may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2% to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.
[0333] The tablets, troches, pills, capsules, and the like may also contain the following diluents and carriers: binders such as gum tragacanth, acacia, corn starch or gelatin;
[0334] excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices.
[0335] The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound can be prepared in water or physiologically acceptable aqueous solution, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
[0336] The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active compound which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid
[0337] polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
[0338] Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation can include vacuum drying and the freeze drying techniques, which yield a powder of the active compound plus any additional desired ingredient present in the previously sterile-filtered solutions.
[0339] For topical administration, the present compounds or pharmaceutically acceptable salts thereof may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
[0340] Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol / glycol blends, in which the present compounds or pharmaceutically acceptable salts thereof can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
[0341] Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
[0342] Examples of useful dermatological compositions which can be used to deliver the compounds of the invention, or pharmaceutically acceptable salts thereof, to the skin are known in the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392; incorporated herein by reference), Geria (U.S. Pat. No. 4,992,478; incorporated herein by reference), Smith et al. (U.S. Pat. No. 4,559, 157; incorporated herein by reference), and Wortzman (U.S. Pat. No. 4,820,508; incorporated herein by reference).
[0343] Useful dosages of the compounds of the invention, or pharmaceutically acceptable salts thereof, can be determined, at least initially, by comparing their in vitro activity and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known in the art; for example, see U.S. Pat. No. 4,938,949 (incorporated herein by reference).
[0344] The amount of the compound, or pharmaceutically acceptable salt thereof, required for use in treatment will vary not only with the particular compound or salt selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
[0345] In general, however, a suitable dose will be in the range of from about 0.5 to about 100 mg / kg body weight of the recipient per day, e.g., from about 3 to about 90 mg / kg of body weight per day, from about 6 to about 75 mg per kilogram of body weight per day, from about of 10 to about 60 mg / kg of body weight per day, or from about 15 to about 50 mg / kg of body weight per day.
[0346] Compounds of the invention, or pharmaceutically acceptable salts thereof, can be conveniently formulated in unit dosage form; for example, containing 5 to 1000 mg, 10 to 750 mg, or 50 to 500 mg of active compound per unit dosage form. In one embodiment, the invention provides a composition comprising a compound of the invention, or
[0347] pharmaceutically acceptable salt thereof, formulated in such a unit dosage form. The desired dose may conveniently be presented in a single dose or as divided doses to be administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub- dose itself may be further divided, e.g., into a number of discrete loosely spaced
[0348] administrations.
[0349] Compounds of the invention, or pharmaceutically acceptable salts thereof, can also be administered in combination with other therapeutic agents, for example, other agents that are useful for treating or preventing a disease or condition whose treatment would benefit from ALK2 kinase inhibition.
[0350] Other delivery systems can include time-release, delayed release, or sustained release delivery systems such as are well-known in the art. Such systems can avoid repeated administrations of the active compound, increasing convenience to the subject and the physician. Many types of release delivery systems are available and known to those of ordinary skill in the art. Use of a long-term sustained release implant may be desirable. Long-term release, as used herein, means that the delivery system or is implant constructed and arranged to deliver therapeutic levels of the active compound for at least 30 days, and preferably 60 days.
[0351] In certain embodiments, a compound of the invention, or pharmaceutically acceptable salt thereof, is formulated for intraocular administration, for example direct injection or insertion within or in association with an intraocular medical device.
[0352] The compounds of the invention, or pharmaceutically acceptable salts thereof, may be formulated for depositing into a medical device, which may include any of a variety of conventional grafts, stents, including stent grafts, catheters, balloons, baskets, or other device that can be deployed or permanently implanted within a body lumen. As a particular example, it would be desirable to have devices and methods which can deliver compounds of the invention, or pharmaceutically acceptable salts thereof, to the region of a body which has been treated by interventional technique.
[0353] In exemplary embodiments, a compound of the invention, or pharmaceutically acceptable salt thereof, may be deposited within a medical device, such as a stent, and delivered to the treatment site for treatment of a portion of the body.
[0354] Stents have been used as delivery vehicles for therapeutic agents (i.e., drugs).
[0355] Intravascular stents are generally permanently implanted in coronary or peripheral vessels. Stent designs include those of U.S. Pat. No. 4,733,655 (Palmaz), U.S. Pat. No. 4,800,882 (Gianturco), or U.S. Pat. No. 4,886,062 (Wiktor). Such designs include both metal and polymeric stents, as well as self-expanding and balloon-expandable stents. Stents may also be used to deliver a drug at the site of contact with the vasculature, as disclosed in U.S. Pat. No. 5, 102,417 (Palmaz), U.S. Pat. No. 5,419,760 (Narciso, Jr.), U.S. Pat. No. 5,429,634 (Narciso, Jr.), and in International Patent Application Nos. WO 91 / 12779 (Medtronic, Inc.) and WO 90 / 13332 (Cedars-Sanai Medical Center), for example.
[0356] The term "deposited" means that the active compound is coated, adsorbed, placed, or otherwise incorporated into the device by methods known in the art. For example, the active compound may be embedded and released from within ("matrix type") or surrounded by and released through ("reservoir type") polymer materials that coat or span the medical device. In the latter example, the active compound may be entrapped within the polymer materials or coupled to the polymer materials using one or more the techniques for generating such materials known in the art. In other formulations, the active compound may be linked to the surface of the medical device without the need for a coating, for example by means of detachable bonds, and release with time or can be removed by active mechanical or chemical processes. In other formulations, the active compound may be in a permanently immobilized form that presents the active compound at the implantation site.
[0357] In certain embodiments, the active compound may be incorporated with polymer compositions during the formation of biocompatible coatings for medical devices, such as stents. The coatings produced from these components are typically homogeneous and are useful for coating a number of devices designed for implantation.
[0358] The polymer may be either a biostable or a bioabsorbable polymer depending on the desired rate of release or the desired degree of polymer stability, but frequently a
[0359] bioabsorbable polymer is suitable for this embodiment because, unlike a biostable polymer, it will typically not be present long after implantation to cause any adverse, chronic local response. Bioabsorbable polymers that could be used include, but are not limited to, poly(L- lactic acid), polycaprolactone, polyglycolide (PGA), poly(lactide-co-glycolide) (PLLA / PGA), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(D-lactic acid), poly(L -lactic acid), poly(D, L-lactic acid), poly(D, L-lactide) (PLA), poly (L-lactide) (PLLA), poly(glycolic acid-co-trimethylene carbonate) (PGA / PTMC), polyethylene oxide (PEO), polydioxanone (PDS),
[0360] polyphosphoester, polyphosphoester urethane, poly(amino acids), cyanoacrylates,
[0361] poly(trimethylene carbonate), poly(iminocarbonate), copoly(ether-esters) (e.g., PEO / PLA), polyalkylene oxalates, polyphosphazenes and biomolecules such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, cross linked or amphipathic block copolymers of hydrogels, and other suitable bioabsorbable poplymers known in the art. Also, biostable polymers with a relatively low chronic tissue response such as polyurethanes, silicones, and polyesters could be used, and other polymers could also be used if they can be dissolved and cured or polymerized on the medical device such as polyolefins, polyisobutylene and ethylene-alphaolefin copolymers; acrylic polymers and copolymers, vinyl halide polymers and copolymers, such as polyvinyl chloride;
[0362] polyvinylpyrrolidone; polyvinyl ethers, such as polyvinyl methyl ether; polyvinylidene halides, such as polyvinylidene fluoride and polyvinylidene chloride; polyacrylonitrile, polyvinyl ketones; polyvinyl aromatics, such as polystyrene, polyvinyl esters, such as polyvinyl acetate; copolymers of vinyl monomers with each other and olefins, such as ethylene-m ethyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers; pyran copolymer; polyhydroxy-propyl-methacrylamide- phenol; polyhydroxyethyl-aspartamide-phenol; polyethyleneoxide-polylysine substituted with palmitoyl residues; polyamides, such as Nylon 66 and polycaprolactam; alkyd resins, polycarbonates; polyoxymethylenes; polyimides; polyethers; epoxy resins, polyurethanes; rayon; rayon-triacetate; cellulose, cellulose acetate, cellulose butyrate; cellulose acetate butyrate; cellophane; cellulose nitrate; cellulose propionate; cellulose ethers; and
[0363] carboxymethyl cellulose.
[0364] Polymers and semipermeable polymer matrices may be formed into shaped articles, such as valves, stents, tubing, prostheses and the like.
[0365] In certain embodiments of the invention, the compound of the invention, or pharmaceutically acceptable salt thereof, is coupled to a polymer or semipermeable polymer matrix that is formed as a stent or stent-graft device.
[0366] Typically, polymers are applied to the surface of an implantable device by spin coating, dipping, or spraying. Additional methods known in the art can also be utilized for this purpose. Methods of spraying include traditional methods as well as microdeposition techniques with an inkjet type of dispenser. Additionally, a polymer can be deposited on an implantable device using photo-patterning to place the polymer on only specific portions of the device. This coating of the device provides a uniform layer around the device which allows for improved diffusion of various analytes through the device coating.
[0367] In certain embodiments of the invention, the compound of the invention, or pharmaceutically acceptable salt thereof, is formulated for release from the polymer coating into the environment in which the medical device is placed. Preferably, the active compound is released in a controlled manner over an extended time frame (e.g., months) using at least one of several well-known techniques involving polymer carriers or layers to control elution. Some of these techniques are described in U.S. Patent Application 2004 / 0243225 Al, the entire disclosure of which is incorporated herein in its entirety.
[0368] Moreover, as described for example in U.S. Pat. No. 6,770,729, which is incorporated herein in its entirety, the reagents and reaction conditions of the polymer compositions can be manipulated so that the release of the active compound from the polymer coating can be controlled. For example, the diffusion coefficient of the one or more polymer coatings can be modulated to control the release of the active compound from the polymer coating. In a variation on this theme, the diffusion coefficient of the one or more polymer coatings can be controlled to modulate the ability of an analyte that is present in the environment in which the medical device is placed (e.g., an analyte that facilitates the breakdown or hydrolysis of some portion of the polymer) to access one or more components within the polymer composition (and for example, thereby modulate the release of the active compound from the polymer coating). Yet another embodiment of the invention includes a device having a plurality of polymer coatings, each having a plurality of diffusion coefficients. In such embodiments of the invention, the release of the active compound from the polymer coating can be modulated by the plurality of polymer coatings.
[0369] In yet another embodiment of the invention, the release of the active compound from the polymer coating is controlled by modulating one or more of the properties of the polymer composition, such as the presence of one or more endogenous or exogenous compounds, or alternatively, the pH of the polymer composition. For example, certain polymer
[0370] compositions can be designed to release an active compound in response to a decrease in the pH of the polymer composition.
[0371] Kits
[0372] The invention also provides a kit, comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, at least one other therapeutic agent, packaging material, and instructions for administering the compound of the invention or the
[0373] pharmaceutically acceptable salt thereof and the other therapeutic agent or agents to a mammal to treat or prevent a disease or condition that would benefit from ALK2 inhibition. In one embodiment, the mammal is a human.
[0374] It will be understood by one of ordinary skill in the relevant arts that other suitable modifications and adaptations to the compositions and methods described herein are readily apparent from the description of the invention contained herein in view of information known to the ordinarily skilled artisan, and may be made without departing from the scope of the invention or any embodiment thereof.
[0375] EXAMPLES
[0376] Having now described the present invention in detail, the same will be more clearly understood by reference to the following examples, which are included herewith for purposes of illustration only and are not intended to be limiting of the invention. Part 1 shows the synthesis of exemplary compounds of the invention. Part 2 shows the preparation of various exemplary 3-substituted-(4-amino-lH-imidazol-l-yl) reagents. Part 3 presents biological assay data for the exemplary compounds of the invention.
[0377] For purposes of the present invention, the numerical descriptors "pyrrolo[2,l- f][l,2,4]triazine" and "pyrrolo[l,2-f][l,2,4]triazine" and the like in the context of a chemical name provided for a compound disclosed herein are understood to be synonymous and, therefore, may be and sometimes are used interchangeably. As a non-limiting example, the chemical names "2,4-dichloropyrrolo[2, l-f][l,2,4]triazine" and "2,4-dichloropyrrolo[l,2- f][l,2,4]triazine" are both understood to refer to a compound having the following structure:
[0378]
[0379] 4a
[0380] As another non-limiting example, the chemical names "2-chloro-N-(l-methyl-lH-imidazol-4- yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine" and "2-chloro-N-( 1 -methyl- lH-imidazol -4- yl)pyrrolo[l,2-f][l,2,4]triazin-4-amine" are both understood to refer to a compound having the following structure:
[0381]
[0382] 4b Part 1: Synthesis of imidazole-containing inhibitors of ALK2 kinase
[0383] Scheme 1
[0384]
[0385] 1 a 1 b
[0386] Preparation of 2-chloro-N-(l-methyl-lH-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (lb) To a solution of 2,4-dichlorofuro[3,2-d]pyrimidine (la) (0.71 g, 3.74 mmol; CAS # 956034- 07-4) in 2-Propanol (20 mL) was added DIPEA (1.63 mL, 9.36 mmol), 1 -methyl- 1H- imidazol-4-amine hydrochloride (0.5 g, 3.74 mmol) and heated at reflux for 24 h. The reaction mixture was concentrated in vacuum to dryness and the residue obtained was triturated with water. The solid obtained was collected by filtration and dried in vacuum to afford 2-chloro-N-(l-methyl-lH-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (lb) (550 mg,
[0387] 59 % yield) as brown solid; ^ MR (300 MHz, DMSO-^) δ 10.89 (s, 1H, D20
[0388] exchangeable), 8.35 (d, J = 2.1 Hz, 1H), 7.52 (d, J = 1.6 Hz, 1H), 7.39 (d, J = 1.3 Hz, 1H), 7.03 (d, J = 2.1 Hz, 1H), 3.71 (s, 3H); MS (ES+): 250.3 (M+l), 272.3, 274.3 (M+Na), (ES-): 248.2 (M-l).
[0389] Scheme 2
[0390]
[0391] 2a
[0392] Preparation of (S)-(l-(4-((l-methyl-lH-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2- yl)pyrrolidin-2-yl)methanol (2a)
[0393] A stirred suspension of 2-chloro-N-(l -methyl- lH-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (lb) (100 mg, 0.40 mmol), (S)-pyrrolidin-2-ylmethanol (122 mg, 1.20 mmol) in N-Methyl-2- pyrrolidinone (1 mL) was subjected to microwave irradiation at 150 °C for 2 h. The reaction mixture was diluted with ethyl acetate (50 mL), washed with brine (2 x 20 mL), dried, filtered and concentrated in vacuum. The crude residue was purified by combiflash (silica gel, 12 g, eluting with chloroform / CMA-80) to afford (S)-(l-(4-((l-methyl-lH-imidazol-4- yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (2a) (43 mg, 34 % yield) as a light yellow solid; ¾ NMR (300 MHz, DMSO-i¾) δ 9.90 (s, 1H, D20 exchangeable), 8.00 (d, J = 2.1 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 4.94 (s, 1H, D2O exchangeable), 4.13 (s, 1H), 3.83 - 3.69 (m, 1H), 3.64 (s, 3H), 3.62 - 3.49 (m, 1H), 3.48 - 3.23 (m, 2H), 2.07 - 1.83 (m, 4H); MS (ES+): 315.4 (M+l), 337.5 (M+Na), (ES-): 313.4 (M- 1). HPLC purity: 98.70%.
[0394] Scheme 3
[0395]
[0396] Preparation of (R)-(l-(4-((l-methyl-lH-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2- yl)pyrrolidin-2-yl)methanol (3a)
[0397] Reaction of 2-chloro-N-(l-methyl-lH-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (lb) (100 mg, 0.40 mmol) with (R)-pyrrolidin-2-ylmethanol (122 mg, 1.20 mmol) in NMP (1 mL) according to the procedure as reported in Scheme 2 gave after workup and purification (R)-(l- (4-((l -methyl- lH-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (3a) (65 mg, 52 % yield) as a buff color solid; ¾ NMR (300 MHz, DMSO-^e) δ 9.91 (s, 1H, D2O exchangeable), 8.00 (d, J= 2.2 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J= 1.4 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 4.93 (s, 1H, D2O exchangeable), 4.13 (s, 1H), 3.82 - 3.69 (m, 1H), 3.64 (s, 3H), 3.61 - 3.48 (m, 1H), 3.48 - 3.23 (m, 2H), 2.06 - 1.80 (m, 4H);MS (ES+): 315. 4 (M+l), 337.4 (M+Na), (ES-): 313.3 (M-l).
[0398] Scheme 4
[0399] Preparation of N-(l-methyl-lH-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-l-yl)pyrrolo[l,2- f][l,2,4]triazin-4-amine (4c)
[0400] Step-1 : Preparation of 2-chloro-N-(l -methyl- lH-imidazol-4-yl)pyrrolo[2, l-f][ l,2,4]triazin-4- amine (4b) Compound 4b was prepared from compound 4a according to the procedure reported by Mastalerz, Harold et al; in PCT Int. Appl., WO 2008 / 005956, 10 Jan 2008 (incorporated by reference). This gave 2-chloro-N-(l -methyl- lH-imidazol-4-yl)pyrrolo[2, l-f][l,2,4]triazin-4- amine (4b) as a pale-off colored solid; ¾ MR (300 MHz, OMSO-de) δ 1 1.15 (s, 1H), 7.75 - 7.67 (m, 1H), 7.54 (s, 1H), 7.44 (s, 1H), 7.35 (dd, J = 4.5, 1.5 Hz, 1H), 6.68 (dd, J = 4.4, 2.6 Hz, 1H), 3.70 (s, 3H); MS (ES+): 249.3 (M+l), 271.3 (M+Na); MS (ES-): 247.2(M-1).
[0401] Step-2: Preparation of N-(l-methyl-lH-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-l- yl)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-4-amine (4c)
[0402] Compound 4c was prepared from 2-chloro-N-(l-methyl-lH-imidazol-4-yl)pyrrolo[l,2- f][l,2,4]triazin-4-amine (4b) (100 mg, 0.40 mmol), 2-(pyrrolidin-2-yl)pyridine (179 mg, 1.21 mmol), and DIPEA (0.21 mL, 1.21 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by flash chromatography [silica (24 g), eluting with CMA80 in CHCb from 0 to 20%] ] N-(l-methyl-lH-imidazol-4-yl)-2-(2-(pyridin- 2-yl)pyrrolidin-l-yl)pyrrolo[l,2-f][l,2,4]triazin-4-amine (4c) (50 mg, 35 % yield) as a yellow solid; ¾ MR (300 MHz, DMSO-^6) δ 10.24 (s, 1H), 8.67 - 8.56 (m, 1H), 7.67 (td, J = 7.7, 1.8 Hz, 1H), 7.44 - 7.32 (m, 2H), 7.28 - 7.15 (m, 2H), 7.06 (dd, J = 4.4, 1.7 Hz, 1H), 6.86 - 6.67 (m, 1H), 6.36 (dd, J = 4.4, 2.5 Hz, 1H), 5.29 (d, J = 8.3 Hz, 1H), 3.81 (t, J = 9.0 Hz, 1H), 3.67 - 3.54 (m, 1H), 3.53 (s, 3H), 2.46 - 2.24 (m, 1H), 2.09 - 1.75 (m, 3H); MS (ES+): 361.5 (M+l); MS (ES-) 359.4 (M-l).
[0403] Scheme 5
[0404]
[0405] Preparation of N-(l -methyl- lH-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin- l-yl)furo[3,2- d]pyrimidin-4-amine (5a)
[0406] Compound 5a was prepared from 2-chloro-N-(l-methyl-lH-imidazol-4-yl)furo[3,2- d]pyrimidin-4-amine (lb) (100 mg, 0.40 mmol), DIPEA (155 mg, 1.20 mmol) and 2- (pyrrolidin-2-yl)pyridine hydrochloride (148 mg, 0.8 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by flash
[0407] chromatography [silica (12 g), eluting with CMA80 in CHCb from 0 to 20%] N-(l-methyl- lH-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-l-yl)furo[3,2-d]pyrimidin-4-amine (5a) (22 mg, 15 % yield) as an off white solid; ^ NMR (300 MHz, DMSO-d6) δ 9.83 (s, 1H, D20 exchangeable), 8.61 (s, 1H), 8.00 (s, 1H), 7.66 (td, J = 7.6, 1.8 Hz, 1H), 7.38 - 7.27 (m, 1H), 7.26 - 7.18 (m, 1H), 7.15 (d, J = 7.8 Hz, 1H), 6.84 - 6.67 (m, 1H), 6.67 - 6.44 (m, 1H), 5.29 (d, J = 8.2 Hz, 1H), 3.99 - 3.81 (m, 1H), 3.78 - 3.60 (m, 1H), 3.52 (s, 3H), 2.46 - 2.27 (m, 1H), 2.06 - 1.74 (m, 3H); MS (ES+): 362.4 (M+l), 384.5 (M+Na).
[0408] Scheme 6
[0409]
[0410] Preparation of (S)-( 1 -(4-( 1 -methyl- lH-imidazol-4-ylamino)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-2- yl)pyrrolidin-2-yl)methanol (6a)
[0411] Compound 6a was prepared from 2-chloro-N-(l-methyl-lH-imidazol-4-yl)pyrrolo[l,2- f][l,2,4]triazin-4-amine (4b) (50 mg, 0.2 mmol), (,S)-pyrrolidin-2-ylmethanol (61 mg, 0.6 mmol) and DIPEA (0.1 1 mL, 0.6 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by flash chromatography [silica (24 g), eluting with CMA-80 in CHCb from 0 to 40%] (S)-( l-(4-(l -methyl- lH-imidazol-4- ylamino)pyrrolo[l,2-f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (6a) (34 mg, 54 % yield); ¾ NMR (300 MHz, DMSO-d) δ 10.32 (s, 1H), 7.47 (s, 2H), 7.35 (dd, J = 2.4, 1.7 Hz, 1H), 7.08 (d, J= 3.5 Hz, 1H), 6.36 (dd, J = 4.4, 2.4 Hz, 1H), 4.81 (t, J = 5.0 Hz, 1H), 4.16 - 4.07 (m, 1H), 3.82 - 3.70 (m, 1H), 3.65 (s, 3H), 3.54 - 3.42 (m, 1H), 3.36 - 3.25 (m, 2H), 2.12 - 1.79 (m, 4H); MS (ES+): 314.4 (M+l); MS (ES-): 312.4 (M-l).
[0412] Scheme 7
[0413] Preparation of (R)-(l -(4-( 1 -methyl- lH-imidazol-4-ylamino)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-2- yl)pyrrolidin-2-yl)methanol (7a)
[0414] Compound 7a was prepared from 2-chloro-N-(l-methyl-lH-imidazol-4-yl)pyrrolo[l,2- f][l,2,4]triazin-4-amine (4b) (50 mg, 0.2 mmol), (R)-pyrrolidin-2-ylmethanol (61 mg, 0.6 mmol) and DIPEA (0.11 mL, 0.6 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by flash chromatography [silica (24 g), eluting with CMA-80 in CHCb from 0 to 40%] (R)-(l-(4-(l-methyl-lH-imidazol-4- ylamino)pyrrolo[l,2-f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (7a) (27 mg, 43 % yield); ¾ NMR (300 MHz, DMSO-d) δ 10.32 (s, 1H), 7.47 (s, 2H), 7.35 (dd, J= 2.5, 1.7 Hz, 1H), 7.08 (dd, J= 4.5, 1.7 Hz, 1H), 6.36 (dd, J= 4.4, 2.4 Hz, 1H), 4.81 (t, J= 5.0 Hz, 1H), 4.20 - 4.04 (m, 1H), 3.82 - 3.69 (m, 1H), 3.65 (s, 3H), 3.54 - 3.42 (m, 1H), 3.35 - 3.24 (m, 2H), 2.11 - 1.78 (m, 4H); MS (ES+): 314.5 (M+l), 336.5 (M+Na).
[0415] Scheme 8
[0416]
[0417] Preparation of (S)-(l-(4-((l-phenyl-lH-imidazol-4-yl)amino)pyrrolo[2, l-f][l,2,4]triazin-2- yl)pyrrolidin-2-yl)methanol (8c)
[0418] Step- 1 : Preparation of 2-chloro-N-( 1 -phenyl- lH-imidazol-4-yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4- amine (8b) Compound 8b was prepared according to the procedure reported in Scheme 1 from 2,4-dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (240 mg, 1.28 mmol; CAS # 918538-05- 3) in 2-Propanol (5 mL) using DIPEA (0.67 mL, 3.83 mmol) and 1 -phenyl- lH-imidazol -4- amine, HCI (8a) (250 mg, 1.28 mmol; prepared according to the procedure reported by Sakamoto, Toshihiro et al in Bioorganic & Medicinal Chemistry, 17(14), 5015-5026; 2009 and Francini, Cinzia Maria et al, in Chern, Med. Chem, 10(12), 2027-2041 ). This gave 2- chloro-N-(l -phenyl- lH-imidazol-4-yl)pyrrolo[l,2-f][l,2,4]triazin-4-amine (8b) (302 mg, 76 % yield); ¾ NMR (300 MHz, DMSO-i¾) δ 11.35 (s, 1H), 8.35 - 8.18 (m, 1H), 7.95 - 7.87 (m, 1H), 7.81 - 7.73 (m, 1H), 7.65 (d, J= 7.9 Hz, 2H), 7.56 (t, J= 7.7 Hz, 2H), 7.46 - 7.35 (m, 2H), 6.80 - 6.66 (m, 1H); MS (ES+): 311.3 (M+l); MS (ES-): 309.3 (M-l).
[0419] Step-2: Preparation of (S)-(l-(4-((l-phenyl-lH-imidazol-4-yl)amino)pyrrolo[2,l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (8c)
[0420] Compound 8c was prepared from 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (8b) (100 mg, 0.32 mmol), (Sj-pyrrolidin-2-ylmethanol (98 mg, 0.97 mmol), and DIPEA (0.17 mL, 0.97 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by flash chromatography
[0421] [silica (24 g), eluting with CMA-80 in CHCh from 0 to 40%] (S)-(l-(4-((l-phenyl-lH- imidazol-4-yl)amino)pyrrolo[2, l-f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (8c) (29 mg, 24 % yield) TFA salt as a pale off-white solid (obtained by reverse phase column purification of final compound using 0.1%TFA in acetonitrile / water as a mobile phase); ¾ MR (300 MHz, DMSO-i¾) δ 10.58 (s, 1H), 8.32 (s, 1H), 7.98 (s, 1H), 7.76 (d, J= 7.8 Hz, 2H), 7.51 (t, J= 7.7 Hz, 2H), 7.43 - 7.37 (m, 1H), 7.37 - 7.31 (m, 1H), 7.23 - 7.09 (m, 2H), 7.00 (s, 1H), 6.48 - 6.31 (m, 1H), 4.26 - 4.09 (m, 1H), 3.84 - 3.68 (m, 1H), 3.59 - 3.44 (m, 1H), 3.44 - 3.28 (m, 2H), 2.15 - 1.78 (m, 4H);19F NMR (282 MHz, DMSO-i¾)) δ -74.29; MS (ES+): 376.5 (M+l); MS (ES-): 374.4 (M-l), 410.4 (M+Cl).
[0422] Scheme 9
[0423]
[0424] Preparation of N-( 1 -phenyl- lH-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin- 1 -yl)pyrrolo[2, 1 - f][l,2,4]triazin-4-amine (9a)
[0425] Compound 9a was prepared from 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)pyrrolo[2,l- f][l,2,4]triazin-4-amine (8b) (100 mg, 0.32 mmol), 2-(pyrrolidin-2-yl)pyridine hydrochloride (149 mg, 0.81 mmol), and DIPEA (0.28 mL, 1.61 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by flash chromatography [silica (24 g), eluting with CMA-80 in CHCb from 0 to 40%] N-(l-phenyl- lH-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin- 1 -yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine (9a) (27 mg, 20 % yield) as a light brown solid; ¾ MR (300 MHz, DMSO-^e) δ 10.55 (s, 1H), 8.43 (s, 1H), 8.26 - 8.08 (m, 1H), 8.04 - 7.76 (m, 1H), 7.67 - 7.52 (m, 6H), 7.49 - 7.34 (m, 3H), 7.20 - 7.10 (m, 1H), 6.42 (dd, J = 4.4, 2.5 Hz, 1H), 5.47 (d, J = 8.3 Hz, 1H), 3.91 - 3.78 (m, 1H), 3.70 - 3.62 (m, 1H), 2.53 - 2.36 (m, 1H), 2.14 - 1.73 (m, 3H);19F NMR (282 MHz, DMSO-i¾) δ -74.26; MS (ES+): 423.5 (M+1), 445.5 (M+Na); MS (ES-): 421.4 (M-1).
[0426] Scheme 10
[0427]
[0428] Preparation of N-( 1 -methyl- lH-imidazol-4-yl)-2-(2-phenylpyrroli din- 1 -yl)pyrrolo[2, 1 - f][l,2,4]triazin-4-amine (10a)
[0429] Compound 10a was prepared from 2-chloro-N-(l-methyl-lH-imidazol-4-yl)pyrrolo[l,2- f][l,2,4]triazin-4-amine (4b) (80 mg, 0.32 mmol), 2-phenylpyrrolidine (142 mg, 0.97 mmol), and DIPEA (0.17 mL, 0.97 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by flash chromatography [silica (24 g), eluting with CMA-80 in CHCb from 0 to 40%] N-(l-methyl-lH-imidazol-4-yl)-2-(2- phenylpyrrolidin-l-yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (10a) (31 mg, 27 % yield) as a pale-off white solid; ¾ NMR (300 MHz, DMSO-i¾) δ 10.20 (s, 1H), 7.41 - 7.25 (m, 6H), 7.24 - 7.15 (m, 1H), 7.05 (dd, J= 4.4, 1.7 Hz, 1H), 6.78 - 6.66 (m, 1H), 6.35 (dd, J= 4.4, 2.4 Hz, 1H), 5.32 (d, J= 8.0 Hz, 1H), 3.84 - 3.70 (m, 1H), 3.64 - 3.54 (m, 1H), 3.49 (s, 3H), 2.41 - 2.30 (m, 1H), 2.01 - 1.76 (m, 3H); MS (ES+): 360.5 (M+1), 382.5 (M+Na); MS (ES-): 358.4 (M-1), 394.5 (M+Cl); HPLC purity: 95.75%.
[0430] Scheme 11
[0431]
[0432] Preparation of N-(l -methyl- lH-imidazol-4-yl)-2-(2-(pyridin-3-yl)pyrrolidin- l-yl)furo[3,2- d]pyrimidin-4-amine (11a)
[0433] Compound 11a was prepared from 2-chloro-N-(l-methyl-lH-imidazol-4-yl)furo[3,2- d]pyrimidin-4-amine (lb) (100 mg, 0.4 mmol), 3-(pyrrolidin-2-yl)pyridine (1 19 mg, 0.8 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water 0-100%] N-( 1 -methyl- 1 H- imidazol-4-yl)-2-(2-(pyridin-3-yl)pyrrolidin-l-yl)furo[3,2-d]pyrimidin-4-amine (11a) (23 mg, 16 % yield) as an off white solid; ^ MR (300 MHz, OMSO-de) δ 9.83 (s, 1H, D20 exchangeable), 8.54 (s, 1H), 8.41 (dd, J = 4.8, 1.6 Hz, 1H), 8.01 (d, J = 2.2 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.32 (dd, J = 7.8, 4.7 Hz, 2H), 6.72 (s, 1H), 6.70 - 6.30 (m, 1H), 5.35 (d, J = 7.9 Hz, 1H), 3.98 - 3.81 (m, 1H), 3.77 - 3.60 (m, 1H), 3.51 (s, 3H), 2.47 - 2.33 (m, 1H), 2.02 - 1.73 (m, 3H); MS (ES+): 362.5 (M+l), 384.5 (M+Na), 745.8 (2M+Na), (ES-): 360.4 (M-l). heme 12
[0434]
[0435] Preparation of N-(l -methyl- lH-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin- l-yl)thieno[3, 2- d]pyrimidin-4-amine (12c)
[0436] Step-1 : Preparation of 2-chloro-N-(l-methyl-lH-imidazol-4-yl)thieno[3,2-d]pyrimidin-4- amine (12b) Compound 12b was prepared from 2,4-dichlorothieno[3,2-d]pyrimidine (12a) (0.31 g, 1.5 mmol; CAS # 16234-14-3) in 2-Propanol (10 mL) using 1 -methyl- lH-imidazol-4-amine hydrochloride (0.2 g, 1.5 mmol) and DIPEA (0.65 mL, 3.74 mmol) according to the procedure reported in Scheme 1. This gave after workup and purification by flash column chromatography (silica gel, 24 g eluting with CMA-80 in chloroform) 2-chloro-N-(l-methyl- lH-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (12b) (165 mg, 42 % yield) as a yellow solid; !H MR (300 MHz, DMSO-i%) δ 10.82 (s, 1H), 8.21 (d, J = 5.4 Hz, 1H), 7.55 (s, 1H),
[0437] 7.41 (s, 1H), 7.36 (d, J = 5.4 Hz, 1H), 3.71 (s, 3H); MS (ES+): 266.3 (M+l), 288.3 (M+Na), (ES-): 264.2 (M-l).
[0438] Step-2: Preparation of N-(l-methyl-lH-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-l- yl)thieno[3,2-d]pyrimidin-4-amine (12c)
[0439] Compound 12c was prepared from 2-chloro-N-(l-methyl-lH-imidazol-4-yl)thieno[3,2- d]pyrimidin-4-amine (12b) (100 mg, 0.38 mmol), 2-(pyrrolidin-2-yl)pyridine (167 mg, 1.13 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica C-18, 30 g), eluting with 0.1% TFA in acetonitrile and 0.1% TFA in water] N-(l-methyl-lH-imidazol-4-yl)-2-(2- (pyridin-2-yl)pyrrolidin-l-yl)thieno[3,2-d]pyrimidin-4-amine (12c) (86 mg, 61 % yield) as an off-white solid; ¾ MR (300 MHz, DMSO-i%) δ 9.81 (s, 1H, D20 exchangeable), 8.62 (s,
[0440] 1H), 8.02 - 7.80 (m, 1H), 7.66 (td, J = 7.6, 1.8 Hz, 1H), 7.31 (s, 1H), 7.27 - 7.05 (m, 3H), 6.62 (s, 1H), 5.34 (d, J = 8.2 Hz, 1H), 4.01 - 3.84 (m, 1H), 3.79 - 3.64 (m, 1H), 3.64 - 3.43 (m, 3H), 2.44 (s, 1H), 2.08 - 1.77 (m, 3H); MS (ES+): 378.5 (M+l), 400.5 (M+Na), (ES-): 376.4 (M-l).
[0441] Scheme 13
[0442]
[0443] Preparation of N-(l -methyl- lH-imidazol-4-yl)-2-(2-phenylpyrroli din- l-yl)furo[3, 2- d]pyrimidin-4-amine (13a) Compound 13a was prepared from 2-chloro-N-(l-methyl-lH-imidazol-4-yl)furo[3,2- d]pyrimidin-4-amine (lb) (100 mg, 0.4 mmol), 2-phenylpyrrolidine (147 mg, 1.0 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, N-(l-methyl-lH-imidazol-4-yl)-2-(2-phenylpyrrolidin-l-yl)furo[3,2-d]pyrimidin-
[0444] 4-amine (13a) (8 mg, 6 % yield) as a colorless solid; ^ MR (300 MHz, DMSO-i%) δ 11.50
[0445] (s, 1H, D20 exchangeable), 8.33 (s, 1H), 7.68 (s, 1H), 7.36 (d, J = 5.6 Hz, 4H), 7.32 - 7.20
[0446] (m, 1H), 6.97 (s, 1H), 6.58 (s, 1H), 5.47 (d, J = 7.2 Hz, 1H), 3.96 (s, 1H), 3.74 - 3.63 (m, 1H), 3.54 (s, 3H), 2.49 - 2.34 (m, 1H), 2.08 (s, 1H), 2.01 - 1.83 (m, 2H); MS (ES+): 361.5 (M+l). heme 14
[0447]
[0448] Preparation of (S)-(l-(4-((l-phenyl-lH-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2- yl)pyrrolidin-2-yl)methanol (14b)
[0449] Step-1 : Preparation of 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)furo[3,2-d]pyrimidin-4-
[0450] (14a)
[0451] Compound 14a was prepared according to the procedure reported in Scheme 1 from 2,4- dichlorofuro[3,2-d]pyrimidine (la) (400 mg, 2.12 mmol) in 2-Propanol (30 mL) using DIPEA (0.92 mL, 5.29 mmol) and 1 -phenyl- lH-imidazol-4-amine, HC1 (8a) (414 mg, 2.12 mmol). This gave 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine
[0452] (14a) (267 mg, 41 % yield) as a light brown solid; H NMR (300 MHz, DMSO-^) 5 11.01
[0453] (s, 1H), 8.38 (d, J = 2.2 Hz, 1H), 8.23 (d, J = 1.6 Hz, 1H), 7.88 (d, J = 1.7 Hz, 1H), 7.70 - 7.63 (m, 2H), 7.63 - 7.50 (m, 2H), 7.45 - 7.35 (m, 1H), 7.06 (d, J = 2.2 Hz, 1H); MS (ES+): 312.3 (M+l), 334.3 (M+Na), 310.3 (M-l).
[0454] Step-2: Preparation of (S)-(l-(4-((l-phenyl-lH-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2- yl)pyrrolidin-2-yl)methanol (14b)
[0455] Compound 14b was prepared from 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)furo[3,2- d]pyrimidin-4-amine (14a) (100 mg, 0.32 mmol), (^-pyrrolidin-2-ylmethanol (81 mg, 0.8 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l-phenyl-lH-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-
[0456] 2-yl)pyrrolidin-2-yl)methanol (14b) (65 mg, 54 % yield) as a brown solid; ΪΗ NMR (300 MHz, DMSO-d6) δ 10.13 (s, 1H, D20 exchangeable), 8.18 (d, J = 1.6 Hz, 1H), 8.04 (d, J = 2.1 Hz, 1H), 7.95 (d, J = 1.7 Hz, 1H), 7.80 - 7.64 (m, 2H), 7.51 (t, J = 7.7 Hz, 2H), 7.34 (t, J = 7.4 Hz, 1H), 6.74 (d, J = 2.1 Hz, 1H), 5.00 (s, 1H, D20 exchangeable), 4.20 (s, 1H), 3.85 -
[0457] 3.69 (m, 1H), 3.66 - 3.54 (m, 1H), 3.55 - 3.41 (m, 2H), 2.09 - 1.83 (m, 4H); MS (ES+): 377.5 (M+l), (ES-): 375.4 (M-l).
[0458] Scheme 15
[0459]
[0460] Preparation of (S)-N-(l-methyl-lH-imidazol-4-yl)-2-(2-phenylpyrrolidin-l-yl)pyrrolo[2, 1- f][l,2,4]triazin-4-amine (15a)
[0461] Compound 15a was prepared from 2-chloro-N-(l-methyl-lH-imidazol-4-yl)pyrrolo[l,2- f][l,2,4]triazin-4-amine (4b) (80 mg, 0.32 mmol), (S)-2-phenylpyrrolidine (142 mg, 0.97 mmol), DIPEA (0.17 mL, 0.97 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-N-(l -methyl- lH-imidazol-4-yl)-2- (2-phenylpyrrolidin-l-yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (15a) (42 mg, 36 % yield) as an off white solid; ¾ NMR (300 MHz, DMSO-i%) δ 10.20 (s, 1H, D20 exchangeable), 7.40 - 7.34 (m, 2H), 7.34 - 7.26 (m, 4H), 7.25 - 7.15 (m, 1H), 7.05 (dd, J = 4.3, 1.7 Hz, 1H), 6.73 (s, 1H), 6.36 (dd, J = 4.4, 2.4 Hz, 1H), 5.33 (d, J = 8.0 Hz, 1H), 3.86 - 3.70 (m, 1H), 3.66 - 3.50 (m, 1H), 3.49 (s, 3H), 2.42 - 2.28 (m, 1H), 2.02 - 1.71 (m, 3H); MS (ES+): 360.5 (M+l), (ES- ): 358.5 (M-l). Scheme 16
[0462]
[0463] Preparation of (S)-(l-(4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2- yl)pyrrolidin-2-yl)methanol (16b)
[0464] Step-1 : Preparation of 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)thieno[3,2-d]pyrimidin-4- amine (16a)
[0465] Compound 16a was prepared according to the procedure reported in Scheme 1 from 2,4- dichlorothieno[3,2-d]pyrimidine (12a) (500 mg, 2.44 mmol) in 2-Propanol (30 mL) using DIPEA (1.07 mL, 6.1 mmol) and 1 -phenyl- lH-imidazol-4-amine, HCI (8a) (477 mg, 2.45 mmol). This gave 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine
[0466] (16a) (340 mg, 43 % yield) as a light pink solid; H NMR (300 MHz, DMSO-i%) δ 10.97 (s,
[0467] 1H, D20 exchangeable), 8.27 (s, 1H), 8.24 (d, J = 5.4 Hz, 1H), 7.96 (d, J = 1.7 Hz, 1H), 7.73
[0468] - 7.65 (m, 2H), 7.62 - 7.52 (m, 2H), 7.46 - 7.36 (m, 2H); MS (ES+): 328.3 (M+1) (ES-): 326.3
[0469] (M-l).
[0470] Step-2: Preparation of (S)-(l-(4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin- 2-yl)pyrrolidin-2-yl)methanol (16b)
[0471] Compound 16b was prepared from 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)thieno[3,2- d]pyrimidin-4-amine (16a) (100 mg, 0.31 mmol), (^-pyrrolidin-2-ylmethanol (77 mg, 0.76 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[3,2- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (16b) (95 mg, 79 % yield) as a brown solid; H
[0472] NMR (300 MHz, DMSO-i%) δ 10.14 (s, 1H, D20 exchangeable), 8.20 (d, J = 1.6 Hz, 1H),
[0473] 7.98 (d, J = 1.6 Hz, 1H), 7.93 (d, J = 5.4 Hz, 1H), 7.72 (s, 2H), 7.51 (t, J = 7.8 Hz, 2H), 7.35 (t, J = 7.4 Hz, 1H), 7.10 (d, J = 5.4 Hz, 1H), 5.03 (s, 1H, D20 exchangeable), 4.24 (s, 1H),
[0474] 3.87 - 3.70 (m, 1H), 3.70 - 3.45 (m, 1H), 3.43 - 3.36 (m, 2H), 2.12 - 1.78 (m, 4H); MS (ES+): 393.5 (M+1), 415.5 (M+Na), (ES-): 391.4 (M-l). Scheme 17
[0475]
[0476] Preparation of (S)-N4-(l-phenyl-lH-imidazol-4-yl)-N2-(l-phenylethyl)thieno[3,2- d]pyrimidine-2,4-diamine (17a)
[0477] Compound 17a was prepared from 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)thieno[3,2- d]pyrimidin-4-amine (16a) (100 mg, 0.31 mmol), (S)-l-phenylethanamine (111 mg, 0.92 mmol) and DIPEA (0.2 mL, 1.2 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-N4-(l-phenyl-lH-imidazol-4-yl)-N2- (l-phenylethyl)thieno[3,2-d]pyrimidine-2,4-diamine (17a) (65 mg, 52 % yield) as an off white solid; !H MR (300 MHz, DMSO-i¾) δ 10.10 (s, 1H, D20 exchangeable), 8.33 - 8.16 (m,
[0478] 1H), 8.14 (s, 1H), 7.97 - 7.87 (m, 1H), 7.76 - 7.63 (m, 2H), 7.57 (t, J = 7.8 Hz, 2H), 7.48 - 7.30 (m, 3H), 7.33 - 7.19 (m, 3H), 7.22 - 7.07 (m, 1H), 7.04 (d, J = 5.4 Hz, 1H), 5.32 - 5.16 (m, 1H), 1.50 (d, J = 7.0 Hz, 3H); MS (ES+): 413.5 (M+l), (ES-): 411.5 (M-l); HPLC purity: 91.57 %.
[0479] Scheme 18
[0480]
[0481] Preparation of (S)-N-(l -methyl- lH-imidazol -4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-l- yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine (18a)
[0482] Compound 18a was prepared from 2-chloro-N-(l-methyl-lH-imidazol-4-yl)pyrrolo[2,l- f][l,2,4]triazin-4-amine (4b) (100 mg, 0.4 mmol), (S)-2-(pyrrolidin-2-yl)pyridine dihydrochloride (98 mg, 0.44 mmol) and DIPEA (0.17 mL, 0.97 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-N-(l -methyl- lH-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-l-yl)pyrrolo[2,l- f][l,2,4]triazin-4-amine (18a) (11 mg, 8 % yield) as a light yellow solid;!H NMR (300 MHz, DMSO-i%) δ 10.24 (s, 1H, D20 exchangeable), 8.66 - 8.56 (m, 1H), 7.67 (td, J = 7.7,
[0483] 1.8 Hz, 1H), 7.43 - 7.31 (m, 2H), 7.27 - 7.16 (m, 2H), 7.06 (dd, J = 4.5, 1.7 Hz, 1H), 6.75 (bs, 1H), 6.36 (dd, J = 4.4, 2.4 Hz, 1H), 5.29 (d, J = 8.2 Hz, 1H), 3.87 - 3.74 (m, 1H), 3.66 - 3.56 (m, 1H), 3.53 (s, 3H), 2.44 - 2.31 (m, 1H), 2.05 - 1.79 (m, 3H); MS (ES+): 361.5 (M+l), 383.5 (M+Na).
[0484] Scheme 19
[0485]
[0486] Preparation of N-(l -methyl- lH-imidazol-4-yl)-2-(2-(pyridin-3-yl)pyrrolidin-l-yl)pyrrolo[2,l- f][l,2,4]triazin-4-amine (19a)
[0487] Compound 19a was prepared from 2-chloro-N-(l-methyl-lH-imidazol-4-yl)pyrrolo[2,l- f][l,2,4]triazin-4-amine (4b) (100 mg, 0.4 mmol), 3-(pyrrolidin-2-yl)pyridine (119 mg, 0.804 mmol),and DIPEA (0.21 mL, 1.21 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, N-(l-methyl-lH- imidazol-4-yl)-2-(2-(pyridin-3 -yl)pyrrolidin- 1 -yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine (19a)
[0488] (11 mg, 8 % yield) as a light yellow solid; !H NMR (300 MHz, DMSO-i¾) δ 10.24 (s, 1H,
[0489] D20 exchangeable), 8.66 - 8.56 (m, 1H), 7.67 (td, J = 7.7, 1.8 Hz, 1H), 7.43 - 7.31 (m, 2H),
[0490] 7.27 - 7.16 (m, 2H), 7.06 (dd, J = 4.5, 1.7 Hz, 1H), 6.75 (bs, 1H), 6.36 (dd, J = 4.4, 2.4 Hz, 1H), 5.29 (d, J = 8.2 Hz, 1H), 3.87 - 3.74 (m, 1H), 3.66 - 3.56 (m, 1H), 3.53 (s, 3H), 2.44 - 2.31 (m, 1H), 2.05 - 1.79 (m, 3H); MS (ES+): 361.5 (M+l), 383.5 (M+Na).
[0491] Scheme 20
[0492]
[0493] Preparation of N-(l-methyl-lH-imidazol-4-yl)-2-(2-(pyridin-4-yl)pyrrolidin-l-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (20a)
[0494] Compound 20a was prepared from 2-chloro-N-(l-methyl-lH-imidazol-4-yl)pyrrolo[2,l- f][l,2,4]triazin-4-amine (4b) (100 mg, 0.4 mmol), 4-(pyrrolidin-2-yl)pyridine (119 mg, 0.8 mmol) and DIPEA (0.21 mL, 1.21 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, N-(l-methyl-lH-imidazol-4-yl)-2-(2- (pyridin-4-yl)pyrrolidin-l-yl)pyrrolo[2,l-f][l,2,4]triazin-4-amine (20a) (23 mg, 16 % yield) as a light brown solid; ^ NMR (300 MHz, DMSO-i%) δ 10.26 (s, 1H, D20 exchangeable), 8.55 - 8.42 (m, 2H), 7.37 (s, 2H), 7.34 - 7.30 (m, 2H), 7.07 (dd, J = 4.4, 1.7 Hz, 1H), 6.74 (s, 1H), 6.36 (dd, J = 4.5, 2.4 Hz, 1H), 5.30 (d, J = 8.3 Hz, 1H), 3.86 - 3.73 (m, 1H), 3.68 - 3.58 (m, 1H), 3.52 (s, 3H), 2.47 - 2.30 (m, 1H), 2.01 - 1.73 (m, 3H); MS (ES+): 361.5 (M+l), 383.5 (M+Na), (ES-): 359.4 (M-l).
[0495] Scheme 21
[0496] Preparation of (S)-N4-(l-methyl-lH-imidazol-4-yl)-N2-(l-phenylethyl)quinazoline-2,4- diamine (21c)
[0497] Step-1 : Preparation of 2-chloro-N-(l-methyl-lH-imidazol-4-yl)quinazolin-4-amine (21b) Compound 21b was prepared according to the procedure reported by Su, Qibin et al in Journal of Medicinal Chemistry, 57(1), 144-158; 2014. This gave 2-chloro-N-(l-methyl-lH-imidazol-
[0498] 4-yl)quinazolin-4-amine (21b) as a light brown solid;!H MR (300 MHz, DMSO-i%) δ 10.97
[0499] (s, 1H, D20 exchangeable), 8.72 (dd, J = 8.3, 1.3 Hz, 1H), 7.84 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H),
[0500] 7.68 (dd, J = 8.4, 1.2 Hz, 1H), 7.62 - 7.50 (m, 3H), 3.73 (s, 3H); MS (ES+): 260.3 (M+l), 282.3 (M+Na), (ES-): 258.3 (M-l).
[0501] Step-2: Preparation of (S)-N4-(l-methyl-lH-imidazol-4-yl)-N2-(l-phenylethyl)quinazoline- 2,4-diamine (21c)
[0502] Compound 21c was prepared from 2-chloro-N-(l-methyl-lH-imidazol-4-yl)quinazolin-4- amine (21b) (100 mg, 0.39 mmol), (S)-l-phenylethanamine (140 mg, 1.16 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)- N4-(l-methyl-lH-imidazol-4-yl)-N2-(l-phenylethyl)quinazoline-2,4-diamine (21c) (24 mg,
[0503] 18 % yield) as a light brown solid; 1H NMR (300 MHz, DMSO-d6) δ 9.96 (s, 1H, D20 exchangeable), 8.36 (d, J = 8.2 Hz, 1H), 7.96 (s, 1H), 7.55 - 7.39 (m, 4H), 7.37 - 7. 3 (m, 5H), 7.08 - 6.93 (m, 1H), 5.29 (s, 1H), 3.69 (s, 3H), 1.50 (d, J = 7.0 Hz, 3H); MS (ES+): 345.5 (M+l), 367.5 (M+Na), (ES-): 343.4 (M-l), 379.5 (M+Cl).
[0504] Scheme 22
[0505]
[0506] Preparation of (S)-(l-(6-methyl-4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[2,3- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (22c)
[0507] Step-1 : Preparation of 2-chloro-6-methyl-N-(l-phenyl-lH-imidazol-4-yl)thieno[2,3- d]pyrimidin-4-amine (22b) Compound 22b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloro-6-methylthieno[2,3-d]pyrimidine (22a) (500 mg, 2.28 mmol, CAS # 76872-23-6) in 2-Propanol (30 mL) using DIPEA (1.0 mL, 5.71 mmol) and l-phenyl-lH-imidazol-4-amine, HC1 (8a) (363 mg, 2.28 mmol). This gave 2-chloro-6-methyl-N-(l -phenyl- lH-imidazol-4- yl)thieno[2,3-d]pyrimidin-4-amine (22b) (340 mg, 44 % yield) as light pink solid; ΪΗ MR (300 MHz, DMSO-i%) δ 10.88 (s, 1H, D20 exchangeable), 8.25 (d, J = 1.7 Hz, 1H), 7.91 (d, J = 1.7 Hz, 1H), 7.72 (s, 1H), 7.70 - 7.63 (m, 2H), 7.57 (dd, J = 8.7, 7.1 Hz, 2H), 7.46 - 7.36 (m, 1H), 2.56 (d, J = 1.2 Hz, 3H); MS (ES+): 364.3 (M+ Na), (ES-): 340.3 (M-l).
[0508] Step-2: Preparation of (S)-(l-(6-methyl-4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[2,3- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (22c)
[0509] Compound 22c was prepared from 2-chloro-6-methyl-N-(l-phenyl-lH-imidazol-4- yl)thieno[2,3-d]pyrimidin-4-amine (22b) (100 mg, 0.29 mmol), (S^-pyrrolidin-2-ylmethanol (89 mg, 0.88 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(6-methyl-4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[2,3- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (22c) (65 mg, 55 % yield) as a light brown solid;
[0510] !H MR (300 MHz, DMSO-i%) δ 9.98 (s, 1H, D20 exchangeable), 8.20 (s, 1H), 7.96 (d, J =
[0511] 1.6 Hz, 1H), 7.84 - 7.60 (m, 2H), 7.57 - 7.42 (m, 3H), 7.40 - 7.29 (m, 1H), 4.94 (s, 1H, D20 exchangeable), 4.42 - 4.02 (m, 1H), 3.87 - 3.39 (m, 2H), 2.63 - 2.51 (m, 1H), 2.49 - 2.35 (m, 4H), 2.13 - 1.76 (m, 4H); MS (ES+): 407.5 (M+l), 429.5 (M+Na), (ES-): 405.4.
[0512] Scheme 23
[0513]
[0514] Preparation of (S)-(l-(6-methyl-4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[3,2- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (23c)
[0515] Step-1 : Preparation of 2-chloro-6-methyl-N-(l-phenyl-lH-imidazol-4-yl)thieno[3,2- d]pyrimidin-4-amine (23b) Compound 23b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloro-6-methylthieno[3,2-d]pyrimidine (23a) (500 mg, 2.28 mmol, CAS # 35265-82-8) in 2-Propanol (30 mL) using DIPEA (1.00 mL, 5.71 mmol) and 1 -phenyl- lH-imidazol-4-amine, HC1 (8a) (363 mg, 2.28 mmol). This gave 2-chloro-6-methyl-N-(l -phenyl- lH-imidazol-4- yl)thieno[3,2-d]pyrimidin-4-amine (23b) (340 mg, 44 % yield) as a light pink solid; ΪΗ NMR (300 MHz, DMSO-i%) δ 10.75 (s, 1H, D20 exchangeable), 8.27 (d, J = 1.6 Hz, 1H), 7.92 (d, J = 1.6 Hz, 1H), 7.68 (dd, J = 7.9, 1.6 Hz, 2H), 7.57 (dd, J = 8.6, 7.1 Hz, 2H), 7.45 - 7.36 (m, 1H), 7.17 - 7.08 (m, 1H), 2.60 (s, 3H); MS (ES+): 342.3 (M+l), 364.3 (M+Na), (ES-): 340.3 (M-l).
[0516] Step-2: Preparation of (S)-(l-(6-methyl-4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[3,2- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (23c)
[0517] Compound 23c was prepared from 2-chloro-6-methyl-N-(l-phenyl-lH-imidazol-4- yl)thieno[3,2-d]pyrimidin-4-amine (23b) (100 mg, 0.29 mmol), (S^-pyrrolidin-2-ylmethanol (89 mg, 0.88 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(6-methyl-4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[3,2- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (23c) (65 mg, 55 % yield) as an off-white solid; ^H NMR (300 MHz, DMSO-i%) δ 9.95 (s, 1H, D20 exchangeable), 8.19 (d, J = 1.6 Hz, 1H), 7.96
[0518] (d, J = 1.6 Hz, 1H), 7.72 (s, 2H), 7.51 (t, J = 7.7 Hz, 2H), 7.34 (t, J = 7.4 Hz, 1H), 6.83 (d, J = 1.5 Hz, 1H), 5.37 - 4.71 (m, 1H, D20 exchangeable), 4.36 - 4.05 (m, 1H), 3.85 - 3.69 (m, 1H),
[0519] 3.70 - 3.38 (m, 3H), 2.52 (s, 3H), 2.10 - 1.80 (m, 4H); MS (ES+): 407.5 (M+l), 429.5 (M+Na), (ES-): 405.5 (M-l).
[0520] Scheme 24
[0521]
[0522] Preparation of (S)-N4-(l -phenyl- lH-imidazol-4-yl)-N2-(l-phenylethyl)quinazoline-2,4- diamine (24b) Step-1 : Preparation of 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)quinazolin-4-amine (24a) Compound 24a was prepared according to the procedure reported in Scheme 1 from 2,4- dichloroquinazoline (21a) (180 mg, 0.9 mmol; CAS # 607-68-1) in 2-Propanol (5 mL) using DIPEA (0.51 mL, 2.92 mmol) and 1 -phenyl- lH-imidazol-4-amine, HC1 (8a) (177 mg, 0.9 mmol). This gave 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)quinazolin-4-amine (24a) (125 mg,
[0523] 43 % yield) as an off-white solid;lH NMR (300 MHz, DMSO-i%) δ 11.18 (s, 1H, D20 exchangeable), 8.77 (d, J = 8.2 Hz, 1H), 8.29 (d, J = 1.7 Hz, 1H), 8.04 (d, J = 1.7 Hz, 1H), 7.87 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H), 7.73 (dd, J = 8.4, 1.2 Hz, 1H), 7.70 - 7.65 (m, 2H), 7.60 (tdd, J = 8.5, 6.9, 1.5 Hz, 3H), 7.46 - 7.37 (m, 1H); MS (ES+): 322.4 (M+l), 344.4 (M+Na), (ES-): 320.3 (M-l).
[0524] Step-2: Preparation of (S)-N4-(l-phenyl-lH-imidazol-4-yl)-N2-(l-phenylethyl)quinazoline- 2,4-diamine (24b)
[0525] Compound 24b was prepared from 2-chloro-N-(l -phenyl- lH-imidazol-4-yl)quinazolin-4- amine (24a) (100 mg, 0.31 mmol), (S)-l-phenylethanamine (113 mg, 0.93 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)- N4-(l-phenyl-lH-imidazol-4-yl)-N2-(l-phenylethyl)quinazoline-2,4-diamine (24b) (86 mg,
[0526] 68 % yield) as an off-white solid;ιϊί NMR (300 MHz, DMSO-i%) δ 11.47 - 10.14 (m, 1H,
[0527] D20 exchangeable), 8.66 - 8.36 (m, 2H), 8.22 (d, J = 1.7 Hz, 1H), 7.82 - 7.63 (m, 1H), 7.59 (t,
[0528] J = 7.6 Hz, 2H), 7.51 - 7.28 (m, 9H), 7.26 - 7.15 (m, 2H), 5.35 (q, J = 7.2 Hz, 1H), 1.57 (d, J = 6.9 Hz, 3H); MS (ES+): 407.5 (M+l), (ES-): 405.6 (M-l).
[0529] Scheme 25
[0530]
[0531] Preparation of (S)-(l-(4-((l-(4-fluorophenyl)-lH-imidazol-4-yl)amino)pyrrolo[2, 1- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (25c) Step-1 : Preparation of 2-chloro-N-(l-(4-fluorophenyl)-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (25b)
[0532] Compound 25b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (323 mg, 1.72 mmol) in 2-Propanol (20 mL) using DIPEA (0.9 mL, 5.15 mmol) and l-(4-fluorophenyl)-lH-imidazol-4-amine (25a) (440 mg, 2.06 mmol; prepared according to the procedure reported by Sakamoto, Toshihiro et al in Bioorganic & Medicinal Chemistry, 17(14), 5015-5026; 2009 and Francini, Cinzia Maria et al; in Chem. Med. Chem, 10(12), 2027-2041). This gave 2-chloro-N-(l-(4-fluorophenyl)-lH- imidazol-4-yl)pyrrolo[2,l-f][l,2,4]triazin-4-amine (25b) (381 mg, 68 % yield) as a pale off- white solid; ¾ NMR (300 MHz, DMSO-^e) δ 11.35 (s, 1H, D20 exchangeable), 8.21 (d, J = 1.6 Hz, 1H), 7.87 (d, 7= 1.6 Hz, 1H), 7.77 (dd, 7= 2.6, 1.5 Hz, 1H), 7.74 - 7.65 (m, 2H), 7.49
[0533] - 7.35 (m, 3H), 6.72 (dd, 7 = 4.5, 2.6 Hz, 1H);19F MR (282 MHz, DMSO) δ -114.97; MS (ES+): 329.3 (M+1); MS (ES-): 327.3 (M-1).
[0534] Step-2: Preparation of (S)-(l-(4-((l-(4-fluorophenyl)-lH-imidazol-4-yl)amino)pyrrolo[2,l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (25c)
[0535] Compound 25c was prepared from 2-chloro-N-(l-(4-fluorophenyl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (25b) (100 mg, 0.32 mmol), (Sj-pyrrolidin-2- ylmethanol (154 mg, 1.52 mmol), and DIPEA (0.16 mL, 0.91 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by flash chromatography [silica (24 g), eluting with CMA-80 in CHCh from 0 to 40%] (S)-(l-(4-((l- (4-fluorophenyl)- lH-imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2- yl)methanol (25c) (40mg, 33 % yield) as white solid; ¾ NMR (300 MHz, DMSO-i¾) δ 10.53 (s, 1H, D2O exchangeable), 8.20 (d, 7 = 1.6 Hz, 1H), 7.93 (d, 7 = 1.6 Hz, 1H), 7.86 - 7.74 (m, 2H), 7.39 (dd, J = 2.4, 1.6 Hz, 1H), 7.38 - 7.29 (m, 2H), 7.15 (dd, 7 = 4.5, 1.7 Hz, 1H), 6.39 (dd, 7= 4.4, 2.4 Hz, 1H), 4.91 (t, 7= 5.0 Hz, 1H, D2O exchangeable), 4.26 - 4.12 (m, 1H), 3.83
[0536] - 3.69 (m, 1H), 3.55 - 3.44 (m, 1H), 3.39 - 3.25 (m, 2H), 2.12 - 1.81 (m, 4H);19F NMR (282 MHz, DMSO-i¾) δ -115.67; MS (ES+): 394.5 (M+1), 416.5 (M+Na); MS (ES-): 392.5 (M-1).
[0537] Scheme 26
[0538] Preparation of (S)-(l-(4-((l-cyclopropyl-lH-imidazol-4-yl)amino)pyrrolo[2, l-f][l,2,4]triazin- 2-yl)pyrrolidin-2-yl)methanol (26c)
[0539] Step-1 : Preparation of 2-chloro-N-(l-cyclopropyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (26b)
[0540] Compound 26b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (268 mg, 1.43 mmol) in 2-Propanol (5 mL) using DIPEA (1.25 mL, 7.14 mmol) and l-cyclopropyl-lH-imidazol-4-amine hydrochloride (26a) (1.4 g, 7.14 mmol). This gave 2-chloro-N-(l-cyclopropyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (26b) (225mg, 57% yield) as a brownish solid; ¾ NMR (300 MHz, DMSO-i¾) δ 11.19 (s, 1H, D20 exchangeable), 7.73 (dd, J= 2.6, 1.5 Hz, 1H), 7.65 (d, J= 1.5 Hz, 1H), 7.50 (d, J= 1.5 Hz, 1H), 7.35 (dd, J= 4.5, 1.6 Hz, 1H), 6.68 (dd, J = 4.5, 2.6 Hz, 1H), 3.62 - 3.46 (m, 1H), 1.14 - 0.89 (m, 4H); MS (ES-): 273.3 (M-l).
[0541] Step-2: Preparation of (S)-(l-(4-((l-cyclopropyl-lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (26c)
[0542] Compound 26c was prepared from 2-chloro-N-(l-cyclopropyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (26b) (70 mg, 0.26 mmol), (Sj-pyrrolidin-2-ylmethanol (129 mg, 1.27 mmol), and DIPEA (0.13 mL, 0.76 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by flash chromatography [silica (24 g), eluting with CMA-80 in CHCh from 0 to 40%] (S)-(l-(4-((l-cyclopropyl-lH-imidazol-4- yl)amino)pyrrolo[2,l-f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (26c) (22 mg, 25% yield) as a white solid; ¾ NMR (300 MHz, OMSO-de) 5 10.31 (s, 1H, D2O exchangeable), 7.60 (d, J= 1.4 Hz, 1H), 7.49 (d, J= 1.6 Hz, 1H), 7.35 (dd, J= 2.4, 1.6 Hz, 1H), 7.09 (dd, J= 4.5, 1.7 Hz, 1H), 6.36 (dd, J = 4.4, 2.4 Hz, 1H), 4.77 (t, J = 5.1 Hz, 1H, D2O exchangeable), 4.21 - 4.01 (m, 1H), 3.80 - 3.64 (m, 1H), 3.59 - 3.38 (m, 2H), 3.39 (s, 2H), 2.13 - 1.77 (m, 4H), 1.07 - 0.83 (m, 4H); MS (ES+): 340.5 (M+l), 362.5 (M+Na).
[0543] Scheme 27
[0544] Preparation of N-( 1 -cyclopropyl- lH-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin- 1 - yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine (27a)
[0545] Compound 27a was prepared from 2-chloro-N-(l-cyclopropyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (26b) (70 mg, 0.26 mmol), 2-(pyrrolidin-2-yl)pyridine (1 13 mg, 0.76 mmol), and DIPEA (0.13 mL, 0.76 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, N-(l -cyclopropyl- lH-imidazol-4-yl)-2- (2-(pyridin-2-yl)pyrrolidin-l-yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (27a) (48 mg, 51 % yield) as a white solid; 1H MR (300 MHz, OMSO-de) δ 10.19 (s, 1H, D20 exchangeable), 8.59 (s, 1H), 7.78 - 7.60 (m, 1H), 7.52 - 7.43 (m, 1H), 7.41 - 7.32 (m, 1H), 7.29 - 7.1 1 (m, 2H), 7.09 - 6.99 (m, 1H), 6.93 - 6.70 (m, 1H), 6.46 - 6.26 (m, 1H), 5.43 - 5.21 (m, 1H), 3.89 - 3.70 (m, 1H), 3.42 (s, 1H), 3.37 - 3.21 (m, 1H), 2.47 - 2.29 (m, 1H), 2.12 - 1.68 (m, 3H), 1.09 - 0.87 (m, 3H), 0.88 - 0.71 (m, 1H); MS (ES+): 387.5 (M+l), 409.5 (M+Na).
[0546] Scheme 28
[0547]
[0548] Preparation of (S)-(l-(4-((l-cyclohexyl-lH-imidazol-4-yl)amino)pyrrolo[2, l-f][l,2,4]triazin- 2-yl)pyrrolidin-2-yl)methanol (28c)
[0549] Step-1 : Preparation of 2-chloro-N-(l-cyclohexyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (28b)
[0550] Compound 28b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (376 mg, 2.0 mmol) in 2-Propanol (10 mL) using DIPEA (1.05 mL, 6.0 mmol) and l-cyclohexyl-lH-imidazol-4-amine hydrochloride (28a) (572 mg, 2.4 mmol). This gave 2-chloro-N-(l-cyclohexyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (28b) (381 mg, 60 % yield) as a pale off-white colored solid; ¾ MR (300 MHz, DMSO-i¾) δ 11.68 (s, 1H), 8.76 (s, 1H), 7.86 (dd, J = 2.6, 1.5 Hz, 1H), 7.78 (d, J = 1.7 Hz, 1H), 7.36 (s, 1H), 6.79 (dd, J = 4.5, 2.6 Hz, 1H), 4.28 (ddd, J = 11.7, 7.9, 3.8 Hz, 1H), 2.10 (d, J= 11.9 Hz, 2H), 1.85 (d, J= 13.3 Hz, 2H), 1.72 (dt, J= 14.9, 11.6 Hz, 3H), 1.40 (q, J= 12.7 Hz, 2H), 1.24 (t, J= 12.5 Hz, 1H); MS (ES+): 317.3 (M+l).
[0551] Step-2: Preparation of (S)-(l-(4-((l-cyclohexyl-lH-imidazol-4-yl)amino)pyrrolo[2,l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (28c)
[0552] Compound 28c was prepared from 2-chloro-N-(l-cyclohexyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (28b) (100 mg, 0.32 mmol), (^-pyrrolidin-2-ylmethanol (160 mg, 1.56 mmol), and DIPEA (0.17 mL, 0.95 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l-cyclohexyl-lH- imidazol-4-yl)amino)pyrrolo[2, l-f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (28c) (25 mg, 21 % yield) as a pale off-white solid; ¾ MR (300 MHz, DMSO-^e) δ 10.31 (s, 1H, D20 exchangeable), 7.66 - 7.51 (m, 2H), 7.43 - 7.28 (m, 1H), 7.18 - 7.01 (m, 1H), 6.45 - 6.22 (m, 1H), 4.93 - 4.76 (m, 1H, D2O exchangeable), 4.20 - 4.07 (m, 1H), 4.07 - 3.92 (m, 1H), 3.83 - 3.65 (m, 1H), 3.54 - 3.20 (m, 3H), 2.13 - 1.84 (m, 6H), 1.89 - 1.70 (m, 4H), 1.72 - 1.54 (m, 1H), 1.47 - 1.12 (m, 3H); MS (ES+): 382.5 (M+l), 404.5 (M+Na); MS (ES-): 380.4 (M-l).
[0553] Scheme 29
[0554]
[0555] Preparation of N-(l-cyclohexyl-lH-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-l- yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine (29a)
[0556] Compound 29a was prepared from 2-chloro-N-(l-cyclohexyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (28b) (100 mg, 0.32 mmol), 2-(pyrrolidin-2-yl)pyridine (140 mg, 0.95
[0557] - I l l - mmol), and DIPEA (0.17 mL, 0.95 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, N-(l-cyclohexyl-lH-imidazol-4-yl)-2-(2- (pyridin-2-yl)pyrrolidin-l-yl)pyrrolo[2,l-f][l,2,4]triazin-4-amine (29a) (47 mg, 35 % yield) as a white solid; ¾ NMR (300 MHz, DMSO-de) δ 10.25 (s, 1H, D20 exchangeable), 8.64 - 8.52 (m, 1H), 7.67 (td, J = 7.7, 1.8 Hz, 1H), 7.49 (d, J = 1.5 Hz, 1H), 7.38 (s, 1H), 7.26 - 7.21 (m, 1H), 7.19 (d, J= 7.9 Hz, 1H), 7.08 (dd, J = 4.4, 1.7 Hz, 1H), 6.91 - 6.83 (m, 1H), 6.36 (dd, J = 4.4, 2.5 Hz, 1H), 5.33 (d, J= 8.1 Hz, 1H), 3.87 - 3.70 (m, 2H), 3.66 - 3.50 (m, 1H), 2.42 - 2.28 (m, 1H), 2.15 - 2.03 (m, 1H), 2.03 - 1.78 (m, 6H), 1.81 - 1.64 (m, 2H), 1.67 - 1.51 (m, 1H), 1.51 - 1.37 (m, 2H), 1.37 - 1.15 (m, 1H). MS (ES+): 429.6 (M+l), 451.6 (M+Na).
[0558] Scheme 30
[0559]
[0560] Preparation of N-(l-cyclopropyl-lH-imidazol-4-yl)-2-(2-phenylpyrrolidin-l-yl)pyrrolo[2,l- f][l,2,4]triazin-4-amine (30a)
[0561] Compound 30a was prepared from 2-chloro-N-(l-cyclopropyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (26b) (100 mg, 0.36 mmol), 2-phenylpyrrolidine (161 mg, 1.09 mmol), and DIPEA (0.19 mL, 1.09 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, N-(l-cyclopropyl-lH-imidazol-4-yl)-2- (2-phenylpyrrolidin-l-yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (30a) (74 mg, 53 % yield) as a pale off-white solid; ¾ NMR (300 MHz, DMSO-de) δ 10.36 (s, 1H, D2O exchangeable), 7.89 (s, 1H), 7.50 - 7.39 (m, 1H), 7.36 - 7.27 (m, 2H), 7.26 (d, J = 7.5 Hz, 2H), 7.23 - 7.16 (m, 1H), 7.08 - 6.90 (m, 2H), 6.40 (dd, J= 4.4, 2.4 Hz, 1H), 5.33 (d, J= 7.9 Hz, 1H), 4.00 - 3.29 (m, 3H), 2.41 - 2.21 (m, 1H), 2.05 - 1.73 (m, 3H), 1.11 - 0.76 (m, 4H). MS (ES+): 386.5 (M+l), 408.5 (M+Na). Scheme 31
[0562]
[0563] Preparation of (S)-(l-(4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2- yl)pyrrolidin-2-yl)methanol (31c)
[0564] Step-1 : Preparation of 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)thieno[2,3-d]pyrimidin-4- amine (31b)
[0565] Compound 31b was prepared according to the procedure reported in Scheme 1 from 2,4- dichlorothieno[2,3-d]pyrimidine (31a) (500 mg, 2.44 mmol; CAS # 18740-39-1) in 2-Propanol (10 mL) using DIPEA (1.70 mL, 9.75 mmol) and l-phenyl-lH-imidazol-4-amine, HC1 (8a) (716 mg, 3.66 mmol). This gave 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)thieno[2,3- d]pyrimidin-4-amine (31b) (640 mg, 80 % yield) as a light pink solid; 1H NMR (300 MHz, OMSO-de) δ 11.06 (s, 1H, D20 exchangeable), 8.26 (d, J = 1.7 Hz, 1H), 8.04 (d, J = 5.6 Hz,
[0566] 1H), 7.94 (d, J = 1.6 Hz, 1H), 7.71 (d, J = 5.9 Hz, 1H), 7.69 - 7.63 (m, 2H), 7.62 - 7.54 (m, 2H), 7.46 - 7.36 (m, 1H); MS (ES+): 328.2 (M+l), 350.2 (M+Na), (ES-): 326.2 (M-l).
[0567] Step-2: Preparation of (S)-(l-(4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin- 2-yl)pyrrolidin-2-yl)methanol (31 c)
[0568] Compound 31c was prepared from 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)thieno[2,3- d]pyrimidin-4-amine (31b) (100 mg, 0.31 mmol), (^-pyrrolidin-2-ylmethanol (93 mg, 0.92 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHC03, (S)-( 1 -(4-(( 1 -phenyl- lH-imidazol-4-yl)amino)thieno[2,3 -d]pyrimidin-2- yl)pyrrolidin-2-yl)methanol (31c) (95 mg, 79 % yield) as a light brown solid;ln NMR (300 MHz, OMSO-de) δ 10.16 (s, 1H, D20 exchangeable), 8.22 (s, 1H), 7.99 (d, J = 1.7 Hz, 1H),
[0569] 7.89 - 7.59 (m, 2H), 7.60 - 7.42 (m, 3H), 7.35 (t, J = 7.3 Hz, 1H), 7.03 (d, J = 6.0 Hz, 1H), 4.96 (s, 1H, D20 exchangeable), 4.46 - 4.00 (m, 1H), 3.95 - 3.36 (m, 4H), 2.17 - 1.82 (m, 4H); MS
[0570] (ES+): 393.5 (M+l), 415.5 (M+Na), (ES-): 391.4 (M-l). Scheme 32
[0571]
[0572] Preparation of (S)-(l-(4-((l-phenyl-lH-imidazol-4-yl)amino)quinazolin-2-yl)pyrrolidin-2- yl)methanol (32a)
[0573] Compound 32a was prepared from 2-chloro-N-(l -phenyl- lH-imidazol-4-yl)quinazolin-4- amine (24a) (100 mg, 0.31 mmol), (S)-pyrrolidin-2-ylmethanol (94 mg, 0.93 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l-phenyl-lH-imidazol-4-yl)amino)quinazolin-2-yl)pyrrolidin-2- yl)methanol (32a) (75 mg, 62 % yield) as light brown solid;lH MR (300 MHz, DMSO-i%) δ 10.49 - 10.15 (m, 1H, D20 exchangeable), 8.48 (d, J = 8.2 Hz, 1H), 8.25 (s, 1H), 8.07 (s,
[0574] 1H), 7.93 - 7.63 (m, 3H), 7.61 - 7.43 (m, 2H), 7.43 - 7.24 (m, 2H), 7.09 (t, J = 7.5 Hz, 1H), 5.16 - 4.88 (m, 1H, D20 exchangeable), 4.49 - 4.14 (m, 1H), 3.93 - 3.56 (m, 3H), 3.54 - 3.36
[0575] (m, 1H), 2.19 - 1.79 (m, 4H); MS (ES+): 387.4 (M+l), (ES-): 385.3 (M-l).
[0576] Scheme 33
[0577]
[0578] Preparation of N-(l-phenyl-lH-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-l-yl)furo[3,2- d]pyrimidin-4-amine (33a)
[0579] Compound 33a was prepared from 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)furo[3,2- d]pyrimidin-4-amine (14a) (100 mg, 0.32 mmol), 2-(pyrrolidin-2-yl)pyridine hydrochloride (148 mg, 0.8 mmol), and DIPEA (0.22 niL, 1.28 mmol) in NMP (1 niL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, N-(l-phenyl-lH-imidazol-4- yl)-2-(2-(pyridin-2-yl)pyrrolidin-l-yl)furo[3,2-d]pyrimidin-4-amine (33a) (61 mg, 45 % yield) as a light brown solid;lH NMR (300 MHz, DMSO-i%) δ 10.03 (s, 1H, D20 exchangeable), 8.26 (s, 1H), 8.17 - 7.90 (m, 2H), 7.80 - 7.45 (m, 5H), 7.39 (p, J = 8.5, 4.2 Hz, 1H), 7.35 - 7.18 (m, 1H), 7.11 (d, J = 7.7 Hz, 2H), 6.77 (s, 1H), 5.39 (s, 1H), 4.01 - 3.82 (m, 1H), 3.79 - 3.54 (m, 1H), 2.45 - 2.28 (m, 1H), 2.11 - 1.88 (m, 2H), 1.88 - 1.71 (m, 1H); MS (ES+): 424.5 (M+l), 446.5 (M+Na).
[0580] Scheme 34
[0581]
[0582] Preparation of N-(l-methyl-lH-imidazol-4-yl)-2-(4-methylpiperazin-l-yl)pyrrolo[2, 1- f][l,2,4]triazin-4-amine (34a)
[0583] Compound 34a was prepared from 2-chloro-N-(l-methyl-lH-imidazol-4-yl)pyrrolo[l,2- f][l,2,4]triazin-4-amine (4b) (100 mg, 0.4 mmol), 1-methylpiperazine (0.13 mL, 1.21 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, N-(l -methyl- lH-imidazol-4-yl)-2-(4-methylpiperazin- 1 -yl)pyrrolo[2, 1 - f][l,2,4]triazin-4-amine (34a) (37 mg, 30 % yield) as an off-white solid; 1H NMR (300 MHz, DMSO-i%) δ 10.32 (s, 1H, D20 exchangeable), 7.49 (d, J = 1.4 Hz, 1H), 7.37 (t, J = 2.1 Hz,
[0584] 1H), 7.30 (d, J = 1.6 Hz, 1H), 7.11 (s, 1H), 6.41 (dd, J= 4.5, 2.5 Hz, 1H), 3.69 (s, 3H), 3.55 (t, J= 4.9 Hz, 4H), 2.41 (q, J= 5.0 Hz, 4H), 2.22 (s, 3H); MS (ES+): 313.4 (M+l), 325.4 (M+Na).
[0585] Scheme 35
[0586] Preparation of 2-(4-methylpiperazin-l-yl)-N-(l-phenyl-lH-imidazol-4-yl)pyrrolo[2, 1- f][l,2,4]triazin-4-amine (35a)
[0587] Compound 35a was prepared from 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (8b) (100 mg, 0.32 mmol), 1-methylpiperazine (0.11 mL, 0.97 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, 2-(4-methylpiperazin- 1 -yl)-N-( 1 -phenyl- lH-imidazol-4-yl)pyrrolo[2, 1 - f][l,2,4]triazin-4-amine (35a) (16 mg, 13% yield) as a brown solid; ΪΗ NMR (300 MHz, DMSO-i%) δ 10.59 (s, 1H, D20 exchangeable), 8.23 (d, J = 1.6 Hz, 1H), 7.83 (d, J = 1.6 Hz, 1H), 7.63 (dd, J = 8.5, 1.5 Hz, 2H), 7.56 (dd, J = 8.7, 7.1 Hz, 2H), 7.45 - 7.39 (m, 1H), 7.39 - 7.34 (m, 1H), 7.16 (d, J= 4.3 Hz, 1H), 6.45 (dd, J = 4.4, 2.5 Hz, 1H), 3.66 - 3.52 (m, 4H), 2.50 - 2.36 (m, 4H), 2.23 (s, 3H); MS (ES+): 375.5 (M+l).
[0588]
[0589] Preparation of (S)-(l-(4-((l-(2-fluorophenyl)-lH-imidazol-4-yl)amino)pyrrolo[2, 1- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (36c)
[0590] Step-1 : Preparation of 2-chloro-N-(l-(2-fluorophenyl)-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (36b)
[0591] Compound 36b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (260 mg, 1.38 mmol) in 2-Propanol (20 mL) using DIPEA (0.73 mL, 4.15 mmol) and l-(2-fluorophenyl)-lH-imidazol-4-amine hydrochloride (36a) (450 mg, 1.8 mmol). This gave 2-chloro-N-(l-(2-fluorophenyl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (36b) (125 mg, 28 % yield) as a pale-off colored solid; ¾ NMR (300 MHz, DMSO-i¾) δ 11.40 (s, 1H, D20 exchangeable), 8.08 (t, J = 1.5 Hz, 1H), 7.83 (t, J = 1.9 Hz, 1H), 7.77 (dd, J = 2.6, 1.5 Hz, 2H), 7.73 (td, J = 7.9, 1.6 Hz, 1H), 7.59 - 7.46 (m, 2H), 7.40 (ddd, J= 9.1, 6.0, 2.0 Hz, 2H);19F MR (282 MHz, DMSO-i¾) δ -125.09; MS (ES+): 329.3 (M+1); MS (ES-): 363.4 (M+Cl).
[0592] Step-2: Preparation of (S)-(l-(4-((l-(2-fluorophenyl)-lH-imidazol-4-yl)amino)pyrrolo[2,l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (36c)
[0593] Compound 36c was prepared from 2-chloro-N-(l-(2-fluorophenyl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (36b) (70 mg, 0.21 mmol), (S^-pyrrolidin-2-ylmethanol (108 mg, 1.07 mmol), and DIPEA (0.11 mL, 0.64 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l-(2-fluorophenyl)- lH-imidazol-4-yl)amino)pyrrolo[2, l-f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (36c) (45 mg, 54 % yield) as a light yellow solid; ¾ NMR (300 MHz, DMSO-^e) δ 10.56 (s, 1H, D2O exchangeable), 8.02 (t, J= 1.8 Hz, 1H), 7.87 (t, J= 1.7 Hz, 1H), 7.76 (td, J= 7.9, 1.7 Hz, 1H), 7.55 - 7.41 (m, 2H), 7.40 - 7.31 (m, 2H), 7.15 (dd, J= 4.5, 1.7 Hz, 1H), 6.39 (dd, J= 4.4, 2.4 Hz, 1H), 4.74 (t, J= 5.2 Hz, 1H, D2O exchangeable), 4.20 - 4.04 (m, 1H), 3.72 - 3.62 (m, 1H), 3.54 - 3.44 (m, 1H), 3.46 - 3.26 (m, 2H), 2.08 - 1.79 (m, 4H);19F NMR (282 MHz, DMSO- de) δ -125.10; MS (ES+): 394.5 (M+1); 416.5 (M+Na); MS (ES-): 392.5 (M-1), 428.5 (M+Cl).
[0594]
[0595] Preparation of N-(l-cyclobutyl-lH-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-l- yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine (37c)
[0596] Step-1 : Preparation of 2-chloro-N-(l-cyclobutyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (37b) Compound 37b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (350 mg, 1.86 mmol) in 2-Propanol (20 mL) using DIPEA (0.98 mL, 5.58 mmol) and l-cyclobutyl-lH-imidazol-4-amine hydrochloride (37a) (420 mg, 2.42 mmol). This gave 2-chloro-N-(l-cyclobutyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (37b) (348 mg, 65 % yield) as a yellowish solid; ¾ NMR (300 MHz, DMSO-i¾) δ 11.16 (s, 1H, D20 exchangeable), 7.83 - 7.62 (m, 2H), 7.53 (d, J= 1.6 Hz, 1H), 7.35 (dd, J= 4.5, 1.6 Hz, 1H), 6.68 (dd, J = 4.4, 2.6 Hz, 1H), 4.88 - 4.61 (m, 1H), 2.55 - 2.19 (m, 4H), 1.96 - 1.64 (m, 2H); MS (ES+): 289.3 (M+l), 311.3 (M+Na); MS (ES-): 287.3 (M- 1).
[0597] Step-2: Preparation of N-(l-cyclobutyl-lH-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-l- yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine (37c)
[0598] Compound 37c was prepared from 2-chloro-N-(l-cyclobutyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (37b) (70 mg, 0.24 mmol), 2-(pyrrolidin-2-yl)pyridine (108 mg, 0.73 mmol), and DIPEA (0.13 mL, 0.73 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, N-(l-cyclobutyl-lH-imidazol-4-yl)-2-(2- (pyridin-2-yl)pyrrolidin-l-yl)pyrrolo[2,l-f][l,2,4]triazin-4-amine (37c) (65 mg, 67 % yield) as a light yellow solid; ¾ NMR (300 MHz, DMSO-^e) δ 10.27 (s, 1H, D2O exchangeable), 8.59 (d, J = 4.8 Hz, 1H), 7.67 (t, J = 7.7 Hz, 1H), 7.56 (s, 1H), 7.38 (s, 1H), 7.29 - 7.12 (m, 2H),
[0599] 7.08 (d, J = 4.4 Hz, 1H), 7.05 - 6.93 (m, 1H), 6.42 - 6.30 (m, 1H), 5.35 (d, J = 8.2 Hz, 1H), 4.55 (q, J= 8.6 Hz, 1H), 3.90 - 3.75 (m, 1H), 3.71 - 3.54 (m, 1H), 2.45 - 2.26 (m, 4H), 2.26 -
[0600] 2.09 (m, 1H), 2.12 - 1.99 (m, 1H), 2.02 - 1.88 (m, 1H), 1.89 - 1.69 (m, 3H). MS (ES+): 401.5 (M+l); 423.5 (M+Na).
[0601] Scheme 38
[0602] Preparation of (S)-(l -(4-(( 1 -(quinolin-3 -yl)- lH-imidazol-4-yl)amino)pyrrolo[2, 1 - f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (38c)
[0603] Step-1 : Preparation of 2-chloro-N-(l-(quinolin-3-yl)-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (38b)
[0604] Compound 38b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (384 mg, 2.04 mmol) in 2-Propanol (20 mL) using DIPEA (1.07 mL, 6.12 mmol) and 1 l -(quinolin-3-yl)-lH-imidazol-4-amine hydrochloride (38a) (730 mg, 2.96 mmol). This gave 2-chloro-N-(l-(quinolin-3-yl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (38b) (264 mg, 36 % yield) as a pale off-white colored solid; ¾ NMR (300 MHz, OMSO-de) δ 1 1.41 (s, 1H), 9.30 (d, J = 2.7 Hz, 1H), 8.68 (d, J = 2.6 Hz, 1H), 8.47 (d, J = 1.6 Hz, 1H), 8.16 - 8.06 (m, 3H), 7.88 - 7.76 (m, 2H), 7.71 (t, J = 7.4 Hz, 1H), 7.42 (d, J = 4.3 Hz, 1H), 6.74 (dd, J = 4.5, 2.6 Hz, 1H); ¾ NMR (300 MHz, DMSO- de / OiO) δ 9.24 (d, J = 2.5 Hz, 1H), 8.63 (d, J = 2.6 Hz, 1H), 8.41 (s, 1H), 8.16 - 8.00 (m, 3H), 7.80 (t, J = 7.7 Hz, 1H), 7.75 (d, J = 2.0 Hz, 1H), 7.69 (t, J = 7.5 Hz, 1H), 7.36 (s, 1H), 6.72 (dd, J = 4.4, 2.5 Hz, 1H); MS (ES+): 362.3 (M+l), 384.3 (M+Na); MS (ES-): 360.2 (M-l). Step-2: Preparation of (S)-(l-(4-((l-(quinolin-3-yl)-lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (38c)
[0605] Compound 38c was prepared from 2-chloro-N-(l-(quinolin-3-yl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (38b) (100 mg, 0.28 mmol), (S)-pyrrolidin-2- ylmethanol (140 mg, 1.38 mmol), and DIPEA (0.15 mL, 0.83 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l- (quinolin-3 -yl)- lH-imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2- yl)methanol (38c) (66 mg, 56 % yield) as a yellow solid; ¾ NMR (300 MHz, OMSO-de) δ 10.63 (s, 1H, D20 exchangeable), 9.42 (d, 7 = 2.7 Hz, 1H), 8.81 (d, 7 = 2.6 Hz, 1H), 8.53 (d, 7 = 1.5 Hz, 1H), 8.15 (d, 7 = 1.6 Hz, 1H), 8.12 - 8.00 (m, 2H), 7.79 (ddd, 7 = 8.4, 6.9, 1.6 Hz, 1H), 7.69 (td, 7 = 7.5, 6.9, 1.3 Hz, 1H), 7.41 (dd, 7 = 2.4, 1.7 Hz, 1H), 7.18 (dd, 7 = 4.4, 1.7 Hz, 1H), 6.41 (dd, 7 = 4.5, 2.4 Hz, 1H), 5.28 - 5.16 (m, 1H, D2O exchangeable), 4.37 - 4.18 (m, 1H), 3.93 - 3.79 (m, 1H), 3.56 - 3.40 (m, 1H), 3.45 - 3.20 (m, 2H), 2.21 - 1.72 (m, 4H). MS (ES+): 427.5 (M+l); 449.5 (M+Na).
[0606] Scheme 39
[0607] Preparation of (S)-(l-(4-((l-(pyridin-3-yl)-lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (39c)
[0608] Step-1 : Preparation of 2-chloro-N-(l-(pyridin-3-yl)-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (39b)
[0609] Compound 39b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (500 mg, 2.66 mmol) in 2-Propanol (20 mL) using DIPEA (1.39 mL, 7.98 mmol) and l-(pyridin-3-yl)-lH-imidazol-4-amine (39a) (511 mg, 3.19 mmol). This gave 2-chloro-N-(l-(pyridin-3-yl)-lH-imidazol-4-yl)pyrrolo[2,l-f][l,2,4]triazin- 4-amine (39b) (728 mg, 88 % yield) as a brownish solid; ¾ MR (300 MHz, OMSO-de) δ 11.38 (s, 1H, D20 exchangeable), 8.96 (d, J= 2.7 Hz, 1H), 8.61 (dd, J= 4.7, 1.4 Hz, 1H), 8.35 (d, J= 1.6 Hz, 1H), 8.13 (ddd, J= 8.3, 2.8, 1.4 Hz, 1H), 7.97 (d, J= 1.6 Hz, 1H), 7.78 (dd, J = 2.6, 1.5 Hz, 1H), 7.61 (dd, J= 8.3, 4.7 Hz, 1H), 7.47 - 7.35 (m, 1H), 6.73 (dd, J= 4.5, 2.6 Hz, 1H); MS (ES+): 312.3 (M+l); MS (ES-): 310.4 (M-l).
[0610] Step-2: Preparation of (S)-(l-(4-((l-(pyridin-3-yl)-lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (39c)
[0611] Compound 39c was prepared from 2-chloro-N-(l-(pyridin-3-yl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (39b) (100 mg, 0.32 mmol), (Sj-pyrrolidin-2- ylmethanol (162 mg, 1.60 mmol), and DIPEA (0.17 mL, 0.96 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l- (pyridin-3-yl)-lH-imidazol-4-yl)amino)pyrrolo[2,l-f][l,2,4]triazin-2-yl)pyrrolidin-2- yl)methanol (39c) (60 mg, 50 % yield) as a brownish solid; ¾ MR (300 MHz, DMSO-d) δ 10.59 (s, 1H, D2O exchangeable), 9.04 (d, J= 2.7 Hz, 1H), 8.55 (dd, J= 4.7, 1.3 Hz, 1H), 8.35 (d, J = 1.5 Hz, 1H), 8.25 - 8.14 (m, 1H), 8.01 (d, J = 1.6 Hz, 1H), 7.54 (dd, J = 8.3, 4.7 Hz, lH), 7.40 (t, J= 2.1 Hz, 1H), 7.16 (dd, J= 4.4, 1.7 Hz, 1H), 6.40 (dd, J= 4.4, 2.5 Hz, 1H), 5.13 - 4.74 (m, 1H, D2O exchangeable), 4.28 - 4.13 (m, 1H), 3.77 (dd, J= 10.1, 3.4 Hz, 1H), 3.55 - 3.44 (m, 1H), 3.46 - 3.25 (m, 2H), 2.18 - 1.77 (m, 4H). MS (ES+): 377.5 (M+l); 399.5 (M+Na).
[0612] Scheme 40
[0613]
[0614] Preparation of N-(l -phenyl- lH-imidazol-4-yl)-2-(2-phenylpyrrolidin-l-yl)furo[3, 2- d]pyrimidin-4-amine (40a)
[0615] Compound 40a was prepared from 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)furo[3,2- d]pyrimidin-4-amine (14a) (100 mg, 0.32 mmol), 2-phenylpyrrolidine (118 mg, 0.8 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, N-(l-phenyl-lH-imidazol-4-yl)-2-(2-phenylpyrrolidin-l-yl)furo[3,2-d]pyrimidin-4- amine (40a) (18 mg, 13 % yield) as a light yellow solid; 1H NMR (300 MHz, DMSO-i¾) δ
[0616] 10.04 (s, 1H, D20 exchangeable), 8.19 - 7.83 (m, 2H), 7.66 - 7.50 (m, 2H), 7.54 - 7.25 (m,
[0617] 2H), 7.26 - 7.14 (m, 3H), 7.16 - 7.00 (m, 4H), 6.74 (s, 1H), 5.41 (s, 1H), 3.99 - 3.57 (m, 2H), 2.40 - 2.24 (m, 1H), 1.98 - 1.63 (m, 3H); MS (ES+) 423.5 (M+l), 445.5 (M+Na).
[0618] Scheme 41
[0619]
[0620] Preparation of (S)-(l-(7-methyl-4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[3,2- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (41c) Step-1 : Preparation of 2-chloro-7-methyl-N-(l-phenyl-lH-imidazol-4-yl)thieno[3,2- d]pyrimidin-4-amine (41b)
[0621] Compound 41b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloro-7-methylthieno[3,2-d]pyrimidine (41a) (500 mg, 2.28 mmol; CAS # 35265-83-9) and DIPEA (1.59 mL, 9.13 mmol) in 2-Propanol (10 mL) using 1 -phenyl- lH-imidazol-4-amine, HCI (8a) (558 mg, 2.85 mmol). This gave 2-chloro-7-methyl-N-(l -phenyl- lH-imidazol-4- yl)thieno[3,2-d]pyrimidin-4-amine (41b) (350 mg, 45 % yield) as an off-white solid; iH NMR (300 MHz, DMSO-i¾) δ 10.72 (s, 1H, D20 exchangeable), 8.27 (d, J = 1.6 Hz, 1H), 7.95 (d, J
[0622] = 1.6 Hz, 1H), 7.89 (s, 1H), 7.72 - 7.63 (m, 2H), 7.57 (dd, J= 8.6, 7.1 Hz, 2H), 7.46 - 7.36 (m, 1H), 2.31 (d, J= 1.2 Hz, 3H); MS (ES+): 342.3 (M+l), 364.3 (M+Na), (ES-): 340.3 (M-l). Step-2: Preparation of (S)-(l-(7-methyl-4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[3,2- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (41c)
[0623] Compound 41c was prepared from 2-chloro-7-methyl-N-(l-phenyl-lH-imidazol-4- yl)thieno[3,2-d]pyrimidin-4-amine (41b) (100 mg, 0.29 mmol) and (^-pyrrolidin-2- ylmethanol (89 mg, 0.88 mmol), in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(7-methyl-4-((l-phenyl-lH-imidazol-4- yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (41c) (82 mg, 69 % yield) as an off-white solid; ^ NMR (300 MHz, DMSO-i%) δ 10.08 (s, 1H, D20 exchangeable), 8.20
[0624] (d, J = 1.5 Hz, 1H), 7.99 (d, J= 1.6 Hz, 1H), 7.71 (s, 2H), 7.57 (d, J= 1.3 Hz, 1H), 7.51 (t, J = 7.7 Hz, 2H), 7.35 (t, J = 7.4 Hz, 1H), 5.65 - 4.81 (m, 1H, D20 exchangeable), 4.26 (s, 1H),
[0625] 3.86 - 3.52 (m, 2H), 3.51 - 3.24 (m, 2H), 2.22 (d, J = 1.2 Hz, 3H), 2.11 - 1.81 (m, 4H); MS (ES+): 407.5 (M+l), 429.5 (M+Na), (ES-): 405.5 (M-l).
[0626] Scheme 42
[0627] Preparation of (S)-(l-(4-((l-(4-fluorophenyl)-lH-imidazol-4-yl)amino)-6-methylthieno[3,2- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (42b)
[0628] Step-1 : Preparation of 2-chloro-N-(l-(4-fluorophenyl)-lH-imidazol-4-yl)-6-methylthieno[3,2- d]pyrimidin-4-amine (42a)
[0629] Compound 42a was prepared according to the procedure reported in Scheme 1 from 2,4- dichloro-6-methylthieno[3,2-d]pyrimidine (23a) (302 mg, 1.38 mmol) in 2-Propanol (10 mL) using DIPEA (0.96 mL, 5.51 mmol), l-(4-fluorophenyl)-lH-imidazol-4-amine hydrochloride (25a) (368 mg, 1.72 mmol). This gave 2-chloro-N-(l-(4-fluorophenyl)-lH-imidazol-4-yl)-6- methylthieno[3,2-d]pyrimidin-4-amine (42a) (100 mg, 21 % yield) as a dark brown solid; 1H NMR (300 MHz, DMSO-i%) δ 10.74 (s, 1H, D20 exchangeable), 8.22 (d, J = 1.6 Hz, 1H),
[0630] 7.88 (d, J = 1.6 Hz, 1H), 7.76 - 7.67 (m, 2H), 7.48 - 7.37 (m, 2H), 7.13 (d, J = 1.3 Hz, 1H),
[0631] 2.60 (s, 3H);19F NMR (282 MHz, DMSO-i¾) δ -115.30; MS (ES+): 382.4 (M+Na), (ES-):
[0632] 358.3 (M-l).
[0633] Step-2: Preparation of (S)-(l-(4-((l-(4-fluorophenyl)-lH-imidazol-4-yl)amino)-6- methylthieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (42b)
[0634] Compound 42b was prepared from 2-chloro-N-(l-(4-fluorophenyl)-lH-imidazol-4-yl)-6- methylthieno[3,2-d]pyrimidin-4-amine (42a) (90 mg, 0.25 mmol) and (^-pyrrolidin-2- ylmethanol (89 mg, 0.88 mmol), in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l-(4-fluorophenyl)-lH-imidazol-4- yl)amino)-6-methylthieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (42b) (27 mg, 25 % yield) as a brown solid; !H NMR (300 MHz, DMSO-i%) δ 9.95 (s, 1H, D20 exchangeable), 8.14 (d, J= 1.6 Hz, 1H), 7.92 (d, J= 1.7 Hz, 1H), 7.86 - 7.62 (m, 2H), 7.35 (t, J= 8.6 Hz, 2H), 6.83 (d, J= 1.3 Hz, 1H), 5.06 (s, 1H, D20 exchangeable), 4.37 - 4.01 (m, 1H), 3.89 - 3.68 (m,
[0635] 1H), 3.68 - 3.44 (m, 3H), 2.52 (d, J = 1.1 Hz, 3H), 2.16 - 1.72 (m, 4H);19F NMR (282 MHz, DMSO-i¾) δ -73.43; MS (ES+): 425.4 (M+l), 447.4 (M+Na), (ES-): 423.4 (M-l).
[0636] Scheme 43
[0637] Preparation of (S)-( 1 -(4-(( 1 -cyclobutyl- lH-imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin- 2-yl)pyrrolidin-2-yl)methanol (43a)
[0638] Compound 43a was prepared from 2-chloro-N-(l-cyclobutyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (37b) (100 mg, 0.35 mmol) and (^-pyrrolidin-2-ylmethanol (175 mg, 1.73 mmol) and DIPEA (0.18 mL, 1.04 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by flash chromatography (silica gel 24 g, eluting with CMA-80 in Chloroform 0-40%) (S)-(l-(4-((l-cyclobutyl-lH-imidazol- 4-yl)amino)pyrrolo[2, l-f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (43a) (67 mg, 55 % yield) as a yellow solid; ¾ NMR (300 MHz, OMSO-de) δ 10.33 (s, 1H, D20 exchangeable), 7.67 - 7.56 (m, 2H), 7.42 - 7.29 (m, 1H), 7.09 (dd, J= 4.4, 1.7 Hz, 1H), 6.36 (dd, J= 4.4, 2.4 Hz, 1H), 4.97 - 4.76 (m, 1H, D2O exchangeable), 4.69 (p, J = 8.5 Hz, 1H), 4.29 - 4.05 (m, 1H), 3.84 - 3.67 (m, 1H), 3.55 - 3.42 (m, 1H), 3.41 - 3.19 (m, 2H), 2.52 - 2.28 (m, 4H), 2.12 - 1.83 (m, 4H), 1.83 - 1.62 (m, 2H);19F NMR (282 MHz, DMSO) δ -73.48; MS (ES+): 354.5 (M+l); 376.5 (M+Na); MS (ES-): 352.4 (M-l).
[0639] Scheme 44
[0640]
[0641] Preparation of (S)-(l-(4-((l-(3-fluorophenyl)-lH-imidazol-4-yl)amino)pyrrolo[2, 1- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (44c)
[0642] Step-1 : Preparation of 2-chloro-N-(l-(3-fluorophenyl)-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (44b)
[0643] Compound 44b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (254 mg, 1.35 mmol) in 2-Propanol (20 mL) using DIPEA (0.71 niL, 4.06 mmol) and l-(3-fluorophenyl)-lH-imidazol-4-amine hydrochloride (44a) (440 mg, 1.76 mmol). This gave 2-chloro-N-(l-(3-fluorophenyl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (44b) (343 mg, 77 % yield) as a pale-off colored solid; ¾ NMR (300 MHz, DMSO-d6) δ 11.35 (s, 1H, D20 exchangeable), 8.33 (d, J = 1.6 Hz, 1H), 7.95 (d, J = 1.6 Hz, 1H), 7.78 (dd, J = 2.6, 1.5 Hz, 1H), 7.67 (dt, J = 10.1, 2.1 Hz, 1H), 7.63 - 7.57 (m, 1H), 7.55 - 7.49 (m, 1H), 7.44 - 7.37 (m, 1H), 7.30 - 7.20 (m, 1H), 6.73 (dd, J = 4.5, 2.6 Hz, 1H); MS (ES+): 329.3 (M+1), 351.3 (M+Na); MS (ES-): 327.3 (M-l).
[0644] Step-2: Preparation of (S)-(l-(4-((l-(3-fluorophenyl)-lH-imidazol-4-yl)amino)pyrrolo[2,l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (44c)
[0645] Compound 44c was prepared from 2-chloro-N-(l-(3-fluorophenyl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (44b) (100 mg, 0.3 mmol), (^-pyrrolidin-2-ylmethanol (154 mg, 1.52 mmol), and DIPEA (0.16 mL, 0.91 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb followed by flash chromatography [silica gel (24 g), eluting with CMA-80 in chloroform, 0 to 40%], (S)-(l-(4- ((l-(3-fluorophenyl)-lH-imidazol-4-yl)amino)pyrrolo[2, l-f][l,2,4]triazin-2-yl)pyrrolidin-2- yl)methanol (44c) (30 mg, 25 % yield) as a white solid; ¾ NMR (300 MHz, OMSO-de) δ 10.54 (s, 1H, D2O exchangeable), 8.33 (d, J = 1.6 Hz, 1H), 7.97 (d, J = 1.6 Hz, 1H), 7.81 - 7.70 (m, 1H), 7.69 - 7.60 (m, 1H), 7.58 - 7.46 (m, 1H), 7.40 (dd, J= 2.4, 1.7 Hz, 1H), 7.23 - 7.13 (m, 2H), 6.39 (dd, J = 4.4, 2.5 Hz, 1H), 5.07 - 4.90 (m, 1H, D2O exchangeable), 4.26 - 4.12 (m, 1H), 3.85 - 3.67 (m, 1H), 3.56 - 3.43 (m, 1H), 3.44 - 3.22 (m, 2H), 2.22 - 1.75 (m, 4H);19F NMR (282 MHz, DMSO) δ -110.92; MS (ES+): 394.5 (M+1); 416.5 (M+Na); MS (ES-): 392.4 (M-l).
[0646] Scheme 45
[0647]
[0648] Preparation of 2-(2,6-difluoro-4-methoxyphenyl)-l-(4-(4-((l -phenyl- lH-imidazol-4- yl)amino)thieno[2,3 -d]pyrimidin-2-yl)piperazin- 1 -yl)ethanone (45d)
[0649] Step-1 : Preparation of tert-butyl 4-(2-(2,6-difluoro-4-methoxyphenyl)acetyl)piperazine-l- carboxylate (45b)
[0650] To a stirred suspension of tert-butyl piperazine-l-carboxylate (1 g, 5.37 mmol), 2-(2,6- difluoro-4-methoxyphenyl)acetic acid (45a) (1.09 g, 5.37 mmol; CAS # 886498-98-2), EDC (1.24 g, 6.44 mmol), in acetonitrile (15 mL) and DMF (1 mL) was added TEA (2.25 mL, 16.11 mmol) and DMAP (33 mg, 0.27 mmol) and stirred at room temperature for 16 h. The reaction was concentrated to remove acetonitrile and diluted with ethyl acetate (100 mL), washed with IN KHSO4 (2 x 20 mL), saturated sodium bicarbonate (2 x 20 mL), water (20 mL), brine (20 mL), dried and concentrated to afford tert-butyl 4-(2-(2,6-difluoro-4- methoxyphenyl)acetyl)piperazine-l-carboxylate (45b) (1.00 g, 50 % yield) as a colorless solid;
[0651] !H NMR (300 MHz, DMSO-i%) δ 6.72 (s, 1H), 6.69 (d, J= 1.4 Hz, 1H), 3.77 (s, 3H), 3.66 (s,
[0652] 2H), 3.57 (t, J= 5.3 Hz, 2H), 3.49 - 3.24 (m, 6H), 1.41 (s, 9H); MS (ES+): 393.5 (+Na) (ES-): 369.3 (M-l).
[0653] Step-2: Preparation of 2-(2,6-difluoro-4-methoxyphenyl)-l-(piperazin-l-yl)ethanone 2,2,2- trifluoroacetate (45c)
[0654] To a stirred solution of tert-butyl 4-(2-(2,6-difluoro-4-methoxyphenyl)acetyl)piperazine-l- carboxylate (45b) (0.95 g, 2.56 mmol) in Dichloromethane (20 mL) was added TFA (1.98 mL, 25.6 mmol) at room temperature and stirred overnight at room temperature. The reaction was concentrated in vacuum to afford 2-(2,6-difluoro-4-methoxyphenyl)-l-(piperazin-l- yl)ethanone 2,2,2-trifluoroacetate (45c) (800 mg, 81 % yield) as an oil;ιϊί NMR (300 MHz, DMSO-i%) δ 8.94 (s, 2H), 6.88 - 6.43 (m, 2H), 3.77 (s, 5H), 3.72 (s, 2H), 3.63 (d, J = 5.6 Hz,
[0655] 2H), 3.14 (d, J = 27.6 Hz, 4H);19F NMR (282 MHz, DMSO-i¾) δ -74.66, -112.12 - -120.42
[0656] (m); MS (ES+) 271.3 (M+l), 293.3 (M+Na), 541.6 (2M+1), 563.5 (2M+Na).
[0657] Step-3 : Preparation of 2-(2,6-difluoro-4-methoxyphenyl)-l-(4-(4-((l-phenyl-lH-imidazol-4- yl)amino)thieno[2,3 -d]pyrimidin-2-yl)piperazin- 1 -yl)ethanone (45d)
[0658] Compound 45d was prepared from 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)thieno[2,3- d]pyrimidin-4-amine (31b) (100 mg, 0.31 mmol), 2-(2,6-difluoro-4-methoxyphenyl)-l- (piperazin-l-yl)ethanone 2,2,2-trifluoroacetate (45c) (371 mg, 0.97 mmol) and DIPEA (0.28 mL, 1.61 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, 2-(2,6-difluoro-4-methoxyphenyl)-l-(4-(4-((l -phenyl- lH-imidazol -4- yl)amino)thieno[2,3-d]pyrimidin-2-yl)piperazin-l-yl)ethanone (45d) (43 mg, 24 % yield) as an off-white solid; ^H NMR (300 MHz, DMSO-i¾) δ 10.30 (s, 1H, D20 exchangeable), 8.29
[0659] (d, J = 1.7 Hz, 1H), 7.87 (d, J = 1.7 Hz, 1H), 7.81 (d, J = 6.0 Hz, 1H), 7.70 - 7.64 (m, 2H), 7.57 (t, J= 7.9 Hz, 2H), 7.43 - 7.34 (m, 1H), 7.15 (d, J= 6.0 Hz, 1H), 6.71 (d, J= 9.5 Hz, 2H), 3.93 - 3.85 (m, 2H), 3.85 - 3.78 (m, 4H), 3.77 (s, 3H), 3.76 - 3.70 (m, 2H), 3.65 - 3.56 (m, 2H);
[0660] 19F NMR (282 MHz, DMSO-i%) δ -113.98; MS (ES+): 562.6 (M+l), 584.6 (M+Na).
[0661] Scheme 46
[0662]
[0663] Preparation of (S)-N-(l-cyclohexyl-lH-imidazol-4-yl)-2-(2-phenylpyrrolidin-l- yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine (46a)
[0664] Compound 46a was prepared from 2-chloro-N-(l-cyclohexyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (28b) (72 mg, 0.23 mmol), (S)-2-phenylpyrrolidine hydrochloride (50 mg, 0.27 mmol) and DIPEA (0.12 mL, 0.68 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-N-(l-cyclohexyl-lH- imidazol-4-yl)-2-(2-phenylpyrrolidin-l-yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (46a) (13 mg, 13 % yield) as a pale off-white solid; ¾ NMR (300 MHz, DMSO-^e) δ 10.42 (s, 1H, D20 exchangeable), 8.06 (s, 1H), 7.44 (s, 1H), 7.38 - 7.13 (m, 6H), 6.98 (dd, J= 4.5, 1.6 Hz, 1H), 6.42 (dd, J = 4.4, 2.5 Hz, 1H), 5.34 (d, J = 7.8 Hz, 1H), 3.99 - 3.81 (m, 1H), 3.80 - 3.68 (m, 1H), 3.66 - 3.49 (m, 1H), 2.42 - 2.22 (m, 1H), 2.05 - 1.64 (m, 9H), 1.62 - 1.32 (m, 3H), 1.32 - 1.14 (m, 1H); MS (ES+): 428.6 (M+l).
[0665] Scheme 47
[0666]
[0667] Preparation of (S)-l-(3-(4-((2-(2-(hydroxymethyl)pyrrolidin-l-yl)pyrrolo[2, l-f][l,2,4]triazin- 4-yl)amino)-lH-imidazol-l-yl)phenyl)ethanone (47c)
[0668] Step-1 : Preparation of l-(3-(4-((2-chloropyrrolo[2,l-f][l,2,4]triazin-4-yl)amino)-lH- imidazol-l-yl)phenyl)ethanone (47b)
[0669] Compound 47b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (185 mg, 1.0 mmol) in 2-Propanol (20 mL) using DIPEA (0.52 mL, 2.96 mmol) and l-(3-(4-amino-lH-imidazol-l-yl)phenyl)ethanone (47a) (238 mg, 1.18 mmol). This gave l-(3-(4-((2-chloropyrrolo[2,l-f][l,2,4]triazin-4-yl)amino)- lH-imidazol-l-yl)phenyl)ethanone (47b) (282 mg, 81 % yield) as a pale off-white solid; ¾ NMR (300 MHz, DMSO-i¾) δ 11.37 (s, 1H, D2O exchangeable), 8.38 (d, J= 1.6 Hz, 1H), 8.14 (t, J = 1.9 Hz, 1H), 8.01 - 7.97 (m, 1H), 7.97 - 7.89 (m, 2H), 7.78 (dd, J = 2.6, 1.5 Hz, 1H), 7.72 (t, J = 7.9 Hz, 1H), 7.40 (d, J = 4.3 Hz, 1H), 6.73 (dd, J = 4.5, 2.6 Hz, 1H), 2.68 (s, 3H); MS (ES+): 353.3 (M+l); MS (ES-): 351.4 (M-l).
[0670] Step-2: Preparation of (S)-l-(3-(4-((2-(2-(hydroxymethyl)pyrrolidin-l-yl)pyrrolo[2,l- f] [ 1 ,2,4]triazin-4-yl)amino)- lH-imidazol- 1 -yl)phenyl)ethanone (47c) Compound 47c was prepared from l-(3-(4-((2-chloropyrrolo[2, l-f][l,2,4]triazin-4-yl)amino)- lH-imidazol-l-yl)phenyl)ethanone (47b) (100 mg, 0.28 mmol), (^-pyrrolidin-2-ylmethanol (143 mg, 1.42 mmol), and DIPEA (0.15 mL, 0.85 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-l-(3-(4-((2-(2- (hydroxymethyl)pyrrolidin- 1 -yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-yl)amino)- lH-imidazol- 1 - yl)phenyl)ethanone (47c) (39 mg, 33 % yield) as a white solid; ¾ NMR (300 MHz, DMSO- de) δ 10.58 (s, 1H, D20 exchangeable), 8.38 (d, J= 1.5 Hz, 1H), 8.24 - 8.16 (m, 1H), 8.07 (d, J= 1.6 Hz, 1H), 8.06 - 7.98 (m, 1H), 7.98 - 7.84 (m, 1H), 7.65 (t, J= 7.9 Hz, 1H), 7.40 (dd, J = 2.4, 1.6 Hz, 1H), 7.15 (dd, J = 4.5, 1.6 Hz, 1H), 6.40 (dd, J = 4.4, 2.5 Hz, 1H), 4.87 (t, J = 5.0 Hz, 1H, D2O exchangeable), 4.29 - 4.03 (m, 1H), 3.84 - 3.70 (m, 1H), 3.63 - 3.46 (m, 1H), 3.47 - 3.22 (m, 2H), 2.68 (s, 3H), 2.10 - 1.85 (m, 4H); MS (ES+): 418.5 (M+l).
[0671] Scheme 48
[0672] 48c
[0673] Preparation of (S)-4-(4-((2-(2-(hydroxymethyl)pyrrolidin- 1 -yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4- yl)amino)- lH-imidazol- 1 -yl)phenol (48c)
[0674] Step-1 : Preparation of 4-(4-((2-chloropyrrolo[2,l-f][l,2,4]triazin-4-yl)amino)-lH-imidazol-l- yl)phenol (48b)
[0675] Compound 48b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (410 mg, 2.18 mmol) in 2-Propanol (20 mL) using DIPEA (1.14 mL, 6.54 mmol) and 4-(4-amino-lH-imidazol-l-yl)phenol (458 mg, 2.61 mmol) (48a) (238 mg, 1.18 mmol). This gave 4-(4-((2-chloropyrrolo[2,l-f][l,2,4]triazin-4-yl)amino)- lH-imidazol-l-yl)phenol (48b) (264 mg, 37 % yield) as solid with a little pink color; ¾ NMR (300 MHz, DMSO-d6) δ 11.34 (s, 1H), 9.78 (s, 1H), 8.04 (d, J = 1.6 Hz, 1H), 7.77 (d, J = 1.6 Hz, 1H), 7.77 - 7.74 (m, 1H), 7.47 - 7.35 (m, 3H), 6.94 - 6.86 (m, 2H), 6.71 (dd, J = 4.5, 2.6 Hz, 1H); MS (ES+): 327.3 (M+l); MS (ES-): 325.2 (M-l), 361.2 (M+Cl). Step-2: Preparation of (S)-4-(4-((2-(2-(hydroxymethyl)pyrrolidin-l-yl)pyrrolo[2,l- f] [ 1 ,2,4]triazin-4-yl)amino)- lH-imidazol- 1 -yl)phenol (48c)
[0676] Compound 48c was prepared from 4-(4-((2-chloropyrrolo[2, l-f][l,2,4]triazin-4-yl)amino)- lH-imidazol-l-yl)phenol (48b) (100 mg, 0.31 mmol), (^-pyrrolidin-2-ylmethanol (155 mg, 1.53 mmol), and DIPEA (0.16 mL, 0.92 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-4-(4-((2-(2- (hydroxymethyl)pyrrolidin- 1 -yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-yl)amino)- lH-imidazol- 1 - yl)phenol (48c) (60 mg, 50 % yield) as a white solid; ¾ NMR (300 MHz, DMSO-^e) δ 10.46 (s, 1H, D20 exchangeable), 9.69 (s, 1H, D2O exchangeable), 8.02 (d, J= 1.5 Hz, 1H), 7.84 (d, J= 1.6 Hz, 1H), 7.51 (d, J= 8.8 Hz, 2H), 7.38 (dd, J= 2.4, 1.6 Hz, 1H), 7.14 (dd, J= 4.4, 1.7 Hz, 1H), 6.85 (d, J= 8.8 Hz, 2H), 6.38 (dd, J = 4.4, 2.4 Hz, 1H), 4.85 (t, J= 5.0 Hz, 1H, D2O exchangeable), 4.26 - 4.06 (m, 1H), 3.81 - 3.65 (m, 1H), 3.55 - 3.42 (m, 1H), 3.45 - 3.23 (m, 2H), 2.11 - 1.81 (m, 4H); MS (ES+): 392.5 (M+l); 414.5 (M+Na); Analysis calculated for C20H21N7O2: C, 61.37; H, 5.41; N, 25.05; Found: C, 60.88; H, 5.54; N, 24.96.
[0677] Scheme 49
[0678]
[0679] Preparation of (S)-(l-(4-((l-(4-chlorophenyl)-lH-imidazol-4-yl)amino)pyrrolo[2, 1- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (49c)
[0680] Step-1 : Preparation of 2-chloro-N-(l-(4-chlorophenyl)-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (49b)
[0681] Compound 49b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (375 mg, 2.0 mmol) in 2-Propanol (20 mL) using DIPEA (1.05 mL, 5.99 mmol) and l-(4-chlorophenyl)-lH-imidazol-4-amine (49a) (464 mg, 2.396 mmol). This gave 2-chloro-N-(l-(4-chlorophenyl)-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (49b) (264 mg, 38 % yield) as a pale-off white solid; ¾ MR (300 MHz, DMSO-ώ) δ 11.36 (s, 1H), 8.29 (d, J = 1.6 Hz, 1H), 7.91 (d, J = 1.7 Hz, 1H), 7.78 (dd, J = 2.6, 1.5 Hz, 1H), 7.74 - 7.68 (m, 2H), 7.66 - 7.60 (m, 2H), 7.40 (d, J = 4.5 Hz, 1H), 6.72 (dd, J = 4.5, 2.6 Hz, 1H); 1H NMR (300 MHz, OMSO-defDiO) δ 8.19 (d, J = 1.7 Hz, 1H), 7.87 (d, J = 1.6 Hz, 1H), 7.73 (dd, J = 2.6, 1.5 Hz, 1H), 7.70 - 7.64 (m, 2H), 7.62 - 7.56 (m, 2H), 7.32 (d, J = 4.3 Hz, 1H), 6.71 (dd, J = 4.5, 2.6 Hz, 1H); MS (ES+): 345.3, 347.3 (M+l).
[0682] Step-2: Preparation of (S)-(l-(4-((l -(4-chlorophenyl)-lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (49c)
[0683] Compound 49c was prepared from 2-chloro-N-(l-(4-chlorophenyl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (49b) (100 mg, 0.29 mmol), (Sj-pyrrolidin-2- ylmethanol (147 mg, 1.45 mmol), and DIPEA (0.15 mL, 0.87 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l-(4- chlorophenyl)-lH-imidazol-4-yl)amino)pyrrolo[2, l-f][l,2,4]triazin-2-yl)pyrrolidin-2- yl)methanol (49c) (55 mg, 46 % yield) as a white solid; ¾ NMR (300 MHz, OMSO-de) δ 10.55 (s, 1H, D20 exchangeable), 8.27 (d, J = 1.5 Hz, 1H), 7.96 (d, 7 = 1.6 Hz, 1H), 7.86 - 7.77 (m, 2H), 7.63 - 7.50 (m, 2H), 7.39 (dd, J = 2.4, 1.6 Hz, 1H), 7.15 (dd, J = 4.5, 1.7 Hz, 1H), 6.39 (dd, J = 4.4, 2.5 Hz, 1H), 5.03 - 4.80 (m, 1H, D2O exchangeable), 4.31 - 4.07 (m, 1H), 3.87 - 3.67 (m, 1H), 3.53 - 3.35 (m, 1H), 3.42 - 3.23 (m, 2H), 2.1 1 - 1.83 (m, 4H). MS (ES+): 410.4 (M+l).
[0684]
[0685] Preparation of (S)-( 1 -(4-(( 1 -cyclopentyl- lH-imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin- 2-yl)pyrrolidin-2-yl)methanol (50c)
[0686] Step-1 : Preparation of 2-chloro-N-(l-cyclopentyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (50b)
[0687] Compound 50b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (392 mg, 2.08 mmol) in 2-Propanol (20 mL) using DIPEA (1.09 mL, 6.25 mmol) and 1 -cyclopentyl- lH-imidazol-4-amine hydrochloride (50a) (469 mg, 2.499 mmol). This gave 2-chloro-N-(l-cyclopentyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (50b) (397 mg, 63 % yield) as a pale-off yellow colored solid; ¾NMR (300 MHz, DMSO-i¾) δ 11.17 (s, 1H, D20 exchangeable), 7.72 (dd, J= 2.6, 1.5 Hz, 1H), 7.68 (d, J= 1.5 Hz, 1H), 7.50 (d, J = 1.6 Hz, 1H), 7.35 (dd, J= 4.5, 1.5 Hz, 1H), 6.68 (dd, J= 4.5, 2.6 Hz, 1H), 4.69 - 4.50 (m, 1H), 2.24 - 2.05 (m, 2H), 1.92 - 1.57 (m, 6H). MS (ES+): 303.3 (M+l), 325.3 (M+Na); MS (ES-): 301.3 (M-l)
[0688] Step-2: Preparation of (S)-(l-(4-((l-cyclopentyl-lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (50c)
[0689] Compound 50c was prepared from 2-chloro-N-(l-cyclopentyl-lH-imidazol-4-yl)pyrrolo[2,l- f][l,2,4]triazin-4-amine (50b) (100 mg, 0.33 mmol), (Sj-pyrrolidin-2-ylmethanol (33 mg, 0.33 mmol), and DIPEA (0.17 mL, 0.99 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l-cyclopentyl-lH-imidazol-4- yl)amino)pyrrolo[2,l-f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (50c) (80 mg, 66 % yield); ¾ NMR (300 MHz, DMSO-i¾) δ 10.32 (s, 1H, D2O exchangeable), 7.59 (d, J= 1.5 Hz, 1H), 7.54 (d, J = 1.6 Hz, 1H), 7.35 (dd, J = 2.4, 1.7 Hz, 1H), 7.09 (dd, J = 4.6, 1.7 Hz, 1H), 6.35 (dd, J= 4.4, 2.4 Hz, 1H), 4.78 (t, J= 5.1 Hz, 1H, D2O exchangeable), 4.52 (p, J= 7.3 Hz, 1H), 4.20 - 4.04 (m, 1H), 3.77 - 3.64 (m, 1H), 3.55 - 3.44 (m, 1H), 3.44 - 3.28 (m, 2H), 2.22 - 1.97 (m, 2H), 1.99 - 1.70 (m, 9H), 1.73 - 1.52 (m, 1H). MS (ES+): 368.5 (M+l); 370.5 (M+Na).
[0690] Scheme 51
[0691]
[0692] Preparation of 2-(2,6-difluoro-4-methoxyphenyl)- 1 -(4-(4-(( 1 -methyl- lH-imidazol -4- yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)piperazin- 1 -yl)ethanone (51a)
[0693] Compound 51a was prepared from 2-chloro-N-(l-methyl-lH-imidazol-4-yl)pyrrolo[2,l- f][l,2,4]triazin-4-amine (4b) (100 mg, 0.4 mmol), 2-(2,6-difluoro-4-methoxyphenyl)-l- (piperazin-l-yl)ethanone 2,2,2-trifluoroacetate (45c) (170 mg, 0.44 mmol) and DIPEA (0.21 mL, 1.21 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, 2-(2,6-difluoro-4-methoxyphenyl)-l-(4-(4-((l-methyl-lH-imidazol-4- yl)amino)pyrrolo[2, l-f][l,2,4]triazin-2-yl)piperazin-l-yl)ethanone (51a) (25 mg, 13 % yield) as a light brown solid;lH NMR (300 MHz, DMSO-i%) δ 10.54 (s, 1H, D20 exchangeable),
[0694] 8.10 (s, 1H), 7.54 - 7.40 (m, 2H), 7.1 1 - 6.97 (m, 1H), 6.72 (d, J = 9.4 Hz, 2H), 6.49 (dd, J = 4.5, 2.4 Hz, 1H), 3.79 (s, 3H), 3.77 (s, 4H), 3.71 (s, 3H), 3.64 (d, J = 4.6 Hz, 2H), 3.57 (s, 4H);
[0695] 19F NMR (282 MHz, DMSO-i%) δ -1 14.02; MS (ES+): 483.5 (M+l), 505.5 (M+Na).
[0696] Scheme 52
[0697]
[0698] Preparation of 2-(2,6-difluoro-4-methoxyphenyl)-l-(4-(4-((l -phenyl- lH-imidazol-4- yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)piperazin- 1 -yl)ethanone (52a)
[0699] Compound 52a was prepared from 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)pyrrolo[l,2- f][l,2,4]triazin-4-amine (8b) (100 mg, 0.32 mmol), 2-(2,6-difluoro-4-methoxyphenyl)-l- (piperazin-l-yl)ethanone 2,2,2-trifluoroacetate (45c) (247 mg, 0.64 mmol) and DIPEA (0.22 mL, 1.28 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, 2-(2,6-difluoro-4-methoxyphenyl)-l-(4-(4-((l -phenyl- lH-imidazol -4- yl)amino)pyrrolo[2, l-f][l,2,4]triazin-2-yl)piperazin-l-yl)ethanone (52a) (25 mg, 14 % yield) as a light brown solid; 1H NMR (300 MHz, DMSO-de) δ 10.63 (s, 1H, D20 exchangeable),
[0700] 8.24 (d, J = 1.6 Hz, 1H), 7.85 (d, J = 1.6 Hz, 1H), 7.72 - 7.64 (m, 2H), 7.57 (dd, J = 8.6, 7.2 Hz, 2H), 7.47 (dd, J = 2.5, 1.7 Hz, 1H), 7.43 - 7.34 (m, 1H), 7.19 (s, 1H), 6.72 (d, J = 9.5 Hz,
[0701] 2H), 6.47 (dd, J = 4.5, 2.5 Hz, 1H), 3.77 (s, 3H), 3.76 - 3.65 (m, 6H), 3.64 - 3.58 (m, 4H);19F NMR (282 MHz, DMSO-i%) δ -114.00 (d, J
[0702] (M+Na), (ES-): 543.5 (M-l).
[0703] Scheme 53
[0704]
[0705] Preparation of 1 -(4-(4-(( 1 -methyl- lH-imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2- yl)piperazin- 1 -yl)-2-phenylethanone (53b)
[0706] Compound 53b was prepared from 2-chloro-N-(l-methyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (4b) (100 mg, 0.4 mmol), 2-phenyl-l-(piperazin-l-yl)ethanone 2,2,2- trifluoroacetate (53a) (256 mg, 0.80 mmol; prepared according to the procedure reported by Levy, Daniel E. et ah in PCX int. AppL, 2003 / 022214, 20 Mar 2003) and DIPEA (0.28 mL, 1.61 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, 1 -(4-(4-(l -methyl- 1 H-imidazol-4-ylamino)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-2- yl)piperazin-l-yl)-2-phenylethanone (11 mg, 7 % yield) as a brown solid; 1H NMR (300 MHz, DMSO-i%) δ 10.38 (s, 1H, D20 exchangeable), 7.50 (d, J = 1.4 Hz, 1H), 7.45 - 7.36 (m, 2H),
[0707] 7.36 - 7.29 (m, 2H), 7.29 - 7.19 (m, 3H), 7.18 - 7.09 (m, 1H), 6.42 (dd, J = 4.4, 2.5 Hz, 1H), 3.78 (s, 2H), 3.70 (s, 3H), 3.67 - 3.59 (m, 4H), 3.60 - 3.43 (m, 4H); MS (ES+): 417.6 (M+l), 439.5 (M+Na), (ES-): 415.5 (M-l).
[0708] Scheme 54
[0709] Preparation of tert-butyl 4-(4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2- yl)piperazine- 1 -carboxylate (54a)
[0710] Compound 54a was prepared from 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)thieno[3,2- d]pyrimidin-4-amine (16a) (100 mg, 0.31 mmol), tert-butyl piperazine-1 -carboxylate (170 mg, 0.92 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, tert-butyl 4-(4-(l-phenyl-lH-imidazol-4-ylamino)thieno[3,2-d]pyrimidin-2- yl)piperazine-l -carboxylate (54a) (92 mg, 63 % yield) as an off-white solid; 1H NMR (300 MHz, DMSO-i%) δ 10.10 (s, 1H), D20 exchangeable, 8.22 (d, J = 1.5 Hz, 1H), 7.97 (d, J= 5.4 Hz, 1H), 7.85 (d, J = 1.7 Hz, 1H), 7.68 (d, J = 1.4 Hz, 1H), 7.65 (dd, J= 1.9, 0.9 Hz, 1H), 7.55 (dd, J = 8.7, 7.1 Hz, 2H), 7.43 - 7.35 (m, 1H), 7.12 (d, J = 5.4 Hz, 1H), 3.85 - 3.71 (m, 4H), 3.50 - 3.38 (m, 4H), 1.43 (s, 9H); MS (ES+): 478.6 (M+l), 500.5 (M+Na).
[0711] Scheme 55
[0712]
[0713] Preparation of (S)-( 1 -(4-(( 1 -(4-methoxyphenyl)- lH-imidazol-4-yl)amino)pyrrolo[2, 1 - f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (55c)
[0714] Step-1 : Preparation of 2-chloro-N-(l-(4-methoxyphenyl)-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (55b)
[0715] Compound 55b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (423 mg, 2.25 mmol) in 2-Propanol (20 mL) using DIPEA (1.18 mL, 6.75 mmol) and 1 -(4-methoxyphenyl)- lH-imidazol-4-amine (55a) (511 mg, 2.70 mmol). This gave 2-chloro-N-(l-(4-methoxyphenyl)-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (55b) (635 mg, 83 % yield) as a yellow solid; ¾ NMR (300 MHz, OMSO-de) δ 11.33 (s, 1H), 8.11 (d, J = 1.6 Hz, 1H), 7.82 (d, J = 1.6 Hz, 1H), 7.76 (dd, J = 2.6, 1.5 Hz, 1H), 7.63 - 7.49 (m, 2H), 7.40 (dd, J = 4.6, 1.5 Hz, 1H), 7.19 - 7.06 (m, 2H), 6.71 (dd, J = 4.5, 2.6 Hz, 1H), 3.81 (s, 3H); ¾ NMR (300 MHz, OMSO-de-DiO) δ 8.02 (d, J = 1.2 Hz, 1H), 7.77 (dd, J = 1.6, 0.8 Hz, 1H), 7.74 - 7.67 (m, 1H), 7.56 - 7.47 (m, 2H), 7.30 (d, J = 4.4 Hz, 1H), 7.12 - 7.00 (m, 2H), 6.70 (dd, J = 4.6, 2.7 Hz, 1H), 3.80 (s, 3H). MS (ES+): 341.3 (M+l), 363.4 (M+Na); MS (ES-): 339.3 (M-l).
[0716] Step-2: Preparation of (S)-(l-(4-((l-(4-methoxyphenyl)-lH-imidazol-4-yl)amino)pyrrolo[2,l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (55c)
[0717] Compound 55c was prepared from 2-chloro-N-(l-(4-methoxyphenyl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (55b) (100 mg, 0.29 mmol), (Sj-pyrrolidin-2- ylmethanol (148 mg, 1.47 mmol), and DIPEA (0.15 mL, 0.87 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l-(4- methoxyphenyl)- lH-imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2- yl)methanol (55c) (83 mg, 70 % yield) as a white solid; ¾ NMR (300 MHz, OMSO-de) δ 10.49 (s, 1H, D20 exchangeable), 8.11 (d, J= 1.5 Hz, 1H), 7.88 (d, J= 1.6 Hz, 1H), 7.65 (d, J = 9.0 Hz, 2H), 7.38 (t, J= 2.0 Hz, 1H), 7.15 (dd, J = 4.5, 1.7 Hz, 1H), 7.04 (d, J= 9.0 Hz, 2H), 6.39 (dd, J = 4.4, 2.5 Hz, 1H), 4.94 - 4.81 (m, 1H, D2O exchangeable), 4.27 - 4.08 (m, 1H), 3.80 (s, 3H), 3.80 - 3.70 (m, 1H), 3.56 - 3.43 (m, 1H), 3.44 - 3.30 (m, 2H), 2.13 - 1.79 (m, 4H); MS (ES+): 406.5 (M+l).
[0718] Scheme 56
[0719]
[0720] Preparation of (S)-(l-(4-((l-(3-methoxyphenyl)-lH-imidazol-4-yl)amino)pyrrolo[2,l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (56c)
[0721] Step-1 : Preparation of 2-chloro-N-(l-(3-methoxyphenyl)-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (56b)
[0722] Compound 56b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (373 mg, 1.99 mmol) in 2-Propanol (20 mL) using DIPEA (1.04 mL, 5.96 mmol) and l-(3-methoxyphenyl)-lH-imidazol-4-amine (56a) (451 mg, 2.38 mmol). This gave 2-chloro-N-(l-(3-methoxyphenyl)-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (56b) (556 mg, 82 % yield) as a pale off-yellow solid;1H MR (300 MHz, DMSO-ώ) δ 1 1.34 (s, 1H), 8.29 (d, J = 1.6 Hz, 1H), 7.91 (d, J = 1.6 Hz, 1H), 7.77 (dd, J = 2.6, 1.5 Hz, 1H), 7.47 (t, J = 8.1 Hz, 1H), 7.40 (d, J = 4.3 Hz, 1H), 7.23 (t, J = 2.2 Hz, 1H), 7.22 - 7.16 (m, 1H), 7.03 - 6.93 (m, 1H), 6.72 (dd, J = 4.5, 2.6 Hz, 1H), 3.85 (s, 3H); ¾ NMR (300 MHz, OMSO-de-DiO) δ 8.22 (d, J = 1.6 Hz, 1H), 7.88 (d, J = 1.6 Hz, 1H), 7.74 (dd, J = 2.6, 1.5 Hz, 1H), 7.53 - 7.41 (m, 1H), 7.34 (d, J = 4.4 Hz, 1H), 7.21 - 7.14 (m, 2H), 7.03 - 6.93 (m, 1H), 6.71 (dd, J = 4.5, 2.6 Hz, 1H), 3.82 (s, 3H); MS (ES+): 341.4 (M+1); MS (ES-): 339.3 (M-l).
[0723] Step-2: Preparation of (S)-(l-(4-((l-(3-methoxyphenyl)-lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (56c)
[0724] Compound 56c was prepared from 2-chloro-N-(l-(3-methoxyphenyl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (56b) (100 mg, 0.29 mmol), (Sj-pyrrolidin-2- ylmethanol (148 mg, 1.47 mmol), and DIPEA (0.15 mL, 0.87 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l-(3- methoxyphenyl)- lH-imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2- yl)methanol (56c) (58 mg, 49 % yield) as a white solid; ¾ NMR (300 MHz, OMSO-de) δ 10.53 (s, 1H, D20 exchangeable), 8.27 (d, J = 1.5 Hz, 1H), 7.97 (d, 7 = 1.6 Hz, 1H), 7.45 - 7.34 (m, 2H), 7.35 - 7.23 (m, 2H), 7.15 (dd, J = 4.4, 1.7 Hz, 1H), 6.97 - 6.86 (m, 1H), 6.39 (dd, J = 4.5, 2.4 Hz, 1H), 5.02 - 4.68 (m, 1H, D2O exchangeable), 4.30 - 4.1 1 (m, 1H), 3.85 (s, 3H), 3.74 (dd, J = 9.9, 3.5 Hz, 1H), 3.61 - 3.46 (m, 1H), 3.47 - 3.26 (m, 2H), 2.17 - 1.77 (m, 4H); MS (ES+): 406.5 (M+1).
[0725] Scheme 57
[0726]
[0727] Preparation of (S)-(l-(4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (57c)
[0728] Step-1 : Preparation of 2-chloro-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)pyrrolo[2, 1- f][l,2,4]triazin-4-amine (57b) Compound 57b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (226 mg, 1.2 mmol) in 2-Propanol (20 mL) using DIPEA (0.63 mL, 3.61 mmol) and l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-amine (57a) (300 mg, 1.02 mmol). This gave 2-chloro-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (57b) (410 mg, 85 % yield) as white solid; ¾ NMR (300 MHz, OMSO-de) δ 1 1.31 (s, 1H), 8.21 (d, J = 1.6 Hz, 1H), 7.89 (d, J = 1.6 Hz, 1H), 7.77 (dd, J = 2.6, 1.6 Hz, 1H), 7.39 (d, J = 4.4 Hz, 1H), 6.93 (s, 2H), 6.72 (dd, J = 4.4, 2.6 Hz, 1H), 3.87 (s, 6H), 3.69 (s, 3H); ¾ NMR (300 MHz, DMSO- de-OiO) δ 8.14 (d, J = 1.6 Hz, 1H), 7.86 (d, J = 1.6 Hz, 1H), 7.72 (dd, J = 2.6, 1.6 Hz, 1H), 7.35 - 7.28 (m, 1H), 6.88 (s, 2H), 6.71 (dd, J = 4.5, 2.6 Hz, 1H), 3.84 (s, 6H), 3.67 (s, 3H); MS (ES+): 401.4 (M+l); MS (ES-): 399.3 (M-l).
[0729] Step-2: Preparation of (S)-(l-(4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (57c)
[0730] Compound 57c was prepared from 2-chloro-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (57b) (100 mg, 0.25 mmol), (Sj-pyrrolidin-2- ylmethanol (126 mg, 1.25 mmol), and DIPEA (0.13 mL, 0.74 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l-(3,4,5- trimethoxyphenyl)- lH-imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2- yl)methanol (57c) (18 mg, 16 % yield) as a white solid; ¾ NMR (300 MHz, OMSO-de) δ 10.54 (s, 1H, D20 exchangeable), 8.24 (d, 7 = 1.5 Hz, 1H), 7.97 (d, 7 = 1.6 Hz, 1H), 7.39 (dd, 7= 2.4, 1.6 Hz, 1H), 7.14 (dd, 7= 4.4, 1.7 Hz, 1H), 6.96 (s, 2H), 6.39 (dd, 7= 4.4, 2.4 Hz, 1H), 4.84 (t, 7= 5.1 Hz, 1H, D2O exchangeable), 4.29 - 4.15 (m, 1H), 3.88 (s, 6H), 3.79 - 3.68 (m, 1H), 3.68 (s, 3H), 3.61 - 3.47 (m, 1H), 3.49 - 3.24 (m, 2H), 2.12 - 1.75 (m, 4H); MS (ES+): 466.5 (M+l), 488.5 (M+Na); Hydrochloride salt of compound 57c was obtained by purification of crude reaction mixture from step-2 above by reverse phase flash chromatography [(silica gel C-18, 24 g) eluting with acetonitrile and 0.1% HC1 in water ] followed by lyophilization; ¾ NMR (300 MHz, DMSO-<fc): δ 10.78 (s, 1H), 8.59 (s, 1H), 8.03 (s, 1H), 7.44 (s, 1H), 7.12 (d, J = 4.5 Hz, 1H), 7.02 (s, 2H), 6.43 (dd, J = 4.4, 2.5 Hz, 1H), 4.26 - 4.13 (m, 1H), 3.88 (s, 6H), 3.78 - 3.21 (m, 7H), 2.08 - 1.80 (m, 4H). MS (ES+): 466.3 (M+l). MS (ES-): 500.2 (M+Cl).
[0731] Scheme 58
[0732] Preparation of (S)-( 1 -(4-(( 1 -(4-fluorophenyl)- lH-imidazol-4-yl)amino)thieno[3 ,2- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (58b)
[0733] Step-1 : Preparation of 2-chloro-N-(l-(4-fluorophenyl)-lH-imidazol-4-yl)thieno[3,2- d]pyrimidin-4-amine (58a)
[0734] Compound 58a was prepared according to the procedure reported in Scheme 1 from 2,4- dichlorothieno[3,2-d]pyrimidine (12a) (261 mg, 1.27 mmol) in 2-Propanol (10 mL) using DIPEA (0.44 mL, 2.54 mmol), and 1 -(4-fluorophenyl)- lH-imidazol-4-amine (25a) (225 mg, 1.27 mmol). This gave 2-chloro-N-(l-(4-fluorophenyl)-lH-imidazol-4-yl)thieno[3,2- d]pyrimidin-4-amine (58a) (268 mg, 61 % yield) as a light pink solid;ιϊί NMR (300 MHz, DMSO-i%) δ 10.96 (s, 1H, D20 exchangeable), 8.29 - 8.18 (m, 2H), 7.91 (d, J= 1.6 Hz, 1H),
[0735] 7.78 - 7.65 (m, 2H), 7.48 - 7.35 (m, 3H);19F NMR (282 MHz, DMSO-i¾) δ -115.27; MS
[0736] (ES+): 346.3 (M+1), 368.3 (M+Na); (ES-): 344.2 (M-l).
[0737] Step-2: Preparation of (S)-(l-(4-((l-(4-fluorophenyl)-lH-imidazol-4-yl)amino)thieno[3,2- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (58b).
[0738] Compound 58b was prepared from 2-chloro-N-(l-(4-fluorophenyl)-lH-imidazol-4- yl)thieno[3,2-d]pyrimidin-4-amine (58a) (100 mg, 0.29 mmol), (^-pyrrolidin-2-ylmethanol (88 mg, 0.86 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [ (silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-(l-(4-fluorophenyl)-lH-imidazol-4-ylamino)thieno[3,2- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (58b) (69 mg, 58 % yield) as a brown solid; ^H NMR (300 MHz, DMSO-i¾) δ 10.14 (s, 1H, D20 exchangeable), 8.15 (d, J = 1.5 Hz, 1H),
[0739] 8.01 - 7.88 (m, 2H), 7.77 (s, 2H), 7.36 (t, J= 8.4 Hz, 2H), 7.10 (d, J= 5.3 Hz, 1H), 5.35 - 4.91 (m, 1H, D20 exchangeable), 4.23 (s, 1H), 3.92 - 3.69 (m, 1H), 3.69 - 3.18 (m, 3H), 2.15 - 1.73
[0740] (m, 4H);19F NMR (282 MHz, DMSO-i¾) δ -116.11; MS (ES+): 411.4 (M+1), 433.4 (M+Na); (ES-): 409.4 (M-l).
[0741] Scheme 59
[0742] Preparation of 3 -(4-((2-(2-(pyridin-2-yl)pyrrolidin- 1 -yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4- yl)amino)-lH-imidazol-l-yl)cyclobutanecarbonitrile (59c)
[0743] Step-1 : Preparation of 3-(4-((2-chloropyrrolo[2,l-f][l,2,4]triazin-4-yl)amino)-lH-imidazol-l- yl)cyclobutanecarbonitrile (59b)
[0744] Compound 59b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (145 mg, 0.77 mmol) in 2-Propanol (10 mL) using DIPEA (0.4 mL, 2.31 mmol) and 3-(4-amino-lH-imidazol-l-yl)cyclobutanecarbonitrile (59a) (125 mg, 0.77 mmol). This gave 3-(4-((2-chloropyrrolo[2,l-f][l,2,4]triazin-4-yl)amino)-lH- imidazol-l-yl)cyclobutanecarbonitrile (59b) (168 mg, 70 % yield) as a yellow solid; ¾ NMR (300 MHz, OMSO-de) δ 11.17 (s, 1H), 7.86 (d, J = 1.5 Hz, 1H), 7.73 (dt, J = 2.9, 1.4 Hz, 1H), 7.57 (d, J = 1.5 Hz, 1H), 7.35 (d, J = 4.4 Hz, 1H), 6.77 - 6.60 (m, 1H), 4.77 (p, J = 8.6 Hz, 1H), 3.31 - 3.12 (m, 1H), 2.96 - 2.81 (m, 2H), 2.79 - 2.63 (m, 2H); MS (ES+): 314.3 (M+l); MS (ES-): 312.3 (M-l); HPLC purity: 98.51%.
[0745] Step-2: Preparation of 3-(4-((2-(2-(pyridin-2-yl)pyrrolidin-l-yl)pyrrolo[2, l-f][l,2,4]triazin-4- yl)amino)-lH-imidazol-l-yl)cyclobutanecarbonitrile (59c)
[0746] Compound 59c was prepared from 3-(4-((2-chloropyrrolo[2, l-f][l,2,4]triazin-4-yl)amino)- lH-imidazol-l-yl)cyclobutanecarbonitrile (59b) (60 mg, 0.19 mmol), 2-(pyrrolidin-2- yl)pyridine (85 mg, 0.57 mmol), and DIPEA (0.1 mL, 0.57 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, 3-(4-((2-(2-(pyridin- 2-yl)pyrrolidin- 1 -yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-yl)amino)- 1 H-imidazol- 1 - yl)cyclobutanecarbonitrile (59c) (41 mg, 50 % yield) as a white solid; ¾ NMR (300 MHz, DMSO-i¾) δ 10.31 (s, 1H, D20 exchangeable), 8.62 (d, J = 4.8 Hz, 1H), 7.71 (d, 7 = 1.5 Hz, 1H), 7.66 (td, J = 7.7, 1.8 Hz, 1H), 7.37 (s, 1H), 7.25 - 7.19 (m, 1H), 7.17 (d, J = 7.9 Hz, 1H), 7.16 - 6.97 (m, 2H), 6.36 (dd, J = 4.4, 2.5 Hz, 1H), 5.32 (d, J = 8.2 Hz, 1H), 4.68 - 4.40 (m, 1H), 3.96 - 3.76 (m, 1H), 3.76 - 3.50 (m, 1H), 3.33 - 3.21 (m, 1H), 3.02 - 2.61 (m, 4H), 2.44 - 2.26 (m, 1H), 2.16 - 1.71 (m, 3H); MS (ES+): 426.5 (M+l), 448.5 (M+Na). Scheme 60
[0747]
[0748] Preparation of (S)-(l-(4-((l-(4-fluorophenyl)-lH-imidazol-4-yl)amino)thieno[2,3- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (60b)
[0749] Step-1 : Preparation of 2-chloro-N-(l-(4-fluorophenyl)-lH-imidazol-4-yl)thieno[2,3- d]pyrimidin-4-amine (60a)
[0750] Compound 60a was prepared according to the procedure reported in Scheme 1 from 2,4- dichlorothieno[2,3-d]pyrimidine (31a) (261 mg, 1.27 mmol) in 2-Propanol (10 mL) using DIPEA (0.44 mL, 2.54 mmol), and l-(4-fluorophenyl)-lH-imidazol-4-amine (25a) (225 mg, 1.27 mmol). This gave 2-chloro-N-(l-(4-fluorophenyl)-lH-imidazol-4-yl)thieno[2,3- d]pyrimidin-4-amine (60a) (270 mg, 61 % yield) as a light pink solid;ιϊί MR (300 MHz, DMSO-i¾) δ 11.06 (s, 1H, D20 exchangeable), 8.21 (d, J= 1.6 Hz, 1H), 8.04 (d, J= 5.8 Hz,
[0751] 1H), 7.90 (d, J= 1.6 Hz, 1H), 7.76 - 7.67 (m, 3H), 7.48 - 7.37 (m, 2H);19F NMR (282 MHz, DMSO-i%) δ -115.31; MS (ES+): 346.3 (M+l), 368.3 (M+Na); (ES-): 344.3 (M-l).
[0752] Step-2: Preparation of (S)-(l-(4-((l-(4-fluorophenyl)-lH-imidazol-4-yl)amino)thieno[2,3- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (60b)
[0753] Compound 60b was prepared from 2-chloro-N-(l-(4-fluorophenyl)-lH-imidazol-4- yl)thieno[2,3-d]pyrimidin-4-amine (60a) (100 mg, 0.29 mmol), (^-pyrrolidin-2-ylmethanol (88 mg, 0.86 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-(l-(4-fluorophenyl)-lH-imidazol-4-ylamino)thieno[2,3- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (60b) (25 mg, 22 % yield) as a brown solid; ^H NMR (300 MHz, DMSO-i¾) δ 10.17 (s, 1H, D20 exchangeable), 8.17 (s, 1H), 7.94 (d, J = 1.6
[0754] Hz, 1H), 7.91 - 7.61 (m, 2H), 7.47 - 7.21 (m, 3H), 7.03 (d, J = 6.0 Hz, 1H), 5.17 - 4.77 (m, 1H,
[0755] D20 exchangeable), 4.39 - 3.99 (m, 1H), 3.89 - 3.19 (m, 4H), 2.13 - 1.81 (m, 4H);19F NMR
[0756] (282 MHz, DMSO-i¾) δ -73.43; MS (ES+) 411.4 (M+l), 433.4 (M+Na). Scheme 61
[0757]
[0758] Preparation of 3,3-dimethyl-l-(4-(4-((l -phenyl- lH-imidazol-4-yl)amino)thieno[2,3- d]pyrimidin-2-yl)piperazin- 1 -yl)butan- 1 -one (61b)
[0759] Compound 61b was prepared from 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)thieno[2,3- d]pyrimidin-4-amine (31b) (100 mg, 0.31 mmol), tert-3,3-dimethyl-l-(piperazin-l-yl)butan-l- one 2,2,2-trifluoroacetate (61a) (182 mg, 0.61 mmol; prepared according to the procedure described By Bisacchi, Gregory S. et al; in U.S. Pat. 6,335,324) and DIPEA (0.21 mL, 1.22 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHC03, 3,3-dimethyl-l-(4-(4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[2,3- d]pyrimidin-2-yl)piperazin-l-yl)butan-l-one (61b) (95 mg, 66 % yield) as a brown solid; 1H NMR (300 MHz, DMSO-i%) δ 10.26 (s, 1H, D20 exchangeable), 8.25 (d, J = 1.6 Hz, 1H),
[0760] 7.86 (d, J = 1.6 Hz, 1H), 7.81 (d, J = 6.0 Hz, 1H), 7.70 - 7.63 (m, 2H), 7.61 - 7.52 (m, 2H), 7.45 - 7.34 (m, 1H), 7.13 (d, J = 6.0 Hz, 1H), 3.87 - 3.74 (m, 4H), 3.71 - 3.54 (m, 4H), 2.30 (s, 2H), 1.01 (s, 9H); MS (ES+): 476.6 (M+1), 498.5 (M+Na), (ES-): 474.6 (M-1). heme 62
[0761]
[0762] Preparation of 2-(ethyl(4-(l-phenyl-lH-imidazol-4-ylamino)thieno[2,3-d]pyrimidin-2- yl)amino)ethanol (62b)
[0763] Compound 62b was prepared from 2-chloro-N-(l-phenyl-lH-imidazol-4-yl)thieno[2,3- d]pyrimidin-4-amine (31b) (100 mg, 0.31 mmol), 2-(ethylamino)ethanol (62a) (82 mg, 0.92 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, 2-(ethyl(4-(l-phenyl-lH-imidazol-4-ylamino)thieno[2,3-d]pyrimidin-2- yl)amino)ethanol (62b) (43 mg, 37 % yield) as a light brown solid;ιϊί NMR (300 MHz, DMSO-i%) δ 10.16 (s, 1H, D20 exchangeable), 8.23 (d, J = 1.5 Hz, 1H), 7.92 (d, J = 1.5 Hz,
[0764] 1H), 7.80 (d, J= 6.0 Hz, 1H), 7.75 - 7.59 (m, 2H), 7.53 (t, J= 7.7 Hz, 2H), 7.42 - 7.27 (m, 1H), 7.02 (d, J = 6.0 Hz, 1H), 4.82 (s, 1H, D20 exchangeable), 3.82 - 3.54 (m, 6H), 1.31 - 1.06 (m,
[0765] 3H); MS (ES+): 381.4 (M+l), 403.4 (M+Na), (ES-): 379.4 (M-l).
[0766] Scheme 63
[0767]
[0768] Preparation of (S)-N-(l -cyclobutyl- lH-imidazol-4-yl)-2-(2-phenylpyrrolidin- 1 - yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine (63a)
[0769] Compound 63a was prepared from 2-chloro-N-(l-cyclobutyl-lH-imidazol-4-yl)pyrrolo[2,l- f][l,2,4]triazin-4-amine (37b) (70 mg, 0.24 mmol), (S)-2-phenylpyrrolidine (54 mg, 0.36 mmol) and DIPEA (0.13 mL, 0.73 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-N-(l-cyclobutyl-lH- imidazol-4-yl)-2-(2-phenylpyrrolidin-l-yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (63a) (65 mg, 67 % yield) as a white solid; ¾ NMR (300 MHz, DMSO-de) δ 10.32 (s, 1H, D20
[0770] exchangeable), 7.88 - 7.79 (m, 1H), 7.42 - 7.37 (m, 1H), 7.36 - 7.23 (m, 4H), 7.23 - 7.15 (m, 1H), 7.09 - 6.97 (m, 2H), 6.39 (dd, J= 4.4, 2.5 Hz, 1H), 5.41 - 5.30 (m, 1H), 4.66 - 4.43 (m, 1H), 3.83 - 3.69 (m, 1H), 3.67 - 3.51 (m, 1H), 2.41 - 2.08 (m, 6H), 2.02 - 1.69 (m, 4H); MS (ES+): 400.6 (M+l), 422.5 (M+Na); HPLC purity: 98.69%.
[0771] Scheme 64
[0772] Preparation of (S)-N-(l-cyclobutyl-lH-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-l- yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine (64a)
[0773] Compound 64a was prepared from 2-chloro-N-(l-cyclobutyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (37b) (60 mg, 0.21 mmol), (S)-2-(pyrrolidin-2-yl)pyridine dihydrochloride (55 mg, 0.25 mmol) and DIPEA (0.11 mL, 0.62 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)- N-(l-cyclobutyl-lH-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-l-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (64a) (10 mg, 12 % yield) as a light yellow solid; ¾NMR (300 MHz, DMSO-i¾) δ 10.26 (s, 1H, D20 exchangeable), 8.67 - 8.48 (m, 1H), 7.67 (td, J= 7.7, 1.8 Hz, 1H), 7.56 (d, J= 1.5 Hz, 1H), 7.38 (s, 1H), 7.30 - 7.13 (m, 2H), 7.08 (dd, J= 4.4, 1.7 Hz, 1H), 7.05 - 6.89 (m, 1H), 6.36 (dd, J = 4.4, 2.5 Hz, 1H), 5.35 (d, J = 8.1 Hz, 1H), 4.65 - 4.36 (m, 1H), 3.90 - 3.72 (m, 1H), 3.68 - 3.49 (m, 1H), 2.47 - 2.25 (m, 4H), 2.26 - 2.11 (m, 1H), 2.12 - 1.99 (m, 1H), 2.01 - 1.90 (m, 1H), 1.90 - 1.65 (m, 3H). MS (ES+): 401.5 (M+l), 423.5 (M+Na); HPLC purity: 96.63%.
[0774] Scheme 65
[0775]
[0776] 65a
[0777] Preparation of (S)-(l-(4-((l-(lH-indol-6-yl)-lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (65c)
[0778] Step-1 : Preparation of N-(l-(lH-indol-6-yl)-lH-imidazol-4-yl)-2-chloropyrrolo[2, l- f][l,2,4]triazin-4-amine (65b) Compound 65b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (199 mg, 1.06 mmol) in 2-Propanol (20 mL) using DIPEA (0.55 mL, 3.18 mmol) and l-(lH-indol-6-yl)-lH-imidazol-4-amine (65a) (231 mg, 1.17 mmol). This gave N-(l-(lH-indol-6-yl)-lH-imidazol-4-yl)-2-chloropyrrolo[2, l- f][l,2,4]triazin-4-amine (65b) (271 mg, 73 % yield) as light pink solid; ¾ NMR (300 MHz, OMSO-de) δ 1 1.36 (s, 2H), 8.18 (d, J = 1.6 Hz, 1H), 7.90 (d, J = 1.6 Hz, 1H), 7.77 (dd, J = 2.6,
[0779] I .6 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.58 (d, J = 2.0 Hz, 1H), 7.46 (dd, J = 3.1, 2.4 Hz, 1H), 7.41 (d, J = 4.1 Hz, 1H), 7.27 (dd, J = 8.4, 2.0 Hz, 1H), 6.72 (dd, J = 4.4, 2.6 Hz, 1H), 6.52 (ddd, J = 3.0, 2.0, 0.9 Hz, 1H); MS (ES+): 350.4 (M+l); MS (ES-): 348.3 (M-l), 384.3 (M+Cl). Step-2: Preparation of (S)-(l-(4-((l-(lH-indol-6-yl)-lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (65c)
[0780] Compound 65c was prepared from N-(l-(lH-indol-6-yl)-lH-imidazol-4-yl)-2- chloropyrrolo[2, l-f][l,2,4]triazin-4-amine (65b) (100 mg, 0.29 mmol), (^-pyrrolidin-2- ylmethanol (145 mg, 1.43 mmol), and DIPEA (0.15 mL, 0.86 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l-(lH- indol-6-yl)- lH-imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2- yl)methanol (65c) (81 mg, 68 % yield) as a white solid; ¾ NMR (300 MHz, OMSO-de) δ
[0781] I I .26 (s, 1H, D20 exchangeable), 10.50 (s, 1H, D2O exchangeable), 8.14 (s, 1H), 7.95 (d, J = 1.6 Hz, 1H), 7.70 - 7.60 (m, 2H), 7.46 - 7.41 (m, 1H), 7.41 - 7.37 (m, 1H), 7.33 (dd, J = 8.5, 2.0 Hz, 1H), 7.20 - 7.1 1 (m, 1H), 6.53 - 6.46 (m, 1H), 6.40 (dd, J = 4.4, 2.4 Hz, 1H), 5.06 - 4.37 (m, 1H), 4.30 - 4.09 (m, 1H), 3.79 - 3.69 (m, 1H), 3.58 - 3.48 (m, 1H), 3.48 - 3.23 (m, 2H), 2.15 - 1.71 (m, 4H); MS (ES+): 415.5 (M+l); HPLC purity: 99.33%.
[0782] Scheme 66
[0783]
[0784] Preparation of (S)-(l-(4-((l-(pyridin-2-yl)-lH-imidazol-4-yl)amino)pyrrolo[2, 1- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (66c) Step-1 : Preparation of 2-chloro-N-(l-(pyridin-2-yl)-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (66b)
[0785] Compound 66b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (1 12 mg, 0.59 mmol) in 2-Propanol (10 mL) using DIPEA (0.31 mL, 1.78 mmol) and l-(pyridin-2-yl)-lH-imidazol-4-amine (66a) (95mg, 0.59 mmol; prepared according to the procedure reported by Bleieher, Konrad et al; in PCX Int. Appl ., 201 1 089132, 28 Jul 201 1). This gave after purification by flash column chromatography [silica (24 g), eluting with DMA-80 in DCM from 0 to 40%] 2-chloro-N-(l-(pyridin-2-yl)-lH- imidazol-4-yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (66b) (27 mg, 15 % yield) as a solid; ¾ MR (300 MHz, OMSO-de) δ 1 1.37 (s, 1H), 8.64 - 8.49 (m, 2H), 8.25 (d, J = 1.5 Hz, 1H), 8.1 1 - 7.97 (m, 1H), 7.86 (d, J = 8.2 Hz, 1H), 7.80 - 7.75 (m, 1H), 7.48 - 7.33 (m, 2H), 6.72 (dd, J = 4.5, 2.6 Hz, 1H); MS (ES+): 312.3 (M+l); MS (ES-): 310.3 (M-l).
[0786] Step-2: Preparation of (S)-(l-(4-((l-(pyridin-2-yl)-lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (66c)
[0787] Compound 66c was prepared from 2-chloro-N-(l-(pyridin-2-yl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (66b) (27 mg, 0.09 mmol), (S)-pyrrolidin-2-ylmethanol (44 mg, 0.43 mmol) and DIPEA (0.05 mL, 0.26 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l-(pyridin-2-yl)-lH- imidazol-4-yl)amino)pyrrolo[2, l-f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (66c) (9 mg, 28 % yield) as a white solid; ¾ NMR (300 MHz, DMSO-^e) δ 10.58 (s, 1H, D20 exchangeable), 8.51 (s, 1H), 8.48 (d, J = 4.4 Hz, 1H), 8.19 (s, 1H), 7.98 (t, J = 7.7 Hz, 1H), 7.90 (d, J= 8.2 Hz, 1H), 7.47 - 7.31 (m, 2H), 7.22 - 7.09 (m, 1H), 6.46 - 6.37 (m, 1H), 5.02 - 4.81 (m, 1H, D2O exchangeable), 4.26 - 4.1 1 (m, 1H), 3.90 - 3.73 (m, 1H), 3.63 - 3.46 (m, 1H), 3.47 - 3.15 (m, 2H), 2.19 - 1.69 (m, 4H); MS (ES+): 377.4 (M+l), 399.4 (M+Na); HPLC purity: 97.04%.
[0788] Scheme 67
[0789] Preparation of (S)-(l-(4-((l-(lH-indol-5-yl)-lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (67c)
[0790] Step-1 : Preparation of N-(l-(lH-indol-5-yl)-lH-imidazol-4-yl)-2-chloropyrrolo[2, l- f][l,2,4]triazin-4-amine (67b)
[0791] Compound 67b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (215 mg, 1.14 mmol) in 2-Propanol (20 mL) using DIPEA (0.6 mL, 3.43 mmol) and l-(lH-indol-5-yl)-lH-imidazol-4-amine (67a) (249 mg, 1.26 mmol). This gave N-(l-(lH-indol-5-yl)-lH-imidazol-4-yl)-2-chloropyrrolo[2, l- f][l,2,4]triazin-4-amine (67b) (314 mg, 79 % yield) as light pink solid; ¾ NMR (300 MHz, OMSO-de) δ 1 1.36 (s, 1H), 1 1.33 (s, 1H), 8.16 - 8.05 (m, 1H), 7.90 - 7.84 (m, 1H), 7.80 - 7.71 (m, 2H), 7.61 - 7.52 (m, 1H), 7.51 - 7.45 (m, 1H), 7.46 - 7.37 (m, 1H), 7.37 - 7.25 (m, 1H), 6.72 (p, J = 3.4, 2.9 Hz, 1H), 6.58 - 6.46 (m, 1H); MS (ES+): 350.4 (M+l), 372.4 (M+Na); MS (ES-): 348.3 (M-l), 384.3 (M+Cl); HPLC purity: 98.41%.
[0792] Step-2: Preparation of (S)-(l-(4-((l-(lH-indol-5-yl)-lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (67c)
[0793] Compound 67c was prepared from N-(l-(lH-indol-5-yl)-lH-imidazol-4-yl)-2- chloropyrrolo[2, l-f][l,2,4]triazin-4-amine (67b) (100 mg, 0.29 mmol), (^-pyrrolidin-2- ylmethanol (145 mg, 1.43 mmol), and DIPEA (0.15 mL, 0.86 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l-(lH- indol-5-yl)-lH-imidazol-4-yl)amino)pyrrolo[2, l-f][l,2,4]triazin-2-yl)pyrrolidin-2- yl)methanol (67c) (80 mg, 68 % yield) as a white solid; ¾ NMR (300 MHz, OMSO-de) δ 1 1.30 (s, 1H, D20 exchangeable), 10.48 (s, 1H, D2O exchangeable), 8.09 (d, J = 1.5 Hz, 1H), 7.95 (d, J = 1.6 Hz, 1H), 7.87 (d, J = 2.0 Hz, 1H), 7.55 - 7.43 (m, 2H), 7.44 - 7.32 (m, 2H), 7.19 - 7.1 1 (m, 1H), 6.53 - 6.47 (m, 1H), 6.39 (dd, J = 4.4, 2.4 Hz, 1H), 4.87 (t, J = 5.1 Hz, 1H, D2O exchangeable), 4.28 - 4.06 (m, 1H), 3.86 - 3.67 (m, 1H), 3.57 - 3.45 (m, 1H), 3.47 - 3.25 (m, 2H), 2.1 1 - 1.81 (m, 4H); MS (ES+): 415.5 (M+l); MS (ES-): 413.5 (M-l), 449.4 (M+Cl); HPLC purity: 99.37 %.
[0794] Scheme 68 CN
[0795] Preparation of (S)-3 -(4-((2-(2-(hydroxymethyl)pyrrolidin- 1 -yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4- yl)amino)-lH-imidazol-l-yl)cyclobutanecarbonitrile (68a)
[0796] Compound 68a was prepared from 3-(4-((2-chloropyrrolo[2, l-f][l,2,4]triazin-4-yl)amino)- lH-imidazol-l-yl)cyclobutanecarbonitrile (59b) (50 mg, 0.16 mmol), (¾)-pyrrolidin-2- ylmethanol (81 mg, 0.8 mmol) and DIPEA (0.08 mL, 0.48 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-3-(4-((2-(2- (hydroxymethyl)pyrrolidin- 1 -yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-yl)amino)- lH-imidazol- 1 - yl)cyclobutanecarbonitrile (68a) (36 mg, 60 % yield) as a light yellow solid; ¾ NMR (300 MHz, DMSO-i¾) δ 10.38 (s, 1H, D20 exchangeable), 7.72 (d, J= 1.5 Hz, 1H), 7.65 (d, J= 1.6 Hz, 1H), 7.36 (dd, J = 2.4, 1.6 Hz, 1H), 7.09 (dd, J = 4.5, 1.7 Hz, 1H), 6.36 (dd, J = 4.4, 2.4 Hz, 1H), 4.80 (t, J= 5.2 Hz, 1H, D2O exchangeable), 4.77 - 4.63 (m, 1H), 4.23 - 4.04 (m, 1H), 3.81 - 3.67 (m, 1H), 3.57 - 3.45 (m, 1H), 3.45 - 3.33 (m, 2H), 3.27 - 3.12 (m, 1H), 2.98 - 2.62 (m, 4H), 2.16 - 1.75 (m, 4H); MS (ES+): 379.5 (M+l); 401.5 (M+Na).
[0797] Scheme 69
[0798]
[0799] Preparation of N-(l-cyclopentyl-lH-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-l- yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine (69a)
[0800] Compound 69a was prepared from 2-chloro-N-(l-cyclopentyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (50b) (50 mg, 0.17 mmol), 2-(pyrrolidin-2-yl)pyridine (73 mg, 0.5 mmol) and DIPEA (0.09 mL, 0.5 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [( silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, N-(l-cyclopentyl-lH-imidazol-4-yl)-2-(2- (pyridin-2-yl)pyrrolidin-l-yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (69a) (48 mg, 70 % yield) as a light yellow solid; ¾ NMR (300 MHz, OMSO-de) δ 10.26 (s, 1H, D20 exchangeable), 8.61 - 8.50 (m, 1H), 7.67 (td, J= 7.7, 1.8 Hz, 1H), 7.51 (d, J= 1.5 Hz, 1H), 7.37 (s, 1H), 7.26 - 7.13 (m, 2H), 7.13 - 7.05 (m, 1H), 7.04 - 6.89 (m, 1H), 6.36 (dd, J = 4.4, 2.4 Hz, 1H), 5.31 (d, J = 8.1 Hz, 1H), 4.43 - 4.23 (m, 1H), 3.79 (t, J = 9.3 Hz, 1H), 3.68 - 3.50 (m, 1H), 2.41 - 2.29 (m, 1H), 2.18 - 1.87 (m, 5H), 1.89 - 1.53 (m, 6H); MS (ES+): 415.5 (M+l), 437.5 (M+Na); HPLC purity: 98.48 %.
[0801] Scheme 70
[0802]
[0803] Preparation of (S)-(l-(6-(hydroxymethyl)-4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[2,3- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (70f)
[0804] Step-1 : Preparation of 2-chloro-4-(methylthio)thieno[2,3-d]pyrimidine (70a)
[0805] To a solution of 2,4-dichlorothieno[2,3-d]pyrimidine (31a) (4 g, 19.51 mmol) in THF (100 mL) at 0 °C was added sodium thiomethoxide (1.418 g, 19.51 mmol) and allowed to come to room temperature. Reaction mixture was quenched by adding 1 N HCI and poured into water (200 mL). The solid separated was collected by filtration, dried in vacuum to afford 2-chloro-4- (methylthio)thieno[2,3-d]pyrimidine (70a) (3.76 g, 89 % yield) as a brown solid; ¾ MR (300 MHz, DMSO-i¾) δ 7.96 (d, J= 6.0 Hz, 1H), 7.50 (d, J= 6.0 Hz, 1H), 2.68 (s, 3H).
[0806] Step-2: Preparation of 2-chloro-4-(methylthio)thieno[2,3-d]pyrimidine-6-carbaldehyde (70b) To a solution of 2-chloro-4-(methylthio)thieno[2,3-d]pyrimidine (70a) (3.68 g, 17.0 mmol) in dry THF (100 mL) at-780C under nitrogen was added dropwise n-butyl lithium (1.6 M solution in hexanes, 21.25 mL, 34.0 mmol). Reaction was stirred at -78 °C for 1 .5 h and quenched slowly by dropwise addition of N,N-dimethylformamide (2.63 mL, 34.0 mmol). The reaction was stirred at -78 °C for 2 h and allowed to warm to room temperature overnight. The reaction mixture was cooled to 0 °C and quenched with 1 N HC1 and extracted with ethyl acetate (2 x 100 mL). The organic layer was separated, washed with water (2 x 20 mL); brine (20 mL) dried, filtered and concentrated in vacuum. The residue obtained was purified by flash column chromatography [silica gel, (40 g) eluting with 0-100% ethyl acetate in hexanes] to afford 2-chloro-4-(methylthio)thieno[2,3-d]pyrimidine-6-carbaldehyde (70b) (2.48 g, 60 % yield) as a brown solid,1H MR (300 MHz, DMSO-^e) δ 10.13 (s, 1H), 8.55 (s, 1H), 2.73 (s, 3H); MS (ES+): 277.2 (M+Na).
[0807] Step 3 : Preparation of 2,4-dichlorothieno[2,3-d]pyrimidine-6-carbaldehyde (70c)
[0808] To a solution of 2-chloro-4-(methylthio)thieno[2,3-d]pyrimidine-6-carbaldehyde (70b) (2 g,
[0809] 8.17 mmol) in acetonitrile (50 mL) and dichloromethane (20 mL) at 0 °C was added sulfuryl chloride (3.32 mL, 40.9 mmol) in dichloromethane (20 mL) over a period of 30 min. The reaction mixture was stirred for 10 min at 0 °C and quenched with saturated sodium bicarbonate solution. The reaction mixture was concentrated in vacuum to remove organic solvents and the aqueous residue was extracted with ethyl acetate (3 x 50 mL). The combined organic layer was washed with brine, dried, filtered, and concentrated under reduced pressure to afford 2,4- dichlorothieno[2,3-d]pyrimidine-6-carbaldehyde (70c) (1.9 g, 100 % yield) as a dark brown solid; ¾ NMR (300 MHz, DMSO-i¾) δ 10.19 (s, 1H), 8.62 (s, 1H).
[0810] Step 4: Preparation of (2,4-dichlorothieno[2,3-d]pyrimidin-6-yl)methanol (70d)
[0811] To a solution of 2,4-dichlorothieno[2,3-d]pyrimidine-6-carbaldehyde (70c) (1 g, 4.29 mmol) in THF (30 mL) and Water (1 mL) was added sodium borohydride (162 mg, 4.29 mmol) at room temperature and stirred for 20 min. The reaction mixture was diluted with ethyl acetate (100 mL), quenched with 1 N HC1. The organic layer was separated washed with brine, dried and concentrated. The residue obtained was purified by flash column chromatography [silica gel (25 g), eluting with 0-100% ethyl acetate in hexanes] to afford (2,4-dichlorothieno[2,3- d]pyrimidin-6-yl)methanol (70d) (450 mg, 45 % yield) as a white solid; ¾ MR (300 MHz, DMSO-de) δ 7.43 (t, J = 1.3 Hz, 1H), 6.07 (t, J = 5.7 Hz, 1H, D20 exchangeable), 4.83 (dd, J = 5.8, 1.3 Hz, 2H).
[0812] Step 5: Preparation of (2-chloro-4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[2,3- d]pyrimidin-6-yl)methanol (70e)
[0813] Compound 70e was prepared according to the procedure reported in Scheme 1 from (2,4- dichlorothieno[2,3-d]pyrimidin-6-yl)methanol (70d) (40 mg, 0.17 mmol) in 2-Propanol (10 mL) using DIPEA (0.12 mL, 0.68 mmol), and 1 -phenyl- lH-imidazol-4-amine hydrochloride (8a) (50 mg, 0.26 mmol). This gave (2-chloro-4-(l-phenyl-lH-imidazol-4-ylamino)thieno[2,3- d]pyrimidin-6-yl)methanol (70e) (25 mg, 41 % yield) as light pink solid. iH MR (300 MHz, DMSO-i¾) δ 10.95 (s, 1H, D20 exchangeable), 8.25 (d, J = 1.6 Hz, 1H), 7.92 (d, J = 1.6 Hz,
[0814] 1H), 7.87 (s, 1H), 7.66 (dd, J= 8.4, 1.4 Hz, 2H), 7.57 (t, J= 7.9 Hz, 2H), 7.46 - 7.35 (m, 1H), 5.83 (t, J= 5.8 Hz, 1H, D20 exchangeable), 4.72 (d, J= 5.6 Hz, 2H); MS (ES+): 380.3(M+Na),
[0815] (ES-): 356.2 (M-l).
[0816] Step 6: Preparation of (S)-(l-(6-(hydroxymethyl)-4-((l-phenyl-lH-imidazol-4- yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (70f)
[0817] Compound 70f was prepared from (2-chloro-4-(l-phenyl-lH-imidazol-4-ylamino)thieno[2,3- d]pyrimidin-6-yl)methanol (70e) (24 mg, 0.07 mmol), (S^-pyrrolidin-2-ylmethanol (20 mg, 0.2 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [ (silica gel C- 18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHC03, (S)-(l-(6-(hydroxymethyl)-4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[2,3- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (70f) (10 mg, 35 % yield) as a brown solid; ^H MR (300 MHz, OMSO-de) δ 10.07 (s, 1H, D20 exchangeable), 8.20 (s, 1H), 7.97 (d, J= 1.7
[0818] Hz, 1H), 7.85 - 7.67 (m, 2H), 7.65 (s, 1H), 7.58 - 7.42 (m, 2H), 7.39 - 7.28 (m, 1H), 5.50 (t, J = 5.7 Hz, 1H, D20 exchangeable), 5.05 - 4.82 (m, 1H, D20 exchangeable), 4.57 (d, J = 5.7 Hz, 2H), 4.42 - 3.99 (m, 1H), 3.97 - 3.34 (m, 4H), 2.16 - 1.76 (m, 4H); MS (ES+): 423.4 (M+l), (ES-): 421.3 (M-l), 457.4 (M+Cl).
[0819] Scheme 71
[0820]
[0821] Preparation of (S)-(l-(4-((l-(lH-pyrazol-3-yl)-lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (71c)
[0822] Step-1 : Preparation of N-(l-(lH-pyrazol-3-yl)-lH-imidazol-4-yl)-2-chloropyrrolo[2, l- f][l,2,4]triazin-4-amine (71b) Compound 71b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (357 mg, 1.9 mmol) in 2-Propanol (10 mL) using DIPEA (1.0 mL, 5.7 mmol) and l-(lH-pyrazol-3-yl)-lH-imidazol-4-amine (71a) (340 mg, 2.28 mmol). This gave N-(l-(lH-pyrazol-3-yl)-lH-imidazol-4-yl)-2-chloropyrrolo[2, l- f][l,2,4]triazin-4-amine (71b) (496 mg, 87 % yield) as yellow solid; ¾ NMR (300 MHz, OMSO-de) δ 12.92 (s, 1H), 1 1.34 (s, 1H), 8.35 - 8.13 (m, 1H), 8.02 - 7.93 (m, 1H), 7.93 - 7.81 (m, 1H), 7.81 - 7.66 (m, 1H), 7.52 - 7.26 (m, 1H), 6.83 - 6.68 (m, 1H), 6.67 - 6.53 (m, 1H); ¾ NMR (300 MHz, OMSO-defDiO) δ 8.14 (d, J = 1.6 Hz, 1H), 7.92 (d, J = 1.5 Hz, 1H), 7.82 (d, J = 2.4 Hz, 1H), 7.72 (dd, J = 2.6, 1.5 Hz, 1H), 7.33 - 7.26 (m, 1H), 6.71 (dd, J = 4.5, 2.6 Hz, 1H), 6.60 (d, J = 2.5 Hz, 1H); MS (ES+): 301.3(M+1); MS (ES-): 299.3(M-1); HPLC purity: 98.56%.
[0823] Step-2: Preparation of (S)-(l-(4-((l-(lH-pyrazol-3-yl)-lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (71c)
[0824] Compound 71c was prepared from N-(l-(lH-pyrazol-3-yl)-lH-imidazol-4-yl)-2- chloropyrrolo[2, l-f][l,2,4]triazin-4-amine (71b) (90 mg, 0.3 mmol), (S -pyrrolidin-2- ylmethanol (151 mg, 1.5 mmol), and DIPEA (0.16 mL, 0.9 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [( silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l- (lH-pyrazol-3-yl)-lH-imidazol-4-yl)amino)pyrrolo[2, l-f][l,2,4]triazin-2-yl)pyrrolidin-2- yl)methanol (71c) (86 mg, 79 % yield) as a white solid; ¾ NMR (300 MHz, OMSO-de) δ 12.94 (s, 1H, D20 exchangeable), 10.54 (s, 1H, D2O exchangeable), 8.15 (d, J = 1.5 Hz, 1H), 7.97 (d, 7 = 1.5 Hz, 1H), 7.86 (dd, J = 2.4, 1.1 Hz, 1H), 7.39 (dd, J = 2.4, 1.7 Hz, 1H), 7.13 (dd, J = 4.4, 1.7 Hz, 1H), 6.69 (s, 1H), 6.39 (dd, J = 4.4, 2.4 Hz, 1H), 4.86 (t, J = 5.6 Hz, 1H, D2O exchangeable), 4.25 - 4.04 (m, 1H), 3.88 - 3.71 (m, 1H), 3.58 - 3.45 (m, 1H), 3.45 - 3.24 (m, 2H), 2.17 - 1.70 (m, 4H); MS (ES+): 366.5(M+1), 388.5 (M+Na); HPLC purity: 99.33%.
[0825] Scheme 72
[0826] Preparation of (S)-(l-(4-((l-(3,5-dimethoxyphenyl)-lH-imidazol-4-yl)amino)pyrrolo[2,l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (72c)
[0827] Step-1 : Preparation of 2-chloro-N-(l-(3,5-dimethoxyphenyl)-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (72b)
[0828] Compound 72b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (313 mg, 1.67 mmol) in 2-Propanol (20 mL) using DIPEA (0.87 mL, 5.0 mmol) and l-(3,5-dimethoxyphenyl)-lH-imidazol-4-amine (72a) (365 mg, 1.67 mmol). This gave 2-chloro-N-(l-(3,5-dimethoxyphenyl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (72b) (492 mg, 80 % yield) as a solid; ¾ NMR (300 MHz, OMSO-de) δ 11.32 (s, 1H, D20 exchangeable), 8.29 (d, J = 1.6 Hz, 1H), 7.90 (d, J = 1.6 Hz, 1H), 7.77 (dd, J = 2.6, 1.6 Hz, 1H), 7.39 (d, J = 4.4 Hz, 1H), 6.80 (d, J = 2.2 Hz, 2H), 6.72 (dd, J = 4.5, 2.6 Hz, 1H), 6.54 (t, J = 2.2 Hz, 1H), 3.83 (s, 6H); MS (ES+): 371.4 (M+1); MS (ES-): 369.3 (M-1); HPLC purity: 98.98%.
[0829] Step-2: Preparation of (S)-(l-(4-((l-(3,5-dimethoxyphenyl)-lH-imidazol-4- yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (72c)
[0830] Compound 72c was prepared from 2-chloro-N-(l-(3,5-dimethoxyphenyl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (72b) (100 mg, 0.27 mmol), (Sj-pyrrolidin-2- ylmethanol (136 mg, 1.35 mmol), and DIPEA (0.14 mL, 0.81 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [( silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l- (3,5-dimethoxyphenyl)-lH-imidazol-4-yl)amino)pyrrolo[2, l-f][l,2,4]triazin-2-yl)pyrrolidin- 2-yl)methanol (72c) (73 mg, 62 % yield) as a white solid; ¾ NMR (300 MHz, OMSO-de) δ 10.53 (s, 1H, D2O exchangeable), 8.27 (d, J= 1.5 Hz, 1H), 7.97 (d, J= 1.6 Hz, 1H), 7.39 (dd, 7 = 2.4, 1.7 Hz, 1H), 7.14 (dd, J = 4.5, 1.7 Hz, 1H), 6.86 (d, J = 2.2 Hz, 2H), 6.47 (t, J = 2.2 Hz, 1H), 6.39 (dd, J = 4.4, 2.4 Hz, 1H), 4.82 (t, J = 5.1 Hz, 1H, D2O exchangeable), 4.27 - 4.13 (m, 1H), 3.82 (s, 6H), 3.78 - 3.65 (m, 1H), 3.62 - 3.48 (m, 1H), 3.49 - 3.24 (m, 2H), 2.10 - 1.79 (m, 4H); MS (ES+): 436.5 (M+1), 458.4 (M+Na); MS (ES-): 434.4 (M-1); HPLC purity: 98.94%.
[0831] Scheme 73
[0832] Preparation of (S)-(l-(4-((l-(3,4-dimethoxyphenyl)-lH-imidazol-4-yl)amino)pyrrolo[2,l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (73c)
[0833] Step-1 : Preparation of 2-chloro-N-(l-(3,4-dimethoxyphenyl)-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (73b)
[0834] Compound 73b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (313 mg, 1.67 mmol) in 2-Propanol (10 mL) using DIPEA (0.87 mL, 5.0 mmol) and l-(3,4-dimethoxyphenyl)-lH-imidazol-4-amine (73a) (365 mg, 1.67 mmol). This gave 2-chloro-N-(l-(3,4-dimethoxyphenyl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (73b) (513 mg, 83 % yield) as a solid; ¾ NMR (300 MHz, DMSO-^) 5 11.32 (s, 1H, D20 exchangeable), 8.16 (d, J = 1.6 Hz, 1H), 7.84 (d, J = 1.6 Hz, 1H), 7.76 (dd, J = 2.6, 1.5 Hz, 1H), 7.49 - 7.34 (m, 1H), 7.25 (t, J = 1.3 Hz, 1H), 7.16 - 7.06 (m, 2H), 6.72 (dd, J = 4.4, 2.6 Hz, 1H), 3.86 (s, 3H), 3.80 (s, 3H); MS (ES+): 371.5 (M+l); MS (ES-): 369.3 (M-l); HPLC purity: 99.51%.
[0835] Step-2: Preparation of (S)-(l-(4-((l-(3,4-dimethoxyphenyl)-lH-imidazol-4- yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (73c)
[0836] Compound 73c was prepared from 2-chloro-N-(l-(3,4-dimethoxyphenyl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (73b) (100 mg, 0.27 mmol), (Sj-pyrrolidin-2- ylmethanol (136 mg, 1.35 mmol), and DIPEA (0.14 mL, 0.81 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 %> TFA in acetonitrile and 0.1%) TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l-(3,4- dimethoxyphenyl)- lH-imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2- yl)methanol (73c) (38 mg, 32 % yield) as a pale off-white solid; ¾ NMR (300 MHz, DMSO- de) δ 10.51 (s, 1H, D2O exchangeable), 8.16 (d, J= 1.5 Hz, 1H), 7.92 (d, J= 1.6 Hz, 1H), 7.42
[0837] - 7.35 (m, 1H), 7.23 (d, J = 8.3 Hz, 2H), 7.14 (dd, 7 = 4.4, 1.7 Hz, 1H), 7.04 (d, J = 8.3 Hz, 1H), 6.39 (dd, J= 4.4, 2.4 Hz, 1H), 4.85 (t, J= 5.1 Hz, 1H, D2O exchangeable ), 4.19 (s, 1H), 3.87 (s, 3H), 3.80 (s, 3H), 3.80 - 3.67 (m, 1H), 3.60 - 3.47 (m, 1H), 3.47 - 3.25 (m, 2H), 2.09
[0838] - 1.80 (m, 4H); MS (ES+): 436.5 (M+l); MS (ES-): 434.4 (M-l). Scheme 74
[0839]
[0840] Preparation of N-(l-(lH-pyrazol-3-yl)-lH-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-l- yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine (74a)
[0841] Compound 74a was prepared from N-(l-(lH-pyrazol-3-yl)-lH-imidazol-4-yl)-2- chloropyrrolo[2,l-f][l,2,4]triazin-4-amine (71b) (90 mg, 0.3 mmol), 2-(pyrrolidin-2- yl)pyridine (133 mg, 0.9 mmol) and DIPEA (0.16 mL, 0.9 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, N-(l-(lH-pyrazol- 3 -yl)- lH-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin- 1 -yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4- amine (74a) (53 mg, 43% yield) as a yellowish solid; ¾ NMR (300 MHz, DMSO-^e) δ 12.93 (s, 1H, D20 exchangeable), 10.43 (s, 1H, D2O exchangeable), 8.40 (d, J= 4.8 Hz, 1H), 8.03 (s, 1H), 7.93 (t, J= 2.0 Hz, 1H), 7.73 - 7.46 (m, 2H), 7.37 (s, 1H), 7.20 (d, J= 7.9 Hz, 1H), 7.17 - 7.03 (m, 2H), 6.69 (t, J = 2.2 Hz, 1H), 6.38 (dd, J = 4.4, 2.4 Hz, 1H), 5.34 (d, J = 8.1 Hz, 1H), 3.98 - 3.78 (m, 1H), 3.78 - 3.50 (m, 1H), 2.44 - 2.27 (m, 1H), 2.11 - 1.71 (m, 3H); MS (ES+): 413.5 (M+l), 435.5 (M+Na); HPLC purity: 98.54%.
[0842] Scheme 75
[0843]
[0844] Preparation of (S)-(l-(4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)amino)thieno[3,2- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (75b)
[0845] Step-1 : Preparation of 2-chloro-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)thieno[3,2- d]pyrimidin-4-amine (75a) Compound 75a was prepared according to the procedure reported in Scheme 1 from 2,4- dichlorothieno[3,2-d]pyrimidine (12a) (304 mg, 1.48 mmol) in 2-Propanol (10 mL) using DIPEA (0.52 mL, 2.97 mmol) and l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-amine (57a) (370 mg, 1.48 mmol). This gave 2-chloro-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)thieno[3,2-d]pyrimidin-4-amine (75a) (403 mg, 65 % yield) as a light pink solid; ¾ NMR (300 MHz, DMSO-i¾) δ 10.86 (s, IH, D20 exchangeable), 8.24 (d, J = 6.0 Hz, 2H), 7.95 (s, IH), 7.39 (d, J= 5.4 Hz, IH), 6.96 (s, 2H), 3.87 (s, 6H), 3.69 (s, 3H); MS (ES+): 440.3 (M+Na), (ES-): 416.3 (M-l).
[0846] Step-2: Preparation of (S)-(l-(4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (75b)
[0847] Compound 75b was prepared from 2-chloro-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)thieno[3,2-d]pyrimidin-4-amine (75a) (100 mg, 0.24 mmol), (S)-pyrrolidin-2-ylmethanol (73 mg, 0.72 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [ (silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- ylamino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (75b) (93 mg, 81 % yield) as a brown solid;lU NMR (300 MHz, DMSO-^e) δ 10.19 (s, IH, D20 exchangeable), 8.22 (d, J =
[0848] 1.5 Hz, IH), 8.09 - 7.98 (m, IH), 7.93 (d, J = 5.4 Hz, IH), 7.10 (d, J = 5.3 Hz, IH), 6.95 (s, 2H), 5.29 - 4.79 (m, IH, D20 exchangeable), 4.53 - 4.04 (m, IH), 3.88 (s, 6H), 3.81 - 3.55 (m,
[0849] 5H), 3.46 - 3.24 (m, 2H), 2.10 - 1.69 (m, 4H); MS (ES+): 483.5 (M+l), 505.5 (M+Na), 965.8 (2M+1), 987.8 (2M+Na), (ES-): 481.5 (M-l).
[0850] Scheme 76
[0851]
[0852] 76a
[0853] Preparation of (S)-(l-(4-((l-(quinolin-5-yl)-lH-imidazol-4-yl)amino)pyrrolo[2,l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (76c) Step-1 : Preparation of 2-chloro-N-(l-(quinolin-5-yl)-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (76b)
[0854] Compound 76b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (0.5 g , 2.65 mmol) in DCM (20 mL) using DIPEA (1.03 g, 7.97 mmol) and l-(quinolin-5-yl)-lH-imidazol-4-amine (76a) (0.67 g, 3.19 mmol). This gave after work up and purification by flash column chromatography (silica gel, eluting with 0-80% ethyl acetate in hexanes) 2-chloro-N-(l-(quinolin-5-yl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (76b) (300 mg, 31 % yield) as an off white solid; ¾ MR (300 MHz, OMSO-de): δ 11.45 (s, 1H), 9.04-9.03 (s, 1H), 8.23-8.20 (d, 1H), 8.11-7.96 (d, 2H), 7.93-7.91 (t, 1H), 7.84-7.82 (m, 3H), 7.77-7.76 (m, 1H), 7.45-7.44 (s, 1H), 6.75-6.74 (s, 1H); MS (ES+): 362.0 (M+l).
[0855] Step-2: Preparation of (S)-(l-(4-((l-(quinolin-5-yl)-lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (76c)
[0856] A stirred solution of 2-chloro-N-(l-(quinolin-5-yl)-lH-imidazol-4-yl)pyrrolo[2,l- f][l,2,4]triazin-4-amine (76b) (300 mg, 0.83 mmol) and (S)-pyrrolidin-2-ylmethanol (838 mg, 8.29 mmol) in MP (10 mL) was heated at 150 °C for 16 h. The reaction mixture was extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with a brine solution (100 mL), dried, filtered and concentrated under reduced pressure. The crude product obtained was purified by flash column chromatography (silica gel, eluting with 0-10% ethyl acetate in methanol) to afford (S)-(l-(4-((l-(quinolin-5-yl)-lH-imidazol-4- yl)amino)pyrrolo[2,l-f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (76c) (110 mg, 31%) as an off-white solid; ^H NMR (300 MHz, DMSO-^6) δ 10.63 (s, 1H, D20 exchangeable), 9.03 (dd,
[0857] J = 4.1, 1.6 Hz, 1H), 8.30 - 8.10 (m, 2H), 8.02 (d, J = 1.4 Hz, 1H), 7.96 - 7.86 (m, 2H), 7.80 (dd, J= 7.4, 1.2 Hz, 1H), 7.66 (dd, J = 8.6, 4.2 Hz, 1H), 7.40 (t, J= 2.0 Hz, 1H), 7.18 (dd, J = 4.5, 1.7 Hz, 1H), 6.41 (dd, J = 4.4, 2.4 Hz, 1H), 4.51 (t, J = 5.3 Hz, 1H, D20 exchangeable),
[0858] 4.10 - 3.96 (m, 1H), 3.63 - 3.49 (m, 1H), 3.47 - 3.20 (m, 3H), 1.98 - 1.68 (m, 4H); MS (ES+) 449.5 (M+Na); HPLC purity: 94.15 %.
[0859] Scheme 77
[0860] Preparation of (S)-(l-(7-(4-methoxyphenyl)-4-((l-phenyl-lH-imidazol-4- yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (77d)
[0861] Step-1 : Preparation of 7-bromo-2-chloro-N-(l-phenyl-lH-imidazol-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (77b)
[0862] Compound 77b was prepared according to the procedure reported in Scheme 1 from 7-bromo- 2,4-dichloropyrrolo[l,2-f][l,2,4]triazine (77a) (50 mg, 0.19 mmol; CAS# 1008112-03-5) in 2- Propanol (6 mL) using DIPEA (0.67 mL, 3.83 mmol) and l-phenyl-lH-imidazol-4-amine, HC1 (8a) (250 mg, 1.28 mmol). This gave after workup and purification by flash column chromatography [silica gel, 40 g eluting with a 9: 1 mixture of ethyl acetate and methanol in hexanes (0 to 100%)] 7-bromo-2-chloro-N-(l-phenyl-lH-imidazol-4-yl)pyrrolo[2,l- f][l,2,4]triazin-4-amine (77b) (22 mg, 30% yield) as a white solid; ¾ MR (300 MHz, OMSO-de) δ 11.50 (s, 1H, D2O exchangeable), 8.27 (d, J = 1.6 Hz, 1H), 7.92 (d, J = 1.6 Hz, 1H), 7.71 - 7.63 (m, 2H), 7.57 (dd, J = 8.8, 7.1 Hz, 2H), 7.52 (d, J = 4.7 Hz, 1H), 7.46 - 7.37 (m, 1H), 6.91 (d, J = 4.7 Hz, 1H). MS (ES+): 389.2, 391.3 (M+2); MS (ES-): 387.2, 389.1 (M+2).
[0863] Step-2: Preparation of (S)-(l-(7-bromo-4-((l-phenyl-lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (77c)
[0864] Compound 77c was prepared from 7-bromo-2-chloro-N-(l-phenyl-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (77b) (50 mg, 0.13 mmol), (^-pyrrolidin-2-ylmethanol (0.04 mL, 0.39 mmol), and DIPEA (0.07 mL, 0.39 mmol) in NMP (0.5 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by flash chromatography [silica (4g), eluting with DMA-80 in CHCh from 0 to 20%] (S)-(l-(7-bromo- 4-(( 1 -phenyl- lH-imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2- yl)methanol (77c), which was used as such in next step without further purification.
[0865] Step-3 : Preparation of (S)-(l-(7-(4-methoxyphenyl)-4-((l-phenyl-lH-imidazol-4- yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (77d)
[0866] A slurry of (S)-(l -(7 -bromo-4-((l -phenyl- lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (77c) (20 mg, 0.04 mmol), 4- methoxyphenylboronic acid (33 mg, 0.22 mmol), Pd(dppf)Cl2 (7 mg, 8.80 μπιοΐ), sodium carbonate (12 mg, 0.11 mmol) in a sealed reactor under a positive flow of nitrogen in Dioxane (3 mL) and Water (1 mL) was stirred at 90 °C for 2 h. The reaction mixture was cooled to room temperature, diluted with EtOAc (50 mL) and filtered though a Celite pad. Reaction mixture was purified by reverse phase flash column chromatography [(silica gel C-18, 24 g) eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water]. The appropriate fractions containing the product were combined and concentrated to remove acetonitrile. The aqueous solution was basified with saturated sodium bicarbonate and the solid obtained was collected by filtration, dried in vacuum to afford (S)-(l-(7-(4-methoxyphenyl)-4-((l-phenyl-lH-imidazol-4- yl)amino)pyrrolo[2,l-f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (77d) (6 mg, 28% yield) as a yellow solid; ¾ MR (300 MHz, OMSO-de): δ 10.53 (s, 1H, D20 exchangeable), 8.29 (d, J = 1.5 Hz, 1H), 8.22 - 8.13 (m, 2H), 8.01 (d, J = 1.7 Hz, 1H), 7.76 (d, J = 7.9 Hz, 2H), 7.51 (t, J= 7.8 Hz, 2H), 7.36 (t, J= 7.3 Hz, 1H), 7.29 (d, J= 4.6 Hz, 1H), 7.04 - 6.96 (m, 2H), 6.81 (d, J= 4.6 Hz, 1H), 4.23 (s, 1H), 3.82 (s, 1H), 3.79 (s, 3H), 3.64 - 3.52 (m, 1H), 3.44 (q, J= 10.0, 9.2 Hz, 2H), 2.16 - 1.82 (m, 4H); MS (ES+): 482.6 (M+l).
[0867]
[0868] Preparation of (S)-(l-(6-(hydroxymethyl)-4-((l-phenyl-lH-imidazol-4-yl)amino
[0869] d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (78f)
[0870] Step-1 : Preparation of 2-chloro-4-(methylthio)thieno[3,2-d]pyrimidine (78a) Compound 78a was prepared from 2,4-dichlorothieno[3,2-d]pyrimidine (12a) (2 g, 9.75 mmol) and sodium thiomethoxide (0.75 g, 10.24 mmol) according to the procedure reported in step-1 of Scheme 70. This gave after workup 2-chloro-4-(methylthio)thieno[3,2-d]pyrimidine (78a) (1.85 g, 88 % yield) as a brown solid; ¾ NMR (300 MHz, DMSO- ck) δ 8.47 (d, J = 5.4 Hz, 1H), 7.60 (d, J= 5.4 Hz, 1H), 2.75 (s, 3H).
[0871] Step-2: Preparation of 2-chloro-4-(methylthio)thieno[3,2-d]pyrimidine-6-carbaldehyde (78b) Compound 78b was prepared from 2-chloro-4-(methylthio)thieno[3,2-d]pyrimidine (78a) (1 g, 4.61 mmol) according to the procedure reported in step-2 of Scheme 70. This gave after workup 2-chloro-4-(methylthio)thieno[3,2-d]pyrimidine-6-carbaldehyde (78b) (1.05 g, 93 % yield) as a red solid; ¾ NMR (300 MHz, DMSO-^e) δ 10.25 (s, 1H), 8.50 (s, 1H), 2.77 (s, 3H).
[0872] Step 3 : Preparation of 2,4-dichlorothieno[3,2-d]pyrimidine-6-carbaldehyde (78c)
[0873] Compound 78c was prepared from 2-chloro-4-(methylthio)thieno[3,2-d]pyrimidine-6- carbaldehyde (78b) (200 mg, 0.82 mmol) according to the procedure reported in step-3 of Scheme 70. This gave after workup 2,4-dichlorothieno[3,2-d]pyrimidine-6-carbaldehyde (78c) (75 mg, 39% yield) as a white solid. ¾ NMR (300 MHz, DMSO- de) δ 10.29 (s, 1H), 8.63 (s, 1H).
[0874] Step 4: Preparation of (2,4-dichlorothieno[3,2-d]pyrimidin-6-yl)methanol (78d)
[0875] Compound 78d was prepared from 2,4-dichlorothieno[3,2-d]pyrimidine-6-carbaldehyde (78c) (70 mg, 0.3 mmol) according to the procedure reported in step-4 of Scheme 70. This gave after workup (2,4-dichlorothieno[3,2-d]pyrimidin-6-yl)methanol (78d) (95 mg) as a light orange solid; ¾ NMR (300 MHz, DMSO-^e) δ 7.43 (t, J = 1.3 Hz, 1H), 6.07 (t, J = 5.7 Hz, 1H, D20 exchangeable), 4.83 (dd, J = 5.8, 1.3 Hz, 2H).
[0876] Step 5: Preparation of (2-chloro-4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[3,2- d]pyrimidin-6-yl)methanol (78e)
[0877] Compound 78e was prepared according to the procedure reported in Scheme 1 from (2,4- dichlorothieno[3,2-d]pyrimidin-6-yl)methanol (78d) (90 mg, 0.38 mmol) in 2-Propanol (10 mL) using DIPEA (0.1 mL, 0.57 mmol), and l-phenyl-lH-imidazol-4-amine hydrochloride (8a) (91 mg, 0.57 mmol). This gave (2-chloro-4-(l-phenyl-lH-imidazol-4-ylamino)thieno[3,2- d]pyrimidin-6-yl)methanol (78e) (45 mg, 33 % yield) as a dark brown solid; ¾ NMR (300 MHz, DMSO-i¾) δ 10.99 - 10.67 (m, 1H, D2O exchangeable), 8.27 (s, 1H), 7.94 (d, J= 1.7 Hz, 1H), 7.68 (d, J = 7.9 Hz, 2H), 7.57 (t, J = 7.8 Hz, 2H), 7.41 (t, J = 7.3 Hz, 1H), 7.21 (s, 1H), 5.92 (s, 1H, D2O exchangeable), 4.78 (d, J = 5.4 Hz, 2H); MS (ES+): 358.3 (M+l), (ES-): 356.3 (M-l). Step 6: Preparation of (S)-(l-(6-(hydroxymethyl)-4-((l-phenyl-lH-imidazol-4- yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (78f)
[0878] Compound 78f was prepared from (2-chloro-4-(l-phenyl-lH-imidazol-4-ylamino)thieno[3,2- d]pyrimidin-6-yl)methanol (78e) (39 mg, 0.11 mmol), (^-pyrrolidin-2-ylmethanol (33 mg, 0.33 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHC03, (S)-(l-(6-(hydroxymethyl)-4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[3,2- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (78f) (12 mg, 26 % yield) as a brown solid; ¾ MR (300 MHz, DMSO-i¾) δ 10.00 (s, 1H, D20 exchangeable), 8.20 (d, J= 1.7 Hz, 1H), 7.97 (d, J= 1.7 Hz, 1H), 7.81 - 7.59 (m, 2H), 7.51 (t, J= 7.7 Hz, 2H), 7.34 (t, J= 7.4 Hz, 1H), 6.93 (d, J = 1.1 Hz, 1H), 5.72 (t, J = 5.8 Hz, 1H, D2O exchangeable), 5.04 (s, 1H, D2O exchangeable), 4.70 (dd, J = 5.8, 1.2 Hz, 2H), 4.22 (s, 1H), 3.88 - 3.69 (m, 1H), 3.69 - 3.49 (m, 2H), 3.44 - 3.24 (m, 1H), 2.12 - 1.81 (m, 4H); MS (ES+): 423.4 (M+l); (ES-): 421 (M-l); HPLC purity: 95.50 %.
[0879] Scheme 79
[0880]
[0881] Preparation of (S)-(l-(7-(pent-l-en-l-yl)-4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (79d)
[0882] Step-1 : Preparation of 2-chloro-4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazine-7-carbaldehyde (79b) Compound 79b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[2,l-f][l,2,4]triazine-7-carbaldehyde (79a) (400 mg, 1.85 mmol) in 2-Propanol (20 mL) using DIPEA (0.97 mL, 5.55 mmol) and l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- amine (57a) (635 mg, 2.22 mmol). This gave 2-chloro-4-((l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-yl)amino)pyrrolo[2, l-f][l,2,4]triazine-7-carbaldehyde (79b) (564 mg, 71 % yield) as a yellow solid; ¾ NMR (300 MHz, DMSO-^e) δ 11.81 (s, 1H), 10.21 (s, 1H), 9.46 (s, OH), 8.25 (d, J= 1.5 Hz, 1H), 7.93 (d, J= 1.6 Hz, 1H), 7.50 (d, J= 4.9 Hz, 1H), 7.35 (d, J= 4.8 Hz, 1H), 6.94 (s, 2H), 3.88 (s, 6H), 3.69 (s, 3H). MS (ES+): 429.5 (M+l); MS (ES-): 427.3 (M-l). Step 2: Preparation of l-(2-chloro-4-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- ylamino)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-7-yl)pentan- 1 -ol (79c)
[0883] To a solution of 2-chloro-4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)pyrrolo[2,l-f][l,2,4]triazine-7-carbaldehyde (79b) (100 mg, 0.23 mmol) in THF (10 mL) at -78°C was added n-BuLi (1.6 M, 0.32 mL, 0.51 mmol) and stirred at -78°C for 4 h. The reaction mixture was quenched with Sat. H4CI and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine, dried, filtered, concentrated under vacuum and purified by flash column chromatography (Silica gel 12 g, eluting with MeOH in DCM from 0 to 20%) to afford l-(2-chloro-4-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- ylamino)pyrrolo[l,2-f][l,2,4]triazin-7-yl)pentan-l-ol (79c) (65 mg, 57 % yield) as yellow solid; ¾ MR (300 MHz, Chloroform-i ) δ 10.51 (s, 1H), 7.94 (d, J= 1.6 Hz, 1H), 7.65 (d, J = 1.6 Hz, 1H), 6.84 (d, J = 4.5 Hz, 1H), 6.65 (s, 2H), 6.58 (d, J = 4.4 Hz, 1H), 5.16 (dd, J = 7.5, 6.1 Hz, 1H), 3.92 (s, 6H), 3.88 (s, 3H), 2.14 - 1.79 (m, 2H), 1.65 - 1.21 (m, 4H), 0.91 (t, J= 7.0 Hz, 3H); MS (ES+): 487.5 (M+l); MS (ES-): 485.5 (M-l).
[0884] Step-3 : Preparation of (S)-(l-(7-(pent-l-en-l-yl)-4-((l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (79d)
[0885] Compound 79d was prepared from l-(2-chloro-4-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol- 4-ylamino)pyrrolo[l,2-f][l,2,4]triazin-7-yl)pentan-l-ol (79c) (65 mg, 0.13 mmol), (S)- pyrrolidin-2-ylmethanol (68 mg, 0.67 mmol), DIPEA (0.07 mL, 0.4 mmol) in MP (2.5 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)- ( 1 -(7-(pent- 1 -en- 1 -yl)-4-(( 1 -(3 ,4, 5 -trimethoxyphenyl)- 1 H-imidazol-4-yl)amino)pyrrolo[2, 1 - f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (79d) (11 mg, 15 % yield) as a white solid; ¾ MR (300 MHz, DMSO-i¾) δ 10.47 (s, 1H, D2O exchangeable), 8.24 (d, J= 1.6 Hz, 1H), 7.97 (d, J= 1.6 Hz, 1H), 7.14 (d, J= 4.6 Hz, 1H), 6.95 (s, 2H), 6.70 (d, J= 16.1 Hz, 1H), 6.55 (d, J = 4.6 Hz, 1H), 6.52 - 6.40 (m, 1H), 4.84 (t, J = 5.1 Hz, 1H, D20 exchangeable), 4.30 - 4.17 (m, 1H), 3.88 (s, 6H), 3.81 - 3.68 (m, 1H), 3.68 (s, 3H), 3.66 - 3.53 (m, 1H), 3.54 - 3.35 (m, 2H), 2.19 (q, J = 7.1 Hz, 2H), 2.10 - 1.81 (m, 4H), 1.56 - 1.39 (m, 2H), 0.93 (t, J = 7.2 Hz, 3H); MS (ES+): 534.6 (M+1); MS (ES-): 532.7 (M-1), 568.6 (M+Cl); HPLC purity: 94.02%.
[0886] Scheme 80
[0887]
[0888] Preparation of (S)-tert-butyl 4-(2-(2-(hydroxymethyl)pyrrolidin-l-yl)-4-(l-phenyl-lH- imidazol-4-ylamino)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-7-yl)-5,6-dihydropyridine- 1 (2H)-carboxylate (80a)
[0889] Compound 80a was prepared from (S)-(l-(7-bromo-4-(l-phenyl-lH-imidazol-4- ylamino)pyrrolo[l,2-f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (77c) (30 mg, 0.07 mmol), l-(tert-butoxycarbonyl)-l,2,3,6-tetrahydropyridin-4-ylboronic acid (30.0 mg, 0.13 mmol), Pd(dppf)Cl2 (9.69 mg, 0.01 mmol), sodium carbonate (17.50 mg, 0.17 mmol) in Dioxane (3 mL) and Water (1 mL) according to the procedure reported in step-3 of Scheme 77. This gave after purification by reverse phase flash column chromatography [(silica gel C-18, 24 g) eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water] (S)-tert-butyl 4-(2-(2- (hydroxymethyl)pyrrolidin- 1 -yl)-4-( 1 -phenyl- 1 H-imidazol-4-ylamino)pyrrolo[ 1 ,2- f][l,2,4]triazin-7-yl)-5,6-dihydropyridine-l(2H)-carboxylate (80a) (7 mg, 19 % yield) as a brown solid; ¾ NMR (300 MHz, OMSO-de): δ 10.52 (s, 1H, D2O exchangeable), 8.27 (d, J = 1.6 Hz, 1H), 7.98 (d, J = 1.6 Hz, 1H), 7.75 (d, J = 7.9 Hz, 2H), 7.51 (t, J = 7.8 Hz, 2H), 7.35 (t, J= 7.3 Hz, 1H), 7.21 (d, J= 4.9 Hz, 1H), 6.50 (d, J= 4.7 Hz, lH), 4.19 (s, 3H), 4.06 (s, 3H), 3.78 (d, J= 9.8 Hz, 1H), 3.54 (s, 3H), 3.38 (s, 1H), 2.59 - 2.53 (m, 1H), 2.10 - 1.91 (m, 4H), 1.43 (s, 9H).19F MR (282 MHz, OMSO-de) δ -73.99; MS (ES+): 557.6 (M+1); 579.6 (M+Na). Scheme 81
[0890]
[0891] Preparation of N-( 1 '-methyl- 1 Ή-[ 1 ,4'-biimidazol]-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin- 1 - yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine (81c)
[0892] Step-1 : Preparation of 2-chloro-N-( -methyl- H-[l,4'-biimidazol]-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (81b)
[0893] Compound 81b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (187 mg, 0.99 mmol) in 2-Propanol (10 mL) using DIPEA (0.52 mL, 2.98 mmol) and 1 '-methyl- m-l,4'-biimidazol-4-amine (81a) (162 mg, 0.99 mmol). This gave 2-chloro-N-(l'-methyl- H-[l,4'-biimidazol]-4-yl)pyrrolo[2, l- f][l,2,4]triazin-4-amine (81b) (205 mg, 66 % yield) as a pale off-white solid; ¾ NMR (300 MHz, DMSO-^) 5 11.31 (s, 1H, D20 exchangeable), 8.03 (d, J = 1.5 Hz, 1H), 7.84 (d, J = 1.5 Hz, 1H), 7.76 (dd, J = 2.6, 1.5 Hz, 1H), 7.65 (d, J = 1.4 Hz, 1H), 7.49 (d, J = 1.5 Hz, 1H), 7.39 (dd, J = 4.5, 1.6 Hz, 1H), 6.71 (dd, J = 4.4, 2.6 Hz, 1H), 3.71 (s, 3H); MS (ES+): 315.3(M+1), 337.3 (M+Na); MS (ES-): 313.3(M-1); HPLC purity: 99.21 %.
[0894] Step-2: Preparation of N-(r-methyl-rH-[l,4'-biimidazol]-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin- 1 -yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine (81c)
[0895] Compound 81c was prepared from 2-chloro-N-( -methyl-l'H-[l,4'-biimidazol]-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (81b) (70 mg, 0.22 mmol), 2-(pyrrolidin-2-yl)pyridine (99 mg, 0.67 mmol) and DIPEA (0.12 mL, 0.67 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, N-(l '-methyl- l'H-[ 1,4'- biimidazol]-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin- 1 -yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine
[0896] (81c) (55 mg, 58 % yield) as a off-white solid; ¾ NMR (300 MHz, DMSO-^e) δ 10.40 (s, 1H, D2O exchangeable), 8.44 (d, J = 4.8 Hz, 1H), 7.89 (d, J = 1.5 Hz, 1H), 7.65 (s, 1H), 7.64 - 7.55 (m, 1H), 7.44 (d, J = 1.5 Hz, 1H), 7.42 - 7.33 (m, 2H), 7.20 (d, J = 7.9 Hz, 1H), 7.21 - 7.10 (m, 1H), 7.12 - 7.08 (m, 1H), 6.38 (dd, J = 4.5, 2.4 Hz, 1H), 5.34 (d, J = 8.1 Hz, 1H), 3.92 - 3.80 (m, 1H), 3.79 (s, 3H), 3.74 - 3.57 (m, 1H), 2.53 - 2.25 (m, 1H), 2.11 - 1.74 (m, 3H); MS (ES+): 427.5 (M+l), 449.5 (M+Na); HPLC purity: 98.90%.
[0897] Scheme 82
[0898]
[0899] Preparation of (S)-( 1 -(4-(( 1 '-methyl- 1 Ή-[ 1 ,4'-biimidazol]-4-yl)amino)pyrrolo[2, 1 - f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (82a)
[0900] Compound 82a was prepared from 2-chloro-N-( -methyl-l'H-[l,4'-biimidazol]-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (81b) (70 mg, 0.22 mmol), (S)-pyrrolidin-2-ylmethanol (112 mg, 1.11 mmol) and DIPEA (0.12 mL, 0.67 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-(( -methyl-l'H-[l,4'- biimidazol]-4-yl)amino)pyrrolo[2, l-f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (82a) (65 mg, 77 % yield) as an off-white solid; ¾ NMR (300 MHz, DMSO-^e) δ 10.52 (s, 1H), 8.01 (d, J = 1.5 Hz, 1H), 7.89 (d, J = 1.6 Hz, 1H), 7.71 - 7.58 (m, 1H), 7.54 (d, J = 1.5 Hz, 1H), 7.39 (dd, J = 2.4, 1.6 Hz, 1H), 7.12 (dd, J = 4.4, 1.7 Hz, 1H), 6.39 (dd, J = 4.4, 2.5 Hz, 1H), 5.26 - 4.98 (m, 1H), 4.31 - 4.00 (m, 1H), 3.95 - 3.76 (m, 1H), 3.73 - 3.65 (m, 3H), 3.53 - 3.25 (m, 3H), 2.16 - 1.84 (m, 4H); MS (ES+): 380.4 (M+l), 402.4 (M+Na); HPLC purity: 99.92%.
[0901] Scheme 83
[0902]
[0903] Preparation of ((S)- 1 -(4-((l -(3 -fluoro-5-((S)-2-(hydroxymethyl)pyrrolidin- 1 -yl)phenyl)- 1H- imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (83c)
[0904] Step-1 : Preparation of 2-chloro-N-(l-(3,5-difluorophenyl)-lH-imidazol-4-yl)pyrrolo[l,2- f][l,2,4]triazin-4-amine (83b) Compound 83b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (365 mg, 1.94 mmol) in 2-Propanol (10 mL) using DIPEA (1.02 mL, 5.83 mmol) and l-(3,5-difluorophenyl)-lH-imidazol-4-amine (83a) (379 mg, 1.94 mmol). This gave 2-chloro-N-(l-(3,5-difluorophenyl)-lH-imidazol-4-yl)pyrrolo[l,2- f][l,2,4]triazin-4-amine (83b) (521 mg, 77 % yield) as a solid; ¾ NMR (300 MHz, DMSO- di δ 11.33 (s, 1H, D20 exchangeable), 8.38 (d, J = 1.6 Hz, 1H), 7.97 (d, J = 1.6 Hz, 1H), 7.79 (dd, J = 2.6, 1.5 Hz, 1H), 7.65 - 7.53 (m, 2H), 7.45 - 7.36 (m, 1H), 7.31 (tt, J = 9.3, 2.2 Hz, 1H), 6.73 (dd, J = 4.5, 2.6 Hz, 1H);19F NMR (282 MHz, OMSO-de) δ -107.50; MS (ES+): 347.3 (M+1); MS (ES-): 345.2 (M-1); HPLC purity: 98.86%.
[0905] Step-2: Preparation of ((S)-l-(4-((l-(3-fluoro-5-((S)-2-(hydroxymethyl)pyrrolidin-l- yl)phenyl)-lH-imidazol-4-yl)amino)pyrrolo[2, l-f][l,2,4]triazin-2-yl)pyrrolidin-2- yl)methanol (83c)
[0906] Compound 83c was prepared from 2-chloro-N-(l-(3,5-difluorophenyl)-lH-imidazol-4- yl)pyrrolo[l,2-f][l,2,4]triazin-4-amine (83b) (100 mg, 0.29 mmol), (Sj-pyrrolidin-2- ylmethanol (146 mg, 1.44 mmol), and DIPEA (0.15 mL, 0.87 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, ((S)-l-(4-((l-(3- fluoro-5-((S)-2-(hydroxymethyl)pyrrolidin-l-yl)phenyl)-lH-imidazol-4- yl)amino)pyrrolo[2,l-f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (83c) (66 mg, 47 % yield) as a white solid; ¾ NMR (300 MHz, OMSO-de) δ 10.55 (s, 1H, D2O exchangeable), 8.24 (d, J= 1.5 Hz, 1H), 7.95 (d, J= 1.6 Hz, 1H), 7.39 (dd, J= 2.5, 1.7 Hz, 1H), 7.14 (dd, J= 4.5, 1.7 Hz, 1H), 6.90 - 6.77 (m, 1H), 6.60 (s, 1H), 6.46 - 6.33 (m, 2H), 4.83 (t, J = 6.1 Hz, 2H, D2O exchangeable), 4.27 - 4.08 (m, 1H), 3.83 - 3.75 (m, 1H), 3.74 - 3.64 (m, 1H), 3.61 - 3.55 (m, 1H), 3.53 - 3.29 (m, 4H), 3.27 - 3.21 (m, 1H), 3.18 - 3.05 (m, 1H), 2.22 - 1.72 (m, 8H);19F NMR (282 MHz, DMSO-d) δ -110.98 - 111.15 (m);19FCPD NMR (282 MHz, DMSO-i¾) δ - 111.06; MS (ES+): 493.5 (M+1); MS (ES-): 491.4 (M-1), 527.6 (M+Cl); HPLC purity: 96.03%.
[0907] Scheme 84
[0908] 57a
[0909] Preparation of (S)-(l-(4-((l-(3,4,5 rimethoxyphenyl)-lH-imidazol-4-yl)amino)thieno[2,3- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (84b)
[0910] Step-1 : Preparation of 2-chloro-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)thieno[2,3- d]pyrimidin-4-amine (84a)
[0911] Compound 84a was prepared according to the procedure reported in Scheme 1 from 2,4- dichlorothieno[2,3-d]pyrimidine (31a) (0.4 g, 1.95 mmol) in 2-Propanol (10 mL) using DIPEA (1.36 mL, 7.8 mmol) and l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-amine (57a) (669 mg, 2.34 mmol). This gave 2-chloro-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)thieno[2,3- d]pyrimidin-4-amine (84a) (275 mg, 34 % yield) as a buff colored solid; ¾ NMR (300 MHz, OMSO-de) δ 11.01 (s, 1H, D20 exchangeable), 8.21 (d, J= 1.6 Hz, 1H), 8.02 (s, 1H), 7.91 (d, J = 1.6 Hz, 1H), 7.71 (d, J = 5.9 Hz, 1H), 6.93 (s, 2H), 3.87 (s, 6H), 3.69 (s, 3H); MS (ES+): 440.3 (M+Na), (ES-): 416.2 (M-1).
[0912] Step-2: Preparation of (S)-(l-(4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (84b)
[0913] Compound 84b was prepared from 2-chloro-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)thieno[2,3-d]pyrimidin-4-amine (84a) (100 mg, 0.24 mmol), (^-pyrrolidin-2-ylmethanol (73 mg, 0.72 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (84b) (65 mg, 56 % yield) as a brown solid; ¾ NMR (300 MHz, DMSO-^e) δ 10.17 (s, 1H, D2O exchangeable), 8.23 (d, J = 1.7 Hz, 1H), 8.08 - 7.94 (m, 1H), 7.79 (d, J= 6.0 Hz, 1H), 7.02 (d, J= 6.0 Hz, 1H), 6.95 (s, 2H), 4.90 (s, 1H, D2O exchangeable), 4.47 - 4.24 (m, 1H), 3.88 (s, 6H), 3.82 - 3.51 (m, 5H), 3.46 - 3.23 (m, 2H), 2.13 - 1.79 (m, 4H); MS (ES+): 483.4 (M+l), 505.4 (M+Na), (ES-): 481.4 (M-1); Hydrochloride salt of compound 84b was prepared by purification of crude reaction mixture from step-2 above by reverse phase flash chromatography [(silica gel C-18, 24 g) eluting with acetonitrile and 0.1% HC1 in water; ¾ NMR (300 MHz, OMSO-de): δ 11.36 (s, 1H), 8.45 (s, 1H), 8.20 - 7.84 (m, 2H), 7.37 (d, J = 5.8 Hz, 1H), 6.99 (s, 2H), 4.68 - 4.19 (m, 1H), 4.14 - 3.07 (m, 13H), 2.20 - 1.76 (m, 4H). MS (ES+): 483.2 (M+l), 505.3 (M+Na); MS (ES-): 517.2 (M+Cl); HPLC purity; 95.1 1%.
[0914] Scheme 85
[0915]
[0916] Preparation of (S)-(l-(7-bromo-4-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- ylamino)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (85b)
[0917] Step-1 : Preparation of 7-bromo-2-chloro-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-4-amine (85a)
[0918] Compound 85a was prepared according to the procedure reported in Scheme 1 from 7-bromo- 2,4-dichloropyrrolo[l,2-f][l,2,4]triazine (77a) (500 mg, 1.87 mmol) in 2-Propanol (20 mL) using DIPEA (0.98 mL, 5.62 mmol) and l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-amine hydrochloride (57a) (0.71 g, 2.47 mmol). This gave after workup and purification by flash column chromatography [silica gel, 40 g eluting with a DCM and methanol (0 to 30%)] 7- bromo-2-chloro-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)pyrrolo[l,2- f][l,2,4]triazin-4-amine (85a) (480 mg, 53% yield) as a brown solid; ¾ MR (300 MHz, OMSO-de) δ 1 1.46 (s, 1H, D20 exchangeable), 8.22 (d, J = 1.6 Hz, 1H), 7.90 (d, 7 = 1.6 Hz, 1H), 7.51 (d, J= 4.7 Hz, 1H), 6.93 (s, 2H), 6.90 (d, J = 4.6 Hz, 1H), 3.87 (s, 6H), 3.69 (s, 3H). MS (ES+): 481.3 (M+2); MS (ES-): 479.2, 481.2 (M+2).
[0919] Step-2: Preparation (S)-(l-(7-bromo-4-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- ylamino)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (85b)
[0920] Compound 85b was prepared from 7-bromo-2-chloro-N-(l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-yl)pyrrolo[l,2-f][l,2,4]triazin-4-amine (85a) (50 mg, 0.1 mmol), (S -pyrrolidin-2- ylmethanol (0.03 mL, 0.31 mmol), and DIPEA (0.06 mL, 0.31 mmol) in NMP (3 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash column chromatography [(silica gel C-18, 24 g) eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water] followed by lyophilization (S)-(l-(7-bromo-4-(l-(3,4,5- trimethoxyphenyl)- lH-imidazol-4-ylamino)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2- yl)methanol (85b) (16 mg, 28% yield) as a white solid; ¾ NMR (300 MHz, OMSO-de): δ 10.68 (s, 1H, D20 exchangeable), 8.26 (d, J= 1.5 Hz, 1H), 7.98 (d, J= 1.6 Hz, 1H), 7.28 (d, J = 4.6 Hz, 1H), 6.96 (s, 2H), 6.55 (d, J = 4.6 Hz, 1H), 4.24 (s, 1H), 3.88 (s, 6H), 3.68 (s, 3H), 3.40 - 3.34 (m, 2H), 2.07 - 1.83 (m, 4H).19F NMR (282 MHz, OMSO-de) δ -74.03; MS (ES+): 544.4, 546.4 (M+2); MS (ES-): 542.4, 544.3 (M+2).
[0921] Scheme 86
[0922]
[0923] Preparation of (S)-(l-(4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)amino)quinazolin-2- yl)pyrrolidin-2-yl)methanol (86b)
[0924] Step-1 : Preparation of 2-chloro-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)quinazolin- 4-amine (86a)
[0925] Compound 86a was prepared according to the procedure reported in Scheme 1 from 2,4- dichloroquinazoline (21a) (0.4 g, 2.01 mmol) in 2-Propanol (10 mL) using DIPEA (1.4 mL, 8.04 mmol) and l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-amine hydrochloride (57a) (0.69 g, 2.41 mmol). This gave 2-chloro-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)quinazolin-4-amine (86a) (1.26 mmol, 63 % yield) as a light pink solid; ¾ NMR (300 MHz, DMSO-i¾) δ 11.12 (s, 1H, D2O exchangeable), 8.75 (d, J= 8.3 Hz, 1H), 8.24 (s, 1H), 8.01 (d, J= 1.7 Hz, 1H), 7.87 (t, J= 7.6 Hz, 1H), 7.72 (d, J= 8.2 Hz, 1H), 7.61 (t, J= 7.7 Hz, 1H), 6.95 (s, 2H), 3.88 (s, 6H), 3.70 (s, 3H); MS (ES+): 412.4 (M+l), 434.3 (M+Na), (ES-): 410.3 (M-
[0926] 1).
[0927] Step-2: Preparation of (S)-(l-(4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)quinazolin-2-yl)pyrrolidin-2-yl)methanol (86b)
[0928] Compound 86b was prepared from 2-chloro-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)quinazolin-4-amine (86a) (100 mg, 0.24 mmol), (S)-pyrrolidin-2-ylmethanol (74 mg, 0.73 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [ (silica gel C- 18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-(l-(4-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-ylamino)quinazolin-2- yl)pyrrolidin-2-yl)methanol (86b) (55 mg, 48 % yield) as a cream color solid; Ή ΜΡ (300 MHz, DMSO-i¾) δ 10.59 - 10.09 (m, 1H, D20 exchangeable), 8.47 (d, J = 8.1 Hz, 1H), 8.27 (s, 1H), 8.20 - 7.94 (m, 1H), 7.54 (t, J= 7.7 Hz, 1H), 7.31 (d, J= 8.4 Hz, 1H), 7.08 (t, J= 7.6 Hz, 1H), 6.98 (s, 2H), 5.09 - 4.67 (m, 1H, D2O exchangeable), 4.56 - 4.14 (m, 2H), 3.89 (s, 6H), 3.69 (s, 5H), 3.57 - 3.17 (m, 1H), 2.18 - 1.79 (m, 4H); MS (ES+): 477.5 (M+l), (ES-): 475.5 (M-l).
[0929]
[0930] Preparation of (S)-(l-(7-bromo-4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[3,2- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (87c)
[0931] Step-1 : Preparation of 7-bromo-2-chloro-N-(l-phenyl-lH-imidazol-4-yl)thieno[3,2- d]pyrimidin-4-amine (87b)
[0932] Compound 87b was prepared according to the procedure reported in Scheme 1 from 7-bromo- 2,4-dichlorothieno[3,2-d]pyrimidine (87a) (0.2 g, 0.70 mmol; CAS # 41102-25-4) in 2- Propanol (6 mL) using DIPEA (0.67 mL, 3.83 mmol) and l-phenyl-lH-imidazol-4-amine, HC1 (8a) (182 mg, 0.93 mmol). This gave after workup and purification by flash column chromatography [silica gel 12 g, eluting with a 9: 1 mixture of ethyl acetate and methanol in hexanes (0 to 100%)] 7-bromo-2-chloro-N-(l-phenyl-lH-imidazol-4-yl)thieno[3,2- d]pyrimidin-4-amine (87b) (122 mg, 43% yield) as a brown solid; ¾NMR (300 MHz, DMSO- d6) δ 11.34 (s, 1H, D2O exchangeable), 8.44 (s, 1H), 8.29 (s, 1H), 7.96 (s, 1H), 7.73 - 7.64 (m, 2H), 7.62 - 7.52 (m, 2H), 7.46 - 7.36 (m, 1H). MS (ES-): 404.1, 406.1 (M-2).
[0933] Step-2: Preparation of (S)-(l-(7-bromo-4-((l-phenyl-lH-imidazol-4-yl)amino)thieno[3,2- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (87c)
[0934] Compound 87c was prepared from 7-bromo-2-chloro-N-(l-phenyl-lH-imidazol-4- yl)thieno[3,2-d]pyrimidin-4-amine (87b) (50 mg, 0.12 mmol), (^-pyrrolidin-2-ylmethanol (0.04 mL, 0.39 mmol), and DIPEA (0.06 mL, 0.37 mmol) in NMP (0.5 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash column chromatography [(silica gel C-18, 24 g) eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water] followed by lyophilization (S)-( 1 -(7 -bromo-4-((l -phenyl- 1 H-imidazol-4- yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (87c) (22 mg, 38 % yield) as a light yellow solid; ¾ NMR (300 MHz, Methanol-^) δ 8.78 - 8.54 (m, 1H), 8.28 (s, 1H), 8.21 - 8.01 (m, 1H), 7.74 - 7.54 (m, 4H), 7.54 - 7.43 (m, 1H), 4.38 - 4.15 (m, 1H), 4.14 - 3.93 (m, 2H), 3.93 - 3.65 (m, 2H), 2.44 - 2.21 (m, 1H), 2.21 - 1.99 (m, 2H), 1.99 - 1.79 (m, 1H);19F NMR (282 MHz, Methanol-^) δ -77.25; MS (ES+): 471.3, 473.3 (M+2). HPLC purity: 97.84 %.
[0935] Scheme 88
[0936]
[0937] Preparation of 2-(4-methoxyphenyl)-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine (88a)
[0938] Compound 88a was prepared from 2-chloro-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)pyrrolo[l,2-f][l,2,4]triazin-4-amine (57b) (200 mg, 0.5 mmol), 4-methoxyphenylboronic acid (114 mg, 0.75 mmol), PdCl2(dppf) (73 mg, 0.100 mmol) in anhydrous 1,4-Dioxane (15 mL) and Water (1 mL) using potassium carbonate (207 mg, 1.5 mmol) according to the procedure reported in step-3 of Scheme 77. This gave after workup 2-(4-methoxyphenyl)-N- ( 1 -(3 ,4,5-trimethoxyphenyl)- lH-imidazol-4-yl)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-4-amine (88a) (52 mg, 22 % yield) as a white solid; ¾ NMR (300 MHz, DMSO-^e) δ 10.89 (s, 1H, D20 exchangeable), 8.33 - 8.29 (m, 1H), 8.28 (s, 1H), 8.24 (s, 1H), 8.20 - 8.15 (m, 1H), 7.78 (s, 1H), 7.34 (s, 1H), 7.08 - 6.97 (m, 4H), 6.73 - 6.67 (m, 1H), 3.93 (s, 6H), 3.82 (s, 3H), 3.71 (s, 3H); MS (ES+): 473.5 (M+1), 495.4 (M+Na), MS (ES-): 471.4 (M-1), 507.4 (M+Cl).
[0939] Scheme 89
[0940] Preparation of (S)-(l-(7-(4-methoxyphenyl)-4-(l -phenyl- lH-imidazol-4-ylamino)thieno[3, 2- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (89a)
[0941] Compound 89a was prepared from (S)-(l-(7-bromo-4-(l-phenyl-lH-imidazol-4- ylamino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (87c) (50 mg, 0.11 mmol), 4- methoxyphenylboronic acid (81 mg, 0.53 mmol), Pd(dppf)Cl2 (4 mg, 5.30 μιηοΐ) in anhydrous 1,4-Dioxane (3 mL) and Water (1 mL) using sodium carbonate (28 mg, 0.27 mmol) according to the procedure reported in step-3 of Scheme 77. This gave after workup, purification by reverse phase flash column chromatography [(silica gel C-18, 24 g) eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water] and lyophilization (S)-(l-(7-(4-methoxyphenyl)-4-(l- phenyl-lH-imidazol-4-ylamino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (89a) (20 mg, 38 % yield) as a yellow solid;1H MR (300 MHz, Methanol -d4): δ 8.20 (s, 1H), 8.03 (d, J= 12.4 Hz, 2H), 7.61 (dd, J= 11.6, 7.7 Hz, 4H), 7.53 - 7.42 (m, 3H), 7.13 - 7.03 (m, 2H), 4.18 (s, 1H), 4.12 - 3.96 (m, 1H), 3.86 (s, 3H), 3.78 (dd, J= 10.4, 2.4 Hz, 1H), 3.73 - 3.63 (m, 1H), 3.60 (s, 1H), 2.34 - 2.17 (m, 1H), 2.05 (s, 2H), 1.87 (s, 1H).19F MR (282 MHz, Methanol-^) δ -77.28; MS (ES+): 499.5 (M+1), 521.5 (M+Na); MS (ES-): 497.5 (M-1).
[0942] Scheme 90
[0943]
[0944] Preparation of (S)-(l-(7-(4-methoxyphenyl)-4-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- ylamino)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (90a) Compound 90a was prepared from (S)-(l-(7-bromo-4-(l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-ylamino)pyrrolo[l,2-f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (85b) (70 mg, 0.13 mmol), 4-methoxyphenylboronic acid (98 mg, 0.64 mmol), Pd(dppf)Cl2 (5 mg, 6.43 μπιοΐ) in anhydrous 1,4-Dioxane (3 mL) and Water (1 mL) using sodium carbonate (34 mg, 0.32 mmol) according to the procedure reported in step-3 of Scheme 77. This gave after workup, purification by reverse phase flash column chromatography [(silica gel C-18, 24 g) eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water] and lyophilization (S)-(l-(7- (4-methoxyphenyl)-4-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-ylamino)pyrrolo[l,2- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (90a) (31 mg, 42 % yield) as a yellow solid; ¾ MR (300 MHz, DMSO-ά): δ 10.57 (s, 1H, D20 exchangeable), 8.33 (s, 1H), 8.17 (d, J= 8.7 Hz, 2H), 8.01 (s, 1H), 7.27 (s, 1H), 7.06 - 6.92 (m, 4H), 6.81 (s, 1H), 4.57 (s, 1H), 4.36 - 4.16 (m, 1H), 4.04 (s, 1H), 3.92 - 3.87 (m, 6H), 3.83 - 3.75 (m, 3H), 3.73 - 3.64 (m, 3H), 3.57 - 3.31 (m, 2H), 2.12 - 1.85 (m, 4H).19F NMR (282 MHz, DMSO-i¾) δ -74.45; MS (ES+): 572.6, 594.6 (M+Na), 610.4 (M+K).
[0945] Scheme 91
[0946]
[0947] Preparation of (S)-l-(4-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-ylamino)pyrrolo[l,2- f][l,2,4]triazin-2-yl)pyrrolidine-2-carboxamide (91a)
[0948] Compound 91a was prepared from the stirred suspension of 2-chloro-N-(l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-yl)pyrrolo[l,2-f][l,2,4]triazin-4-amine (57b) (0.2 g, 0.5 mmol), (S)-pyrrolidine-2-carboxamide (0.17 g, 1.5 mmol) and DIPEA (0.26 mL, 1.5 mmol) in NMP (2 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash column chromatography [(silica gel C-18, 24 g) eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water] followed by lyophilization (S)-l-(4-(l- (3,4,5-trimethoxyphenyl)-lH-imidazol-4-ylamino)pyrrolo[l,2-f][l,2,4]triazin-2- yl)pyrrolidine-2-carboxamide (91a) (50 mg, 19 % yield) as a white solid; ¾ NMR (300 MHz, DMSO-i¾): δ 10.50 (s, 1H, D20 exchangeable), 8.22 (d, J = 5.6 Hz, 1H), 7.92 (d, J = 5.4 Hz, 1H), 7.42 (d, J = 5.4 Hz, 1H), 7.23 (s, 1H, D2O exchangeable), 7.17 (s, 1H), 7.12 - 7.05 (m, 2H), 7.02 (s, 1H, D2O exchangeable), 6.41 (d, J= 5.6 Hz, 1H), 4.41 (s, 1H), 3.93 (t, J= 4.2 Hz, 6H), 3.68 (t, J= 4.2 Hz, 3H), 3.35 (s, 1H), 2.19 (s, 1H), 1.95 (d, J= 13.6 Hz, 4H); MS (ES+): 479.5 (M+l).
[0949] Scheme 92
[0950]
[0951] 57a
[0952] Preparation of (S)-isobutyl 2-(2-(hydroxymethyl)pyrrolidin-l-yl)-4-((l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-yl)amino)thieno[2,3-d]pyrimidine-6-carboxylate (92d) Step-1 : Preparation of isobutyl 2-chloro-4-(methylthio)thieno[2,3-d]pyrimidine-6-carboxylate (92a)
[0953] Compound 92a was prepared according to the procedure reported in step-2 of Scheme 70 from 2-chloro-4-(methylthio)thieno[2,3-d]pyrimidine (70a) (0.5 g, 2.31 mmol) in THF (20 mL) using n-butyl lithium (1.6 M solution in hexanes, 3.03 mL, 4.85 mmol) and quenching with Isobutyl chloroformate (0.6 mL, 4.61 mmol). This gave after workup and purification by flash column chromatography [silica gel, (25 g) eluting with 0-100% ethyl acetate in hexanes] isobutyl 2-chloro-4-(methylthio)thieno[2,3-d]pyrimidine-6-carboxylate (92a) (403 mg, 55 % yield) as a brown solid; ¾ MR (300 MHz, DMSO-^e) δ 8.09 (s, 1H), 4.14 (d, J = 6.6 Hz, 2H), 2.70 (s, 3H), 2.04 (hept, J = 6.6 Hz, 1H), 0.97 (d, J = 6.7 Hz, 6H); MS (ES+): 339.2 (M+Na).
[0954] Step-2: Preparation of isobutyl 2,4-dichlorothieno[2,3-d]pyrimidine-6-carboxylate (92b). Compound 92b was prepared according to the procedure reported in step-3 of Scheme 70 from isobutyl 2-chloro-4-(methylthio)thieno[2,3-d]pyrimidine-6-carboxylate (92a) (375 mg, 1.18 mmol) in acetonitrile (30 mL) and DCM (5 mL) using sulfuryl chloride (0.48 mL, 5.92 mmol). This gave after workup and purification by flash column chromatography [silica gel, (12 g) eluting with 0-100% ethyl acetate in hexanes] isobutyl 2,4-dichlorothieno[2,3-d]pyrimidine-6- carboxylate (92b) (174 mg, 48 % yield) as a syrup;1H NMR (300 MHz, DMSO-de) δ 8.21 (s, 1H), 4.17 (d, J = 6.6 Hz, 2H), 2.06 (dt, J = 13.4, 6.7 Hz, 1H), 0.99 (d, J = 6.8 Hz, 6H).
[0955] Step 3 : Preparation of isobutyl 2-chloro-4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)thieno[2,3-d]pyrimidine-6-carboxylate (92c)
[0956] Compound 92c was prepared according to the procedure reported in Scheme 1 from isobutyl 2,4-dichlorothieno[2,3-d]pyrimidine-6-carboxylate (92b) (160 mg, 0.52 mmol) in 2-Propanol (5mL) using DIPEA (0.27 mL, 1.57 mmol) and l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- amine hydrochloride (57a) (0.22 g, 0.78 mmol). This gave isobutyl 2-chloro-4-(l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-ylamino)thieno[2,3-d]pyrimidine-6-carboxylate (92c) (160 mg, 59 % yield) as a brown solid; ¾ NMR (300 MHz, DMSO-^e) δ 11.43 (s, 1H, D20 exchangeable), 8.87 (s, 1H), 8.22 (d, 7 = 1.6 Hz, 1H), 7.91 (d, 7 = 1.6 Hz, 1H), 6.94 (s, 2H), 4.12 (d, 7 = 6.5 Hz, 2H), 3.88 (s, 6H), 3.70 (s, 3H), 2.09 - 1.96 (m, 1H), 1.01 (d, 7 = 6.7 Hz, 6H); MS (ES+): 540.5 (M+Na), (ES-): 516.5 (M-l).
[0957] Step 4: Preparation of (S)-isobutyl 2-(2-(hydroxymethyl)pyrrolidin-l-yl)-4-((l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-yl)amino)thieno[2,3-d]pyrimidine-6-carboxylate (92d) Compound 92d was prepared from 2-chloro-4-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- ylamino)thieno[2,3-d]pyrimidine-6-carboxylate (92c) (80 mg, 0.15 mmol), (S)-pyrrolidin-2- ylmethanol (46.9 mg, 0.46 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup by pouring reaction the mixture into water and collecting the solid that separated out by filtration followed by drying in vacuum (S)-isobutyl 2-(2- (hydroxymethyl)pyrrolidin- 1 -yl)-4-(l -(3,4,5-trimethoxyphenyl)- lH-imidazol-4- ylamino)thieno[2,3-d]pyrimidine-6-carboxylate (92d) (65 mg, 72 % yield) as a brown solid; ¾ NMR (300 MHz, DMSO-i¾) δ 10.32 (s, 1H, D2O exchangeable), 8.63 (s, 1H), 8.12 (d, 7 = 1.7 Hz, 1H), 7.95 (s, 1H), 6.92 (s, 1H), 4.61 (s, 1H), 4.31 (s, 1H), 4.08 - 3.99 (m, 2H), 3.87 (s, 6H), 3.84 - 3.58 (m, 5H), 3.52 - 3.36 (m, 2H), 2.13 - 1.76 (m, 5H), 1.00 (dd, 7 = 6.6, 1.6 Hz, 6H); MS (ES+): 583.6 (M+l).
[0958] Scheme 93
[0959] HCI
[0960] Preparation of (S)-4-(4-(2-(2-(hydroxymethyl)pyrrolidin- 1 -yl)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-4- ylamino)- lH-imidazol- 1 -yl)benzamide (93c)
[0961] Step-1 : Preparation of 4-(4-(2-chloropyirolo[l,2-f][l,2,4]triazin-4-ylamino)-lH-imidazol-l- yl)benzamide (93b)
[0962] Compound 93b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (180 mg, 0.97 mmol) in 2-Propanol (20 mL) using DIPEA (0.51 mL, 2.92 mmol) and 4-(4-amino-lH-imidazol-l-yl)benzamide hydrochloride (93a) (0.26 g, 1.29 mmol). This gave after work up and purification by flash column chromatography [silica gel, (40 g) eluting with DCM and methanol (0 to 30%)] 4-(4-(2- chloropyrrolo[l,2-f][l,2,4]triazin-4-ylamino)-lH-imidazol-l-yl)benzamide (93b) (0.26 g, 76 % yield) as a brown solid; ¾NMR (300 MHz, OMSO-de): δ 11.37 (s, 1H, D20 exchangeable), 8.38 (d, J= 1.7 Hz, 1H), 8.09 (s, 1H, D2O exchangeable), 8.08 - 8.01 (m, 2H), 7.98 (d, J= 1.7 Hz, 1H), 7.78 (d, J = 2.3 Hz, 2H), 7.75 (s, 1H), 7.50 (s, 1H, D2O exchangeable), 7.40 (d, J =
[0963] 4.4 Hz, 1H), 6.73 (dd, J= 4.5, 2.6 Hz, 1H). MS (ES+): 354.4; MS (ES-): 352.3.
[0964] Step-2: Preparation of (S)-4-(4-(2-(2-(hydroxymethyl)pyrrolidin-l-yl)pyrrolo[l,2- f] [ 1 ,2,4]triazin-4-ylamino)- lH-imidazol- 1 -yl)benzamide (93c)
[0965] Compound 93c was prepared from 4-(4-(2-chloropyrrolo[l,2-f][l,2,4]triazin-4-ylamino)-lH- imidazol-l-yl)benzamide (93b) (160 mg, 0.45 mmol), (^-pyrrolidin-2-ylmethanol (0.13 mL, 1.34 mmol), and DIPEA (0.23 mL, 1.34 mmol) in NMP (1.5 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-4-(4-(2-(2- (hydroxymethyl)pyrrolidin- 1 -yl)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-4-ylamino)- lH-imidazol- 1 - yl)benzamide (93c) (102 mg, 55 % yield) as a brown solid; ¾ NMR (300 MHz, DMSO-ά): δ 10.57 (s, 1H, D2O exchangeable), 8.37 (d, J = 1.5 Hz, 1H), 8.08 (s, 1H, D2O exchangeable),
[0966] 8.05 - 8.01 (m, 2H), 7.99 (s, 1H), 7.86 (d, J = 8.4 Hz, 2H), 7.44 (s, 1H, D2O exchangeable), 7.40 (t, J= 2.0 Hz, 1H), 7.16 (dd, J= 4.4, 1.7 Hz, 1H), 6.40 (dd, J= 4.5, 2.4 Hz, 1H), 4.99 (s, 1H, D2O exchangeable), 4.21 (s, 2H), 3.89 - 3.70 (m, 1H), 3.50 (s, 2H), 2.17 - 1.75 (m, 4H); MS (ES+): 419.4 (M+l); MS (ES-): 453.4 (M+Cl).
[0967] Scheme 94
[0968]
[0969] Preparation of (S)-3 -(4-(2-(2-(hydroxymethyl)pyrrolidin- 1 -yl)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-4- ylamino)- lH-imidazol- 1 -yl)benzamide (94c)
[0970] Step-1 : Preparation of 3-(4-(2-chloropyirolo[l,2-f][l,2,4]triazin-4-ylamino)-lH-imidazol-l- yl)benzamide (94b)
[0971] Compound 94b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (240 mg, 1.29 mmol) in 2-Propanol (20 mL) using DIPEA ((0.68 mL, 3.87 mmol) and 3-(4-amino-lH-imidazol-l-yl)benzamide hydrochloride (94a) (0.4 g, 1.68 mmol). This gave after work up and purification by flash column chromatography [silica gel, (40 g) eluting with DCM and methanol (0 to 30%)] 3-(4-(2- chloropyrrolo[l,2-f][l,2,4]triazin-4-ylamino)-lH-imidazol-l-yl)benzamide (94b) (0.27 g, 60 % yield) as a brown solid; ¾NMR (300 MHz, OMSO-de): δ 11.36 (s, 1H, D2O exchangeable), 8.31 (d, J = 1.6 Hz, 1H), 8.18 (s, 1H), 8.11 (t, J = 1.9 Hz, 1H), 7.96 (d, J = 1.6 Hz, 1H), 7.89 (dt, J = 7.6, 1.3 Hz, 1H), 7.86 - 7.80 (m, 1H), 7.78 (dd, J = 2.6, 1.5 Hz, 1H), 7.65 (t, J = 7.9 Hz, 1H), 7.60 (s, 1H), 7.41 (d, J= 4.4 Hz, 1H), 6.73 (dd, J= 4.5, 2.6 Hz, 1H). MS (ES+): 354.3 (M+l); MS (ES-): 352.3 (M-l).
[0972] Step-2: Preparation of (S)-3-(4-(2-(2-(hydroxymethyl)pyrrolidin-l-yl)pyrrolo[l,2- f] [ 1 ,2,4]triazin-4-ylamino)- lH-imidazol- 1 -yl)benzamide (94c)
[0973] Compound 94c was prepared from 3-(4-(2-chloropyrrolo[l,2-f][l,2,4]triazin-4-ylamino)-lH- imidazol-l-yl)benzamide (94b) (150 mg, 0.42 mmol), (^-pyrrolidin-2-ylmethanol (0.13 mL, 1.34 mmol), and DIPEA (0.22 mL, 1.27 mmol) in MP (1.5 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-3-(4-(2-(2- (hydroxymethyl)pyrrolidin- 1 -yl)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-4-ylamino)- lH-imidazol- 1 - yl)benzamide (94c) (0.12 g, 69 % yield) as a brown solid; ¾ NMR (300 MHz, OMSO-de): δ 10.57 (s, 1H, D20 exchangeable), 8.30 (d, J = 1.5 Hz, 1H), 8.15 - 8.08 (m, 2H), 8.04 (d, J = 1.6 Hz, 1H), 7.92 (dd, J= 8.0, 2.1 Hz, 1H), 7.83 (d, J= 7.7 Hz, 1H), 7.69 - 7.53 (m, 2H), 7.39 (t, J= 2.0 Hz, 1H), 7.14 (dd, J = 4.4, 1.6 Hz, 1H), 6.40 (dd, J = 4.5, 2.4 Hz, 1H), 4.97 (s, 1H, D2O exchangeable), 4.21 (s, 1H), 3.78 (dd, J = 10.0, 3.5 Hz, 1H), 3.51 (d, J = 18.1 Hz, 2H), 3.35 (s, 1H), 2.11 - 1.82 (m, 4H).19F NMR (282 MHz, DMSO-d) δ -73.49; MS (ES+): 419.5 (M+l); MS (ES-): 453.4 (M+Cl).
[0974] Scheme 95
[0975]
[0976] HCI
[0977] Preparation of (S)- 1 -(4-(4-(2-(2-(hydroxymethyl)pyrrolidin- 1 -yl)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin- 4-ylamino)- lH-imidazol- 1 -yl)phenyl)ethanone (95c)
[0978] Step-1 : Preparation of l-(4-(4-(2-chloropyrrolo[l,2-f][l,2,4]triazin-4-ylamino)-lH-imidazol- l-yl)phenyl)ethanone (95b)
[0979] Compound 95b was prepared according to the procedure reported in Scheme 1 from 2,4- dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (240 mg, 1.3 mmol) in 2-Propanol (20 mL) using DIPEA (0.51 mL, 2.92 mmol) and l-(4-(4-amino-lH-imidazol-l-yl)phenyl)ethanone hydrochloride (95a) (0.4 g, 1.68 mmol). This gave after work up and purification by flash column chromatography [silica gel, (40 g) eluting with DCM and methanol (0 to 30%)] l-(4- (4-(2-chloropyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-4-ylamino)- lH-imidazol- 1 -yl)phenyl)ethanone (95b) (0.26 g, 57 % yield) as a brown solid; ¾ NMR (300 MHz, OMSO-de): δ 11.40 (s, 1H, D2O exchangeable), 8.45 (d, J = 1.6 Hz, 1H), 8.18 - 8.09 (m, 2H), 8.01 (d, J = 1.6 Hz, 1H), 7.86 - 7.80 (m, 2H), 7.79 (dd, J= 2.6, 1.5 Hz, 1H), 7.41 (d, J= 4.4 Hz, 1H), 6.73 (dd, J= 4.5, 2.6 Hz, 1H), 2.62 (s, 3H). MS (ES-): 351.3, 353.3 (M-l).
[0980] Step-2: Preparation of (S)-l-(4-(4-(2-(2-(hydroxymethyl)pyrrolidin-l-yl)pyrrolo[l,2- f] [ 1 ,2,4]triazin-4-ylamino)- lH-imidazol- 1 -yl)phenyl)ethanone (95c)
[0981] Compound 95c was prepared from l-(4-(4-(2-chloropyrrolo[l,2-f][l,2,4]triazin-4-ylamino)- lH-imidazol-l-yl)phenyl)ethanone (95b) (150 mg, 0.43 mmol), (^-pyrrolidin-2-ylmethanol (0.13 mL, 1.34 mmol), and DIPEA (0.22 mL, 1.28 mmol) in MP (1.5 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by conversion to free base using NaHCCb, (S)-l-(4-(4-(2-(2- (hydroxymethyl)pyrrolidin- 1 -yl)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-4-ylamino)- lH-imidazol- 1 - yl)phenyl)ethanone (95c) (30 mg, 14 % yield) as a brown solid; ¾ NMR (300 MHz, DMSO- de): δ 10.79 (s, 1H, D20 exchangeable), 8.64 (s, 1H), 8.13 - 8.05 (m, 3H), 7.95 (d, J= 8.5 Hz, 2H), 7.44 (t, J= 2.0 Hz, 1H), 7.16 (dd, J= 4.5, 1.6 Hz, 1H), 6.43 (dd, J = 4.4, 2.4 Hz, 1H), 4.19 (s, 1H), 3.76 (dd, J = 10.0, 3.6 Hz, 1H), 3.58 - 3.42 (m, 1H), 3.36 (dd, J = 11.7, 7.1 Hz, 2H), 2.62 (s, 3H), 2.11 - 1.83 (m, 4H). MS (ES+): 418.5 (M+l); MS (ES-): 452.5 (M+Cl).
[0982] Scheme 96
[0983]
[0984] Preparation of (S)-(l-(2-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)amino)pyrrolo[2,l- f][l,2,4]triazin-4-yl)pyrrolidin-2-yl)methanol (96b)
[0985] Step- 1 : Preparation of (S)-(l-(2-chloropyrrolo[2,l-f][l,2,4]triazin-4-yl)pyrrolidin-2- yl)methanol (96a)
[0986] To a solution of 2,4-dichloropyrrolo[l,2-f][l,2,4]triazine (4a) (0.5 g, 2.7 mmol) in 2-Propanol (6 mL) was added (S)-pyrrolidin-2-ylmethanol (0.39 mL, 4.0 mmol), DIPEA (1.39 mL, 8.0 mmol) and heated at 90 °C for 1 hr. The reaction was cooled to room temperature and solid obtained was collected by filtration to afford (S)-(l-(2-chloropyrrolo[2,l-f][l,2,4]triazin-4- yl)pyrrolidin-2-yl)methanol (96a) (0.49 g, 73 % yield) as a white solid; ¾ NMR (300 MHz, DMSO-i / e): δ 7.70 (dd, J= 2.6, 1.4 Hz, 1H), 6.97 (dd, J= 4.7, 1.6 Hz, 1H), 6.80 - 6.57 (m, 1H), 5.15 (t, J = 5.7 Hz, 1H, D2O exchangeable), 4.87 (t, J= 5.7 Hz, 1H), 4.44 (d, J= 17.8 Hz, 1H), 4.05 - 3.82 (m, 1H), 3.72 - 3.39 (m, 2H), 2.22 - 1.84 (m, 4H). MS (ES+): 253.3, 255.3 (M+2); MS (ES-): 287.2, 289.2 (M+Cl).
[0987] Step-2: Preparation of (S)-(l-(2-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-yl)pyrrolidin-2-yl)methanol (96b) A slurry of (S)-(l-(2-chloropyrrolo[l,2-f][l,2,4]triazin-4-yl)pyrrolidin-2-yl)methanol (96a) (0.1 g, 0.4 mmol), l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-amine hydrochloride (57a) (0.11 g, 0.4 mmol), 2,2'-bis(diphenylphosphino)-l, l'-binaphthyl (30 mg, 0.04 mmol), sodium 2-methylpropan-2-olate (80 mg, 0.79 mmol), Pd2(dba)3(40 mg, 0.04 mmol) in anhydrous Dioxane (4 mL) was heated in a sealed reactor under a positive flow of nitrogen at 90 °C for 18 h. The reaction mixture was diluted with EtOAc (100 mL) and organic layer was separated. The organic layer was washed with water (3 xs), brine, dried, filtered and concentrated in vacuum to dryness. The residue was purified by reverse phase flash column chromatography [(silica gel C-18, 24 g) eluting with acetonitrile and 0.1% HC1 in water] and lyophilized to afford (S)-(l-(2-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)amino)pyrrolo[2,l- f][l,2,4]triazin-4-yl)pyrrolidin-2-yl)methanol (96b) (21 mg, 11 % yield) hydrochloride salt as a yellow solid; ¾NMR (300 MHz, DMSO-^e): δ 9.72 (s, 1H, D20 exchangeable), 9.63 (s, 1H, D20 exchangeable), 9.38 (s, 1H), 7.92 (s, 1H), 7.66 (s, 1H), 7.15 (s, 2H), 6.90 (d, J = 4.5 Hz, 1H), 6.56 (s, 1H), 4.54 (s, 1H), 4.07 - 3.93 (m, 1H), 3.89 (s, 6H), 3.77 (s, 1H), 3.71 (s, 3H), 3.68 - 3.62 (m, 1H), 3.60 - 3.47 (m, 1H), 2.23 - 1.88 (m, 4H). MS (ES+): 466.5 (M+l), 688.5 (M+Na); MS (ES-): 464.6 (M-l).
[0988] Scheme 97
[0989]
[0990] Preparation of (S)-(l-(6-(morpholinomethyl)-4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (97d)
[0991] Step-1 : Preparation of (2-chloro-4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)thieno[2,3 -d]pyrimidin-6-yl)methanol (97a) Compound 97a was prepared according to the procedure reported in Scheme 1 from (2,4- dichlorothieno[2,3-d]pyrimidin-6-yl)methanol (70d) (1.2 g, 5.1 mmol) in 2-Propanol (15 mL) using DIPEA (2.67 mL, 15.31 mmol) and l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-amine hydrochloride (57a) (1.89 g, 6.64 mmol). This gave (2-chloro-4-(l-(3,4,5-trimethoxyphenyl)- lH-imidazol-4-ylamino)thieno[2,3-d]pyrimidin-6-yl)methanol (97a) (1.48 g, 65 % yield) as light brown solid; ¾ NMR (300 MHz, DMSO-^e) δ 10.90 (s, 1H, D20 exchangeable), 8.19 (d, J = 1.6 Hz, 1H), 7.89 (d, J = 1.6 Hz, 1H), 7.84 (s, 1H), 6.93 (s, 2H), 5.82 (t, J = 5.8 Hz, 1H, D2O exchangeable), 4.72 (dd, J= 5.8, 1.2 Hz, 2H), 3.87 (s, 6H), 3.69 (s, 3H); MS (ES+): 448.3 (M+l), 470.3 (M+Na), (ES-): 446.3 (M-l).
[0992] Step-2: Preparation of 2-chloro-6-(chloromethyl)-N-(l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (97b)
[0993] To a stirred suspension of (2-chloro-4-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- ylamino)thieno[2,3-d]pyrimidin-6-yl)methanol (97a) (0.5 g, 1.12 mmol) in DCM (50 mL) at 0 °C was added N,N-Dimethylformamide (5 mL) and thionyl chloride (0.2 mL, 2.79 mmol). The reaction mixture was allowed to warm to room temperature overnight, concentrated in vacuum to dryness triturated with hexanes and filtered to afford 2-chloro-6-(chloromethyl)-N-(l -(3,4,5 - trimethoxyphenyl)-lH-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (97b) (520 mg, 100 % yield) as a solid, which was used as such for next step; ¾ NMR (300 MHz, OMSO-defDiO) δ 11.26 (s, 1H, D2O exchangeable), 8.07 (s, 1H), 8.00 (s, 1H), 7.96 (s, 1H), 7.01 (s, 2H), 5.17 (s, 2H), 3.88 (s, 6H), 3.70 (s, 3H); MS (ES+): 466.4, 468.4 (M+l), (ES-): 464.3, 466.4 (M-l). Step 3 : Preparation of 2-chloro-6-(morpholinomethyl)-N-(l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (97c)
[0994] To a solution of 2-chloro-6-(chloromethyl)-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)thieno[2,3-d]pyrimidin-4-amine (97b) (100 mg, 0.21 mmol) in THF (3 mL) was added morpholine (0.04 mL, 0.43 mmol), DIPEA (0.15 mL, 0.86 mmol) and heated at 50 °C overnight. The reaction mixture was concentrated in vacuum and purified by flash column chromatography to afford 2-chloro-6-(morpholinomethyl)-N-(l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (97c); ¾ NMR (300 MHz, OMSO-de) δ 10.89 (s, 1H), 8.19 (d, J = 1.6 Hz, 1H), 7.88 (d, J = 1.6 Hz, 1H), 6.93 (s, 2H), 3.87 (s, 6H), 3.75 (s, 2H), 3.60 (m, 6H), 2.47 (m, 6H); MS (ES+): 539.4 (M+Na), (ES-): 515.4 (M-l).
[0995] Step 4: Preparation of (S)-(l-(6-(morpholinomethyl)-4-((l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (97d)
[0996] Compound 97d was prepared from 2-chloro-6-(morpholinomethyl)-N-(l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (97c) (50 mg, 0.09 mmol), (^-pyrrolidin-2-ylmethanol (0.03 mL, 0.26 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with eluting with acetonitrile and 0.1% HC1 in water] followed by lyophilization (S)-(l-(6-(mo holinomethyl)-4-(l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-ylamino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2- yl)methanol (97d) (21 mg, 42 % yield) HC1 salt as a yellow solid; ¾ NMR (300 MHz, DMSO- <k): δ 11.70 (s, 1H, D20 exchangeable), 11.49 (s, 1H, D2O exchangeable), 8.52 (s, 1H), 8.11 (s, 1H), 8.07 (s, 1H), 8.02 (s, 1H, D2O exchangeable), 7.01 (s, 2H), 4.60 (s, 2H), 4.50 (s, 1H), 4.34 (s, 1H), 3.96 (s, 1H), 3.88 (s, 6H), 3.81 (s, 2H), 3.68 (s, 3H), 3.60 - 3.41 (m, 4H), 3.40 - 3.07 (m, 4H), 2.15 - 1.86 (m, 4H). MS (ES+): 582.6 (M+l); MS (ES-): 616.6 (M+Cl).
[0997] Scheme 98
[0998]
[0999] Preparation of (S)-fert-butyl 4-(2-(2-(hydroxymethyl)pyrrolidin-l-yl)-4-(l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-ylamino)pyrrolo[l,2-f][l,2,4]triazin-7-yl)-5,6- dihydropyridine- 1 (2H)-carboxylate (98a)
[1000] Compound 98a was prepared from (S)-(l-(7-bromo-4-(l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-ylamino)pyrrolo[l,2-f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (85b) (150 mg, 0.28 mmol), l-(tert-butoxycarbonyl)-l,2,3,6-tetrahydropyridin-4-ylboronic acid (188 mg, 0.83 mmol), Pd(dppf)Cl2 (10 mg, 0.01 mmol), sodium carbonate (73 mg, 0.69 mmol) in Dioxane (3 mL) and Water (1 mL) according to the procedure reported in step-3 of Scheme 77. This gave after purification by reverse phase flash column chromatography [(silica gel C-18, 24 g) eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water] followed by conversion to free base using NaHCC-3, (S)-tert-butyl 4-(2-(2-(hydroxymethyl)pyrrolidin-l-yl)-4-(l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-ylamino)pyrrolo[l,2-f][l,2,4]triazin-7-yl)-5,6- dihydropyridine-l(2H)-carboxylate (98a) (70 mg, 38 % yield) as a white solid; ¾ NMR (300 MHz, DMSO-ά): δ 10.53 (s, 1H, D2O exchangeable), 8.24 (d, J= 1.5 Hz, 1H), 7.98 (d, J= 1.6 Hz, 1H), 7.20 (d, J = 4.6 Hz, 2H), 6.96 (s, 2H), 6.50 (d, J = 4.6 Hz, 1H), 4.85 (s, 1H, D20 exchangeable), 4.21 (s, 2H), 4.06 (s, 2H), 3.88 (s, 6H), 3.79 - 3.71 (m, 1H), 3.68 (s, 3H), 3.54 (s, 2H), 3.42 (d, J = 6.9 Hz, 1H), 3.28 (s, 1H), 2.54 (s, 2H), 2.09 - 1.86 (m, 4H), 1.43 (s, 9H). MS (ES+): 669.7 (M+Na).
[1001] Scheme 99
[1002]
[1003] Preparation of l-(2-((S)-2-(hydroxymethyl)pyrrolidin-l-yl)-4-((l-(3,4,5-trimethoxyphenyl)- lH-imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-7-yl)ethanol (99b)
[1004] Step-1 : Preparation of l-(2-chloro-4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-7-yl)ethanol (99a)
[1005] Compound 99a was prepared according to the procedure reported in step-2 of Scheme 79 from 2-chloro-4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazine-7-carbaldehyde (79b) (200 mg, 0.47 mmol) in THF (10 mL) using MeLi (3 M in THF, 0.33 mL, 1.03 mmol). This gave after workup and purification by flash column chromatography (Silica gel 12 g, eluting with MeOH in DCM from 0 to 10%) l-(2-chloro-4- ((1 -(3 ,4, 5-trimethoxyphenyl)- lH-imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-7- yl)ethanol (99a) (103 mg, 50% yield) as light yellow solid; ¾ MR (300 MHz, DMSO-^e) δ 11.21 (s, 1H), 8.20 (d, J= 1.6 Hz, 1H), 7.88 (d, J= 1.6 Hz, 1H), 7.36 (d, J = 4.5 Hz, 1H), 6.93 (s, 2H), 6.68 (d, J = 4.5 Hz, 1H), 5.31 (d, J = 5.0 Hz, 1H), 5.16 (p, J = 6.4 Hz, 1H), 3.87 (s, 6H), 3.69 (s, 3H), 1.45 (d, J = 6.5 Hz, 3H); MS (ES+): 445.5 (M+l), 467.4 (M+Na).
[1006] Step 2: Preparation of l-(2-((S)-2-(hydroxymethyl)pyrrolidin-l-yl)-4-((l-(3,4,5- trimethoxyphenyl)- lH-imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-7-yl)ethanol (99b) Compound 99b was prepared from l-(2-chloro-4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol- 4-yl)amino)pyrrolo[2, l-f][l,2,4]triazin-7-yl)ethanol (99a) (35 mg, 0.08 mmol), (^-pyrrolidin- 2-ylmethanol (80 mg, 0.79 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1 % TFA in acetonitrile and 0.1% TFA in water], followed by lyophilization l-(2-((S)-2-(hydroxymethyl)pyrrolidin-l-yl)-4-((l-(3,4,5- trimethoxyphenyl)- lH-imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-7-yl)ethanol (99b) (25 mg, 51 % yield) TFA salt as a yellow solid; ¾ NMR (300 MHz, DMSO-^e) δ 10.79 (s, IH, D20 exchangeable), 9.32 (s, IH, D2O exchangeable), 9.20 (s, IH, D2O exchangeable), 8.37 - 8.15 (m, IH), 8.07 - 7.90 (m, IH), 7.25 (dd, J = 10.5, 4.6 Hz, IH), 6.96 (s, 2H), 6.77 (dd, J = 16.6, 4.6 Hz, IH), 5.45 - 5.21 (m, IH), 4.37 - 4.14 (m, IH), 3.88 (s, 6H), 3.68 (s, 3H), 3.67 - 3.49 (m, 2H), 3.47 - 3.18 (m, 3H), 2.17 - 1.76 (m, 4H), 1.76 - 1.65 (m, 3H); MS (ES+): 492.5 (M-OH);19F NMR (282 MHz, DMSO-d) δ -74.28; HPLC purity: 92.61%; Elemental Analysis: Calculated for: C25H31N7O5 -2CF3COOH-3H20: C, 42.29; H, 4.77; N, 11.90; Found: C, 42.02; H, 4.79; N, 12.08. heme 100
[1007]
[1008] Preparation of (S)-(l-(6-bromo-4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (lOOe)
[1009] Step 1 : Preparation of 2-chlorothieno[2,3-d]pyrimidin-4-ol (100a)
[1010] Compound 100a was prepared from 2,4-dichlorothieno[2,3-d]pyrimidine (31a) (4 g, 19.51 mmol) using the procedure reported by Deng, Jifeng et al; in European Journal of Medicinal Chemistry, 46(1), 71-76; 2010. This gave 2-chlorothieno[2,3-d]pyrimidin-4-ol (100a) (2.45 g, 13.13 mmol, 67.3 % yield) as a white solid; ¾ NMR (300 MHz, DMSO-d) δ 13.54 (s, IH, D2O exchangeable), 7.61 (d, J= 5.8 Hz, IH), 7.39 (d, J= 5.8 Hz, IH); MS (ES-): 185.1(M-1). Step 2: Preparation of 6-bromo-2-chlorothieno[2,3-d]pyrimidin-4-ol (100b).
[1011] To a solution of 2-chlorothieno[2,3-d]pyrimidin-4-ol (100a) (2.43 g, 13.02 mmol) in acetic acid (30 mL) was added bromine (2.01 mL, 39.1 mmol) and stirred at room temperature for 10 h. The resulting solid was collected by filtration, washed with water, and dried in vacuum to give 6-bromo-2-chlorothieno[2,3-d]pyrimidin-4-ol (100b) (2.85 g, 82 % yield) as a tan solid; ¾ NMR (300 MHz, DMSO-d) δ 7.94 (s, IH).
[1012] Step 3 : Preparation of 6-bromo-2,4-dichlorothieno[2,3-d]pyrimidine (100c) A mixture of 6-bromo-2-chlorothieno[2,3-d]pyrimidin-4-ol (100b) (2.84 g, 10.70 mmol) and phosphorus oxychloride (9.97 mL, 107 mmol) was heated at reflux for 30 h. The mixture was concentrated to remove excess phosphorus oxychloride, diluted with ice cold water and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with water (20 mL), brine (30 mL), dried, filtered and concentrated in vacuum to afford 6-bromo- 2,4-dichlorothieno[2,3-d]pyrimidine (100c) (1.4 g, 46 % yield) as a white solid; ¾ NMR (300 MHz, DMSO-i¾) δ 7.94 (s, 1H).
[1013] Step 4: Preparation of 6-bromo-2-chloro-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)thieno[2,3-d]pyrimidin-4-amine (lOOd)
[1014] Compound lOOd was prepared according to the procedure reported in Scheme 1 from 6-bromo- 2,4-dichlorothieno[2,3-d]pyrimidine (100c) (0.5 g, 1.76 mmol) in 2-Propanol (10 mL) using DIPEA (0.92 mL, 5.28 mmol) and l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-amine hydrochloride (57a) (654 mg, 2.29 mmol). This gave 6-bromo-2-chloro-N-(l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (lOOd) (718 mg, 82 % yield) as a light purple solid; ¾ NMR (300 MHz, DMSO-^e) δ 11.04 (s, 1H, D20 exchangeable), 8.21 (d, J = 1.6 Hz, 2H), 7.88 (d, J = 1.6 Hz, 1H), 6.93 (s, 2H), 3.87 (s, 6H), 3.70 (s, 3H); MS (ES-): 494.2, 496.3 (M-l).
[1015] Step 5: Preparation of (S)-(l-(6-bromo-4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (lOOe)
[1016] Compound lOOe was prepared from 6-bromo-2-chloro-N-(l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (lOOd) (300 mg, 0.6 mmol), (S)-pyrrolidin-2- ylmethanol (18 mg, 1.81 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup by pouring into water and collecting the solid that separated by filtration followed by drying in vacuum (S)-(l-(6-bromo-4-((l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (lOOe) (35 mg, 10 % yield) as a white solid; !H NMR (300 MHZ, DMSO-d6): δ 11.08 (s, 1H, D20 exchangeable),
[1017] 8.57 (s, 1H), 8.04 (d, J = 15.7 Hz, 2H), 7.01 (s, 2H), 4.42 (s, 1H), 4.20 (s, 1H), 3.94 (s, 1H), 3.88 (s, 6H), 3.81 (s, 1H), 3.68 (s, 3H), 3.44 (d, J = 9.3 Hz, 1H), 2.12 - 1.85 (m, 4H). MS (ES+): 561.3, 564.3 (M+l), (ES-) 595.3 597.4(M+C1).
[1018] Scheme 101
[1019] 101c
[1020] Preparation of (S)-(l-(7-(hydroxymethyl)-4-((l-(3,4,5 rimethoxyphenyl)-lH-imidazol-4- yl)amino)pyrrolo[2,l-f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (101c)
[1021] Step-1 : Preparation of (2,4-dichloropyrrolo[2, l-f][l,2,4]triazin-7-yl)methanol (101a)
[1022] Compound 101a was prepared from 2,4-dichloropyrrolo[l,2-f][l,2,4]triazine-7-carbaldehyde (79a) (100 mg, 0.46 mmol) according to the procedure reported in step-4 of Scheme 70. This gave after workup (2,4-dichloropyrrolo[l,2-f][l,2,4]triazin-7-yl)methanol (101a) (100 mg, 99 % yield) as an oil, which was used in the next reaction without further purification. MS (ES+): 218.1 (M+l).
[1023] Step 2: Preparation of (2-chloro-4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)pyrrolo[2, l-f][l,2,4]triazin-7-yl)methanol (101b)
[1024] Compound 101b was prepared according to the procedure reported in Scheme 1 from (2,4- dichloropyrrolo[2,l-f][l,2,4]triazin-7-yl)methanol (101a) (100 mg, 0.46 mmol) in 2-Propanol (10 mL) using DIPEA (0.24 mL, 1.38 mmol) and l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- amine hydrochloride (57a) (157 mg, 0.55 mmol). This gave (2-chloro-4-(l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-ylamino)pyrrolo[l,2-f][l,2,4]triazin-7-yl)methanol (101b) (85 mg, 43 % yield) as a pale off-white solid; ¾ MR (300 MHz, DMSO-^e) δ 11.24 (s, 1H, D20 exchangeable), 8.20 (d, J= 1.6 Hz, 1H), 7.89 (d, J= 1.6 Hz, 1H), 7.37 (d, J= 4.3 Hz, 1H), 6.93 (s, 2H), 6.69 (d, J = 4.4 Hz, 1H), 5.24 (t, J = 5.6 Hz, 1H, D2O exchangeable), 4.70 (d, J = 5.5 Hz, 2H), 3.87 (s, 6H), 3.69 (s, 3H); MS (ES+): 431.4 (M+l), 453.4 (M+Na); MS (ES-): 429.3 (M-l); HPLC: 98.24%.
[1025] Step 3 : Preparation of (S)-(l-(7-(hydroxymethyl)-4-((l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-yl)amino)pyrrolo[2, l-f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (101c) A slurry of (2-chloro-4-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-ylamino)pyrrolo[l,2- f][l,2,4]triazin-7-yl)methanol (101b) (97 mg, 0.23 mmol), (S)-pyrrolidin-2-ylmethanol (171 mg, 1.69 mmol), di-tert-butyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine (di-t-Bu-XPhos, 14 mg, 0.034 mmol), Pd2(dba)3(14 mg, 0.016 mmol), sodium tert-butoxide (162 mg, 1.69 mmol) in PhMe (5 mL) was degassed and placed in a sealed reactor. The reaction was heated at 100 °C for 48 hr, cooled to room temperature, quenched with saturated aqueous H4CI and extracted with ethyl acetate (3 x 20 mL). The organic layers were combined, washed with water, brine, dried, filtered and concentrated in vacuum to dryness. The residue obtained was purified by flash column chromatography (Silica gel 12 g, eluting with MeOH in DCM from 0 to 40%) to afford (S)-(l-(7-(hydroxymethyl)-4-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- ylamino)pyrrolo[l,2-f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (101c) (12 mg, 11 % yield) as a white solid; ¾ MR (300 MHz, DMSO-^e) δ 10.47 (s, 1H, D20 exchangeable), 8.24 (d, J = 1.5 Hz, 1H), 7.97 (s, 1H), 7.10 (d, J= 4.4 Hz, 1H), 6.96 (s, 2H), 6.37 (d, J = 4.4 Hz, 1H), 4.67 (s, 2H), 4.32 - 4.09 (m, 1H), 3.88 (s, 6H), 3.79 - 3.70 (m, 1H), 3.68 (s, 3H), 3.67 - 3.52 (m, 1H), 3.53 - 3.20 (m, 2H), 2.14 - 1.75 (m, 4H); MS (ES+): 496.5 (M+l), 518.5 (M+Na); MS (ES-): 494.4 (M-l).
[1026] Scheme 102
[1027]
[1028] Preparation of (S)-l-((2-(2-(hydroxymethyl)pyrrolidin-l-yl)-4-((l-(3,4,5-trimethoxyphenyl)- lH-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-6-yl)methyl)piperidin-4-ol (102b)
[1029] Step-1 : Preparation of l-((2-chloro-4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)thieno[2,3-d]pyrimidin-6-yl)methyl)piperidin-4-ol (102a)
[1030] Compound 102a was prepared from 2-chloro-6-(chloromethyl)-N-(l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (97b) (100 mg, 0.21 mmol), DIPEA (0.15 mL, 0.86 mmol) and piperidin-4-ol (43 mg, 0.43 mmol) in THF (3 mL) according to the procedure reported in step-3 of Scheme 97. This gave l-((2-chloro-4-((l- (3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-6- yl)methyl)piperidin-4-ol (102a) (32 mg 28 % yield); MS (ES+): 531.5, 533.5 (M+l), (ES-): 529.4, 531.4 (M-l).
[1031] Step-2: Preparation of (S)-l-((2-(2-(hydroxymethyl)pyrrolidin-l-yl)-4-((l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-6-yl)methyl)piperi ol (102b)
[1032] Compound 102b was prepared from l-((2-chloro-4-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol- 4-ylamino)thieno[2,3-d]pyrimidin-6-yl)methyl)piperidin-4-ol (102a) (0.03 g, 0.06 mmol), (S)- pyrrolidin-2-ylmethanol (0.02 mL, 0.18 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with eluting with acetonitrile and 0.1% HCl water] followed by lyophilization (S)-l-((2-(2-(hydroxymethyl)pyrrolidin-l-yl)-4-((l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-6-yl)methyl)piperidin-4- ol (102b) (13 mg, 36 % yield) HCl salt as a solid; ¾ NMR (300 MHz, OMSO-de): δ 1 1.40 (s, 1H), 10.97 (s, 1H), 8.49 (s, 1H), 8.19 - 7.88 (m, 2H), 7.00 (s, 2H), 4.65 - 4.41 (m, 2H), 4.40 - 3.91 (m, 6H), 3.88 (s, 6H), 3.68 (s, 3H), 3.64 - 2.87 (m, 4H), 2.15 - 1.86 (m, 7H), 1.85 - 1.60 (m, 1H). MS (ES+): 596.6 (M+l); MS (ES-): 630.6 (M+Cl).
[1033] Scheme 103
[1034]
[1035] Preparation of (S)-(l-(4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)amino)furo[3,2- d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (103b)
[1036] Step-1 : Preparation of (2-chloro-furo[3,2-d]pyrimidin-4-yl)-[l-(3,4,5-trimethoxy-phenyl)-lH- imidazol-4-yl]-amine (103a)
[1037] Compound 103a was prepared according to the procedure reported in Scheme 1 from 2,4- dichloro-furo[3,2-d]pyrimidine (la) (1.0 g, 5.29 mmol) in IPA (30 mL) using DIPEA (2.06 mL, 15.87 mmol) and l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-ylamine hydrochloride (57a) (1.81g, 6.34 mmol). This gave after work up (2-chloro-furo[3,2-d]pyrimidin-4-yl)-[l- (3,4,5-trimethoxy-phenyl)-lH-imidazol-4-yl]-amine (103a) (1.0 g, 47 %) as an off-white solid; MS (ES+): 402.0 (M+l); MS (ES-): 400.0 (M+l). Step-2: Preparation of (S)-(l-(4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (103b)
[1038] Compound 103b was prepared according to the procedure reported in step-2 of Scheme 76 from (2-chloro-furo[3,2-d]pyrimidin-4-yl)-[l-(3,4,5-trimethoxy-phenyl)-lH-imidazol-4-yl]- amine (103a) (300 mg, 0.75 mmol) and (S)-pyrrolidin-2-ylmethanol (0.76 g, 7.5 mmol) in NMP (20 mL). This gave after workup and purification by flash chromatography (silica gel, eluting with 0-10% methanol in ethyl acetate) (S)-(l-(4-((l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (103b) (100 mg, 29%) free base as a white solid. The free base was re-purified by reverse phase flash column chromatography [(silica gel C-18 column, 24 g) eluting with acetonitrile and 0.1% HCl water (0-50%)] followed by lyophilization to afford (S)-(l-(4-((l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (103b) (25 mgs) HCl salt as a light yellow solid;1H NMR (300 MHz, DMSO-^e): δ 13.40 (s, 1H), 11.91 (s, 1H), 8.54 (s, 1H), 8.35 (s, 1H), 8.04 (s, 1H), 7.01 (d, J= 10.6 Hz, 3H), 4.44 (s, 1H), 3.87 (d, J= 3.8 Hz, 6H), 3.75 (s, 1H), 3.68 (d, J = 3.7 Hz, 3H), 3.58 - 3.34 (m, 3H), 2.02 (s, 4H). MS (ES+): 467.5 (M+l), 489.5 (M+Na); MS (ES-): 501.5 (M+Cl); HPLC purity: 98.60%.
[1039] Scheme 104
[1040]
[1041] Preparation of (S)-( 1 -(6-((4-methylpiperazin- 1 -yl)methyl)-4-(( 1 -(3 ,4, 5 -trimethoxyphenyl)- lH-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (104b)
[1042] Step-1 : Preparation of 2-chloro-6-((4-methylpiperazin-l-yl)methyl)-N-(l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (104a)
[1043] Compound 104a was prepared from 2-chloro-6-(chloromethyl)-N-(l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (97b) (100 mg, 0.21 mmol), DIPEA (0.15 mL, 0.86 mmol) and 1-methylpiperazine (0.048 mL, 0.43 mmol) in THF (3 mL) according to the procedure reported in step-3 of Scheme 97. This gave 2-chloro-6-((4- methylpiperazin-l-yl)methyl)-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)thieno[2,3- d]pyrimidin-4-amine (104a) (32 mg, 28 % yield); MS (ES+): 530.5, 532.5 (M+l), (ES-): 528.4 (M-l), 564.4, 566.4 (M+Cl). Step-2: Preparation of (S)-(l-(6-((4-methylpiperazin-l-yl)methyl)-4-((l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-yl)amino)thieno[2,3-d]pyri
[1044] yl)methanol (104b)
[1045] Compound 104b was prepared from 2-chloro-6-((4-methylpiperazin-l-yl)methyl)-N-(l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (104a) (0.05 g, 0.09 mmol), (^-pyrrolidin-2-ylmethanol (0.03 mL, 0.26 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with eluting with acetonitrile and 0.1% HCl water] followed by lyophilization (S)-(l-(6-((4-methylpiperazin-l-yl)methyl)-4-((l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2- yl)methanol (104b) (10 mg, 24 % yield) HCl salt as a tan colored solid; ¾ MR (300 MHz, DMSO-i¾): δ 11.14 (s, 1H), 8.43 (s, 1H), 8.07 - 7.85 (m, 2H), 6.98 (d, J= 4.6 Hz, 2H), 4.48 (s, 1H), 4.27 (s, 2H), 3.94 (s, 1H), 3.88 (s, 6H), 3.86 (s, 2H), 3.81 (s, 1H), 3.68 (s, 3H), 3.61 - 3.40 (m, 4H), 3.40 - 3.12 (m, 4H), 2.79 (s, 3H), 2.11 - 1.85 (m, 4H). MS (ES+): 595.6 (M+l).
[1046] Scheme 105
[1047]
[1048] Preparation of (S)-(l-(7-(piperidin-l-ylmethyl)-4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol- 4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (105b)
[1049] Step-1 : Preparation of 2-chloro-7-(piperidin-l-ylmethyl)-N-(l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine (105a)
[1050] To a solution of 2-chloro-4-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-ylamino)pyrrolo[l,2- f][l,2,4]triazine-7-carbaldehyde (79b) (100 mg, 0.23 mmol) in dichloroethane (5 mL) was added piperidine (0.025 mL, 0.26 mmol) and acetic acid (0.03 mL). To this suspension was added NaBH(OAc)3(64 mg, 0.3 mmol) and the reaction was stirred for 8 h. An additional amount of NaBH(OAc)3(64 mg, 0.3) was added and the reaction was allowed to stir for 8 h. The reaction was quenched with 1 N NaOH (2 mL), the organic layer was separated and the aqueous layer was extracted with CH2CI2 (3 x 10 mL). The combined organic layers were dried, filtered and concentrated in vacuum. The crude product was purified by flash column chromatography (Silica gel 12 g, eluting with MeOH in DCM from 0 % to 10%) to afford 2- chloro-7-(piperidin-l-ylmethyl)-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (105a) (43 mg, 37 % yield) as a pale off-white solid; ¾ NMR (300 MHz, Chloroform-i ) δ 10.56 (s, 1H), 7.95 (s, 1H), 7.66 (s, 1H), 7.07 - 6.81 (m, 1H), 6.84 - 6.40 (m, 3H), 4.10 - 3.73 (m, 1 1H), 2.61 - 2.41 (m, 4H), 1.67 - 1.49 (m, 4H), 1.48 - 1.33 (m, 2H); MS (ES+): 498.5 (M+l); MS (ES-): 496.5 (M-l).
[1051] Step 2: Preparation of (S)-(l-(7-(piperidin-l-ylmethyl)-4-((l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (105b)
[1052] Compound 105b was prepared from 2-chloro-7-(piperidin-l-ylmethyl)-N-(l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (105a) (43 mg, 0.09 mmol), (^-pyrrolidin-2-ylmethanol (87 mg, 0.86 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by flash chromatography (Silica gel 4 g, eluting with MeOH in DCM from 0 % to 10%) (S)-(\-(7- (piperidin- 1 -ylmethyl)-4-( 1 -(3 ,4,5-trimethoxyphenyl)- lH-imidazol-4-ylamino)pyrrolo[ 1 ,2- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (105b) (6 mg, 13 % yield) as a white solid; ¾ NMR (300 MHz, Methanol-^) δ 7.98 (d, J= 1.6 Hz, 1H), 7.93 (d, J= 1.6 Hz, 1H), 6.88 - 6.83 (m, 3H), 6.45 (d, J = 4.5 Hz, 1H), 4.33 - 4.16 (m, 1H), 3.91 (s, 6H), 3.87 (s, 2H), 3.88 - 3.78 (m, 1H), 3.79 (s, 3H), 3.75 - 3.50 (m, 2H), 3.40 - 3.25 (m, 1H), 2.64 - 2.45 (m, 4H), 2.14 - 1.86 (m, 4H), 1.72 - 1.53 (m, 4H), 1.49 - 1.36 (m, 2H); MS (ES+): 563.6 (M+l), 585.6 (M+Na). Hydrochloride salt of compound 105b was obtained by purification of crude reaction mixture from step-2 above by reverse phase flash chromatography [(silica gel C-18, 24 g) eluting with acetonitrile and 0.1% HCl in water ] followed by lyophilization as a yellow solid.1H NMR (300 MHz, OMSO-de): δ 10.90 (s, 1H), 10.36 (s, 1H), 8.46 (s, 1H), 8.01 (s, 1H), 7.23 (d, J = 4.6 Hz, 1H), 6.99 (s, 2H), 6.72 (d, J = 4.5 Hz, 1H), 4.49 (s, 2H), 4.29 - 4.14 (m, 1H), 3.88 (s, 6H), 3.84 - 3.26 (m, 9H), 2.86 (d, J = 1 1.4 Hz, 2H), 2.13 - 1.16 (m, 10H). MS (ES+): 563.3 (M+l); MS (ES-): 597.4 (M+Cl). HPLC purity: 95.10 %.
[1053] Scheme 106
[1054]
[1055] 79b 106a 106b Preparation of (S)-( 1 -(7-((4-cy clopropylpiperazin- 1 -yl)methyl)-4-(( 1 -(3 ,4, 5 - trimethoxyphenyl)- lH-imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2- yl)methanol (106b)
[1056] Step-1 : Preparation of 2-chloro-7-((4-cyclopropylpiperazin-l-yl)methyl)-N-(l-(3,4,5- trimethoxyphenyl)- lH-imidazol-4-yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine (106a)
[1057] Compound 106a was prepared according to the procedure reported for reductive amination in step-1 of Scheme 105 from 2-chloro-4-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- ylamino)pyrrolo[l,2-f][l,2,4]triazine-7-carbaldehyde (79b) (100 mg, 0.23 mmol) in dichloroethane (3 mL) using 1-cyclopropylpiperazine (44 mg, 0.35 mmol), acetic acid (0.03 mL) and NaBH(OAc)3(74 mg, 0.35 mmol). This gave after workup and purification by flash column chromatography (Silica gel 12 g, eluting with DMA-80 in DCM from 0 % to 10%) to afford 2-chloro-7-((4-cyclopropylpiperazin-l-yl)methyl)-N-(l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-yl)pyrrolo[2,l-f][l,2,4]triazin-4-amine (106a) (46 mg, 37 % yield) as a solid; ¾ NMR (300 MHz, Chloroform-d) δ 10.64 (s, 1H), 7.95 (s, 1H), 7.65 (s, 1H), 6.91 (d, J = 4.5 Hz, 1H), 6.66 (s, 2H), 6.61 (d, J = 4.5 Hz, 1H), 4.18 - 3.61 (m, 11H), 3.36 - 2.11 (m, 8H), 1.68 - 1.47 (m, 1H), 0.62 - 0.15 (m, 4H); MS (ES+): 539.5 (M+l), 561.5 (M+Na); MS (ES-): 537.5 (M-l).
[1058] Step 2: Preparation of (S)-(l-(7-((4-cyclopropylpiperazin-l-yl)methyl)-4-((l-(3,4,5- trimethoxyphenyl)- lH-imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2- yl)methanol (106b)
[1059] Compound 106b was prepared from 2-chloro-7-((4-cyclopropylpiperazin-l-yl)methyl)-N-(l- (3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)pyrrolo[2,l-f][l,2,4]triazin-4-amine (106a) (46 mg, 0.09 mmol), (^-pyrrolidin-2-ylmethanol (86 mg, 0.85 mmol) in MP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g) eluting with 0.1 % TFA of acetonitrile and 0.1% TFA water] followed by lyophilization (S)-(l-(7-((4-cyclopropylpiperazin-l-yl)methyl)- 4-(( 1 -(3 ,4,5-trimethoxyphenyl)- lH-imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2- yl)pyrrolidin-2-yl)methanol (106b) (14 mg, 27 % yield) as a solid; ¾ NMR (300 MHz, DMSO-de) δ 10.47 (s, 1H, D20 exchangeable), 8.24 (d, J = 1.5 Hz, 1H), 7.97 (d, J = 1.6 Hz, 1H), 7.13 (d, J = 4.4 Hz, 1H), 6.95 (s, 2H), 6.33 (d, J = 4.5 Hz, 1H), 4.89 - 4.79 (m, 1H, D2O exchangeable), 4.26 - 4.08 (m, 1H), 3.87 (s, 6H), 3.85 - 3.66 (m, 3H), 3.68 (s, 3H), 3.64 - 3.54 (m, 1H), 3.52 - 3.38 (m, 2H), 2.67 - 2.25 (m, 8H), 2.11 - 1.81 (m, 4H), 1.65 - 1.49 (m, 1H), 0.37 (s, 2H), 0.28 - 0.18 (m, 2H); MS (ES+): 604.7 (M+l), 626.6 (M+Na); Hydrochloride salt of compound 106b was obtained by purification of crude reaction mixture from step-2 above by reverse phase flash chromatography [(silica gel C-18, 24 g) eluting with acetonitrile and 0.1% HCl water ] followed by lyophilization as a yellow solid. ¾ NMR (300 MHz, DMSO- d6): δ 10.49 (s, 1H), 8.23 (s, 1H), 7.97 (s, 1H), 7.13 (d, J = 4.4 Hz, 1H), 6.95 (s, 2H), 6.34 (d, J = 4.2 Hz, 1H), 4.83 (s, 1H), 4.19 (s, 1H), 3.87 (s, 6H), 3.79 (s, 2H), 3.68 (s, 3H), 3.58 (s, 1H), 3.52 - 3.42 (m, 2H), 3.42 - 3.20 (m, 9H), 2.11 - 1.71 (m, 4H), 1.67 - 1.40 (m, 1H), 0.44 - 0.13 (m, 4H). MS (ES-): 602.6 (M-l). HPLC purity: 93.61%.
[1060] Scheme 107
[1061]
[1062] Preparation of (S)-(l-(7-(l,2,3,6-tetrahydropyridin-4-yl)-4-(l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-ylamino)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (107a)
[1063] To a solution of (S)-tert-butyl 4-(2-(2-(hydroxymethyl)pyrrolidin-l-yl)-4-(l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-ylamino)pyrrolo[l,2-f][l,2,4]triazin-7-yl)-5,6- dihydropyridine-l(2H)-carboxylate (98a) (0.06 g, 0.05 mmol) in DCM (5 mL) was added 2,2,2-trifluoroacetic acid (0.04 mL, 0.54 mmol) and stirred at room temperature overnight. The reaction mixture was diluted with EtOAc (50 mL), washed with water (3x), brine, dried, filtered and concentrated in vacuum. The residue was purified by reverse phase flash column chromatography [(silica gel C-18, 24 g) eluting with acetonitrile and 0.1% HCl water] and lyophilized to afford (S)-(l-(7-(l,2,3,6-tetrahydropyridin-4-yl)-4-(l-(3,4,5- trimethoxyphenyl)- lH-imidazol-4-ylamino)pyrrolo[ 1 ,2-f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2- yl)methanol (107a) (8 mg, 27 % yield) as a HCl salt; ¾ NMR (300 MHz, DMSO-i¾) δ 10.68 (s, 1H), 9.16 (s, 2H), 8.37 (s, 1H), 8.01 (s, 1H), 7.29 (s, 1H), 7.22 (d, J= 4.6 Hz, 1H), 6.98 (s, 2H), 6.58 (d, J = 4.7 Hz, 1H), 4.20 (s, 1H), 4.00 - 3.25 (m, 17H), 2.83 - 2.68 (m, 2H), 2.11 - 1.83 (m, 4H); MS (ES+): 547.6. HPLC purity: 96.94 %.
[1064] Scheme 108
[1065]
[1066] Preparation of (S)-( 1 -(6-((4-(pyridin-2-yl)piperazin- 1 -yl)methyl)-4-(( 1 -(3 ,4, 5 - trimethoxyphenyl)-lH-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2- yl)methanol (108b)
[1067] Step-1 : Preparation of 2-chloro-6-((4-(pyridin-2-yl)piperazin-l-yl)methyl)-N-(l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (108a)
[1068] Compound 108a was prepared from 2-chloro-6-(chloromethyl)-N-(l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (97b) (100 mg, 0.21 mmol), DIPEA (0.15 mL, 0.86 mmol) and l-(pyridin-2-yl)piperazine (0.065 mL, 0.43 mmol) in THF (3 mL) according to the procedure reported in step-3 of Scheme 97. This gave 2- chloro-6-((4-(pyridin-2-yl)piperazin-l-yl)methyl)-N-(l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (108a) (60 mgs, 47%) as a solid. MS (ES+): 593.5 (M+l), (ES-): 591.4 (M-l), 627.5, 629.5 (M+Cl).
[1069] Step-2: Preparation of (S)-(l-(6-((4-(pyridin-2-yl)piperazin-l-yl)methyl)-4-((l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2- yl)methanol (108b)
[1070] Compound 108b was prepared from 2-chloro-6-((4-(pyridin-2-yl)piperazin-l-yl)methyl)-N- (l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (108a) (0.06 g, 0.1 mmol), (^-pyrrolidin-2-ylmethanol (0.03 mL, 0.3 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. This gave after workup and purification by reverse phase flash chromatography [(silica gel 18, 24 g), eluting with eluting with acetonitrile and 0.1% HCl water] followed by lyophilization (S)-(l-(6-((4-(pyridin-2-yl)piperazin-l-yl)methyl)-4-((l- (3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2- yl)methanol (108b) (10 mg, 15 % yield) HC1 salt as a white solid; ¾NMR (300 MHz, DMSO- <k) b 12.16 (s, 1H), 11.60 (s, 1H), 8.58 (s, 1H), 8.19 - 7.93 (m, 5H), 7.37 (d, J = 8.9 Hz, 1H), 7.00 (d, J = 8.5 Hz, 2H), 4.74 - 4.30 (m, 4H), 3.88 (s, 6H), 3.81 - 3.19 (m, 13H), 2.16 - 1.89 (m, 4H); . MS (ES+): 658.5; MS (ES-): 692.5 (M+Cl). HPLC purity: 97.78%.
[1071] Scheme 109
[1072]
[1073] Preparation of 3-(6-(hydroxymethyl)-4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)thieno[2,3-d]pyrimidin-2-yl)benzaldehyde (109a)
[1074] Compound 109a was prepared from (2-chloro-4-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- ylamino)thieno[2,3-d]pyrimidin-6-yl)methanol (97a) (0.2 g, 0.44 mmol), using 3- formylphenylboronic acid (0.1 g, 0.67 mmol), PdCl2(dppf) (65 mg, 0.09 mmol), potassium carbonate (185 mg, 1.34 mmol) in 1,4-Dioxane (10 mL) and Water (1 mL) according to the procedure reported in step-3 of Scheme 77. This gave after workup, purification by flash column chromatography [(silica gel, 12 g) eluting with DMA 80 in dichloromethane] 3-(6- (hydroxymethyl)-4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)amino)thieno[2,3- d]pyrimidin-2-yl)benzaldehyde (109a) (134 mg, 58 % yield) as a yellow solid; ¾ MR (300 MHz, DMSO-i¾) δ 10.63 (s, 1H, D20 exchangeable), 10.14 (s, 1H), 8.95 (d, J= 1.9 Hz, 1H), 8.76 (d, J= 7.8 Hz, 1H), 8.28 (d, J= 1.6 Hz, 1H), 8.18 (d, J= 1.6 Hz, 1H), 8.03 (d, J= 7.6 Hz, 1H), 7.94 (s, 1H), 7.73 (t, J= 7.7 Hz, 1H), 7.03 (s, 2H), 5.84 (s, 1H, D2O exchangeable), 4.76 (s, 2H), 3.90 (s, 6H), 3.71 (s, 3H); MS (ES+): 518.5 (M+l), 540.3 (M+Na), (ES-): 516.5 (M- 1).
[1075] Scheme 110
[1076] Preparation of 3-(4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)amino)pyrrolo[2, 1- f] [ 1 ,2,4]triazin-2-yl)benzaldehyde (110a)
[1077] Compound 110a was prepared from 2-chloro-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (57b) (0.2 g, 0.5 mmol), using 3-formylphenylboronic acid (1 12 mg, 0.75 mmol), PdCl2(dppf) (73 mg, 0.1 mmol), potassium carbonate (207 mg,
[1078] 1.5 mmol) in 1,4-Dioxane (10 mL) and Water (1 mL) according to the procedure reported in step-3 of Scheme 77. This gave after workup, purification by flash column chromatography [(silica gel, 12 g) eluting with DMA 80 in dichloromethane] 3-(4-((l-(3,4,5- trimethoxyphenyl)- lH-imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)benzaldehyde (110a) (45 mg, 19 % yield) as a white solid; ¾ NMR (300 MHz, DMSO-^e) δ 11.02 (s, 1H, D20 exchangeable), 10.13 (s, 1H), 8.82 (t, J= 1.7 Hz, 1H), 8.64 (dt, J= 7.8, 1.5 Hz, 1H), 8.30 (d, J= 1.6 Hz, 1H), 8.18 (d, J= 1.7 Hz, 1H), 8.04 (dt, J= 7.7, 1.4 Hz, 1H), 7.88 (dd, J = 2.6, 1.6 Hz, 1H), 7.73 (t, J= 7.7 Hz, 1H), 7.51 - 7.25 (m, 1H), 7.03 (s, 2H), 6.77 (dd, J= 4.4,
[1079] 2.6 Hz, 1H), 3.90 (s, 6H), 3.71 (s, 3H); MS (ES+): 471.4 (M+l), (ES-): 469.4 (M-l).
[1080] Scheme 111
[1081]
[1082] 1 1 1 b
[1083] Preparation of (S)-(l-(7-(morpholinomethyl)-4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (111b)
[1084] Step-1 : Preparation of 2-chloro-7-(morpholinomethyl)-N-(l-(3,4,5-trimethoxyphenyl)-lH- imidazol-4-yl)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-4-amine (111a) Compound 111a was prepared according to the procedure reported for reductive amination in step-1 of Scheme 105 from 2-chloro-4-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4- ylamino)pyrrolo[l,2-f][l,2,4]triazine-7-carbaldehyde (79b) (200 mg, 0.47 mmol) in dichloroethane (3 mL) using 1- morpholine (0.045 mL, 0.51 mmol), acetic acid (0.05 mL) and NaBH(OAc)3(129 mg, 0.61 mmol). This gave after workup and purification by flash column chromatography (Silica gel 12 g, eluting with MeOH in DCM from 0 % to 10%) 2- chloro-7-(morpholinomethyl)-N-(l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)pyrrolo[l,2- f][l,2,4]triazin-4-amine (111a) (131 mg, 56 % yield) as a little pink solid;1H MR (300 MHz, DMSO-i¾) δ 11.24 (s, 1H, D20 exchangeable), 8.20 (d, J= 1.6 Hz, 1H), 7.88 (d, J = 1.6 Hz, 1H), 7.40 (d, J= 4.4 Hz, 1H), 6.93 (s, 2H), 6.67 (d, J= 4.5 Hz, 1H), 3.87 (s, 6H), 3.78 (s, 2H), 3.69 (s, 3H), 3.56 (t, J= 4.6 Hz, 4H), 2.47 - 2.37 (m, 4H); MS (ES+): 500.4 (M+l), 522.4 (M+Na); HPLC purity: 95.21%.
[1085] Step 2: Preparation of (S)-(l-(7-(morpholinomethyl)-4-((l -(3,4,5 -trimethoxyphenyl)- 1H- imidazol-4-yl)amino)pyrrolo[2, 1 -f] [ 1 ,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (111b)
[1086] Compound 111b was prepared from 2-chloro-7-(morpholinomethyl)-N-(l-(3,4,5- trimethoxyphenyl)-lH-imidazol-4-yl)pyrrolo[2, l-f][l,2,4]triazin-4-amine (111a) (106 mg, 0.21 mmol), (,S)-pyrrolidin-2-ylmethanol (161 mg, 1.59 mmol), di-tert-butyl(2',4',6'- triisopropylbiphenyl-2-yl)phosphine (di-t-Bu-XPhos) (14 mg, 0.032 mmol), Pd2(dba)3(14 mg, 0.015 mmol) and sodium tert-butoxide (153 mg, 1.59 mmol) in toluene (5 mL) according to the procedure reported in step-3 on Scheme 101. This gave after workup and purification by flash chromatography (Silica gel 24 g, eluting with MeOH in DCM from 0 % to 10%) (S)-(l- (7-(mo holinomethyl)-4-((l-(3,4,5-trimethoxyphenyl)-lH-imidazol-4-yl)amino)pyrrolo[2, l- f][l,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (111b) (75 mg, 63 % yield) as a solid; ¾ NMR (300 MHz, DMSO-i¾) δ 10.48 (s, 1H, D2O exchangeable), 8.24 (s, 1H), 7.98 (s, 1H), 7.14 (d, J = 4.4 Hz, 1H), 6.95 (s, 2H), 6.35 (d, J = 4.4 ...
Claims
CLAIMSWhat is claimed is:
1. A compound represented by formula (I) or formula (II):or a pharmaceutically acceptable salt thereof; wherein:A is a fused optionally substituted aromatic ring, heteroaromatic ring, partially unsaturated cycloalkyl ring, or partially unsaturated heterocycloalkyl ring;W is C or N;Rarepresents H or alkyl;R1represents heteroarylene;Rlarepresents H or optionally substituted -C(0)alkyl, -C(0)aryl, -C(0)heteroaryl, -C(0)0(alkyl), -C(0)(heterocyclyl), -C(0) R¾y, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;J represents H, halo, -OR2, - R2R3, -C(0) R2R3, -C(0)0(alkyl), -C(0)OH, aryl, orheteroaryl, wherein aryl or heteroaryl is optionally substituted by one or more occurrences of R2a;R2represents optionally substituted alkyl, aralkyl, heteroaralkyl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, or hydroxyalkyl;R3represents H or alkyl; orR2and R3, taken together, form a heterocycloalkyl ring, optionally substituted by one or more occurrences of R2a;R2a, independently for each occurrence, represents halo, hydroxyl, -C(0)H, oxo, - H2, - C(0) H2, -C(0)OH, -C(0)R5, -C(0)OR5, -C(0) H(R5), or optionally substituted alkyl, alkoxyl, hydroxyalkyl, heteroaryl, aryl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, or -N(alkyl)2; or any two germinal or vicinal occurrences of R2a, taken together, may form a spiro or fused cycloalkyl ring;R5, independently for each occurrence, represents optionally substituted alkyl, aralkyl, aryl, heteroaralkyl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, or(heterocycloalkyl)alkyl; andRxand Ryeach independently represent H, alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, orhydroxyalkyl.The compound of claim 1, wherein the compound is represented by formula (la) or formula (Ha):wherein: valence permitting, Q, T, U, and V each independently represent CH, CH2, N, H, O, or S02, wherein any hydrogen of a CH, CH2, or NH group is optionally replaced by an occurrence of R4;R4, independently for each occurrence, represents halo, cyano, or optionally substituted alkyl, alkenyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkenyl, (heterocycloalkyl)alkyl, cycloalkyl, (cycloalkyl)alkyl, halocycloalkyl, hydroxycycloalkyl, aminocycloalkyl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, -CH2C(0) H2, -C(0)R5, - C(0)OR5, or -S(0)2R5; m is an integer from 0-4, as permitted by valence.
3. The compound of claim 2, wherein the compound is represented by formula (lb) or (lib):Ra(lib); wherein Q represents CH or N; and V represents CH or N.The compound of claim 2, wherein the compound is represented by formula (Ic) or (lie):
5. The compound of claim 2, wherein the compound is represented by formula (Id) or (lid):wherein T represents CH2, NH, O, or SO2; and U represents CH2, NH, O, or SO2.The compound of claim 2, wherein the compound is represented by formula (Ie) or (He):The compound of claim 3, wherein Q is N; and V is CH.
8. The compound of claim 3, wherein Q is CH; and V is N.The compound of claim 5, wherein T is NH; and U is CH2.
10. The compound of claim 5, wherein T is CH2; and U is NH.
11. The compound of any one of claims 2-10, wherein m is 0 or 1.
12. The compound of claim 1, wherein the compound is represented by formula (Ij) or formula (Ilj):wherein: W is C or N; valence permitting, X, Y, and Z each independently represent CH, CH2, CO, N, NH, O, S, or SO2, wherein any hydrogen of a CH, CH2, or NH group is optionally replaced by an occurrence of R4;R4, independently for each occurrence, represents cyano, halo, or optionally substituted alkyl, alkenyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkenyl, (heterocycloalkyl)alkyl, cycloalkyl, (cycloalkyl)alkyl, halocycloalkyl, hydroxycycloalkyl, aminocycloalkyl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, -CH2C(0)NH2, -C(0)R5, - C(0)OR5, or -S(0)2R5; n is an integer from 0-4, as permitted by valence.
13. The compound of claim 12, wherein the compound is represented by formula (Ik) or (Ilk):(Ik)wherein X, Y, and Z each independently represent CH, N, NH, O, S, or SO2.
14. The compound of claim 13, wherein the compound is represented by formula (Ik') or (Ilk'):
15. The compound of claim 13, wherein the compound is represented by formula (Ik") or (Ilk"):wherein at least one of X and Z is selected from the group consisting of O, N, NH, and S.
16. The compound of claim 15, wherein one of X and Z is selected from the group consisting of O, H, and S; and the other of X and Z is CH.
17. The compound of claim 15 or 16, wherein X is selected from the group consisting of O, NH, and S.
18. The compound of claim 15 or 16, wherein Z is selected from the group consisting of O, NH, and S.
19. The compound of claim 15, wherein each of X and Z are selected from the group consisting of O, N, NH, and S.
20. The compound of claim 19, wherein one of X and Z is N and the other of X and Z is NH.
21. The compound of claim 13, wherein the compound is represented by formula (In) or (Iln):wherein each of Y and Z are selected from the group consisting of O, N, NH, and S.
22. The compound of claim 21, wherein Y is N and Z is NH.
23. The compound of claim 12, wherein the compound is represented by formula (Im) or (Urn):wherein X, Y, and Z each independently represent CH2, CO, H, O, S, or SO2.
24. The compound of claim 23, wherein each of X, Y, and Z is CH2.
25. The compound of claim 23, wherein one of X, Y, and Z is N or O.
26. The compound of any one of claims 12-25, wherein n is 0 or 1.
27. The compound of any one of claims 1-26, wherein R4, if present, is selected from the group consisting of optionally substituted alkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, and (heterocycloalkyl)alkyl.
28. The compound of any one of claims 1-27, wherein Rais H.
29. The compound of any one of claims 1-28, wherein R1is a nitrogen-containingheteroarylene.
30. The compound of any one of claims 1-29, wherein R1is a 5-membered nitrogen- containing heteroarylene.
31. The compound of any one of claims 1-30, wherein R1is imidazolene.Γ N— R32. The compound of any one of claims 1-31, wherein -Rx-Rlarepresents33. The compound of any one of claims 1-32, wherein Rlais H.
34. The compound of any one of claims 1-32, wherein Rlais optionally substitutedphenyl.
35. The compound of any one of claims 1-32, wherein Rais phenyl, substituted by one or more occurrences of halo, hydroxyl, cyano, -C(0) H2, hydroxyalkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, -C(0)alkyl, -C(0)0-alkyl, heterocycloalkyl, - C(0) H(alkyl), -C(0)N(alkyl)2, -C(0)heterocycloalkyl, -C(0)(prolinol), - C(0) H((cycloalkyl)alkyl), or -C(0) H(cycloalkyl).
36. The compound of any one of claims 1-32, wherein Rlais phenyl, substituted by two or more occurrences of alkoxy.
37. The compound of claim 36, wherein Rlais 3,4,5-trimethoxyphenyl.
38. The compound of any one of claims 1-32, wherein Rlais substituted phenyl, wherein two adjacent substituents on the phenyl, taken together with the intervening atoms, form an optionally substituted cycloalkyl or heterocycloalkyl ring.
39. The compound of any one of claims 1-32, wherein Rlais optionally substitutedheteroaryl, such as quinoline.
40. The compound of any one of claims 1-39, wherein J is aryl, optionally substituted by one or more occurrences of R2a.
41. The compound of any one of claims 1-39, wherein J is -NR2R3.
42. The compound of claim 41, wherein R2and R3, taken together, form aheterocycloalkyl ring, optionally substituted by one or more occurrences of R2a.
43. The compound of claim 42, wherein R2and R3, taken together, form a pyrrolidine ring, optionally substituted by one or more occurrences of R2a.
44. The compound of any one of claims 40-43, wherein R2a, independently for eachoccurrence, represents -C(0) H2, -C(0)R5, hydroxyalkyl, heteroaryl, or aryl.
45. The compound of any one of claims 40-44, wherein R2ais -C(0) H2.
46. The compound of any one of claims 40-44, wherein R2ais hydroxyalkyl.
47. The compound of claim 1, selected from the following table:-684--687--688 -The compound of claim 1, selected from the following table:The compound of claim 1, selected from the following table:
1. The compound of claim 1, selected from the following table:The compound of claim 1, selected from the following table:The compound of claim 1, selected from the following table:The compound of claim 1, selected from the following table:The compound of claim 1, selected from the following table:-718--719-The compound of claim 1, selected from the following table:-732-58. A compound represented by formula (III) or formula (IV):or a pharmaceutically acceptable salt thereof; wherein:A is a fused optionally substituted aromatic ring, heteroaromatic ring, partially unsaturated cycloalkyl ring, or partially unsaturated heterocycloalkyl ring;W is C or N;B is CH or N;D is CH or N; provided that when B is CH, then D is N; or when D is CH, then B is N; Rarepresents H or alkyl; R1represents heteroarylene;Rlarepresents H or optionally substituted— C(0)alkyl, -C(0)aryl, -C(0)heteroaryl, -C(0)0(alkyl), -C(0)(heterocyclyl), -C(0) RxRy, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;J represents H, halo, -OR2, - R2R3, -C(0) R2R3, -C(0)0(alkyl), -C(0)OH, aryl, orheteroaryl, wherein aryl or heteroaryl is optionally substituted by one or more occurrences of R2a;R2represents optionally substituted alkyl, aralkyl, heteroaralkyl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, or hydroxyalkyl;R3represents H or alkyl; orR2and R3, taken together, form a heterocycloalkyl ring, optionally substituted by one or more occurrences of R2a;R2a, independently for each occurrence, represents halo, hydroxyl, -C(0)H, oxo, - H2, - C(0) H2, -C(0)OH, -C(0)R5, -C(0)OR5, -C(0) H(R5), or optionally substituted alkyl, alkoxyl, hydroxyalkyl, heteroaryl, aryl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, or -N(alkyl)2; or any two germinal or vicinal occurrences of R2a, taken together, may form a spiro or fused cycloalkyl ring;R5, independently for each occurrence, represents optionally substituted alkyl, aralkyl, aryl, heteroaralkyl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, or(heterocycloalkyl)alkyl; andRxand Ryeach independently represent H, alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, orhydroxyalkyl.
59. The compound of claim 58, wherein the compound is represented by formula (Ilia) or formula (IVa):wherein: valence permitting, Q, T, U, and V each independently represent CH, CH2, N, H, O, or S02, wherein any hydrogen of a CH, CH2, or NH group is optionally replaced by an occurrence of R4;R4, independently for each occurrence, represents halo, cyano, or optionally substituted alkyl, alkenyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkenyl, (heterocycloalkyl)alkyl,cycloalkyl, (cycloalkyl)alkyl, halocycloalkyl, hydroxycycloalkyl, aminocycloalkyl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, -CH2C(0) H2, -C(0)R5, - C(0)OR5, or -S(0)2R5; m is an integer from 0-4, as permitted by valence.The compound of claim 59, wherein the compound is represented by formula (Illb) (IVb):(IVb); wherein Q represents CH or N; and V represents CH or N.
61. The compound of claim 59, wherein the compound is represented by formula (IIIc) or (IVc):(IVc).
62. The compound of claim 59, wherein the compound is represented by formula (Hid) or (IVd):wherein T represents CH2, NH, O, or SO2; and U represents CH2, NH, O, or SO2.
63. The compound of claim 59, wherein the compound is represented by formula (Hie) or (IVe):).
64. The compound of claim 60, wherein Q is N; and V is CH.
65. The compound of claim 60, wherein Q is CH; and V is N.
66. The compound of claim 62, wherein T is NH; and U is CH2.
67. The compound of claim 62, wherein T is CH2; and U is NH.
68. The compound of any one of claims 59-67, wherein m is 0 or 1.The compound of claim 58, wherein the compound is represented by formula (Illj) formula (IVj):wherein: W is C or N; valence permitting, X, Y, and Z each independently represent CH, CH2, CO, N, NH, O, S, or SO2, wherein any hydrogen of a CH, CH2, or NH group is optionally replaced by an occurrence of R4;R4, independently for each occurrence, represents halo, cyano, or optionally substituted alkyl, alkenyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkenyl, (heterocycloalkyl)alkyl, cycloalkyl, (cycloalkyl)alkyl, halocycloalkyl, hydroxycycloalkyl, aminocycloalkyl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, -CH2C(0)NH2, -C(0)R5, - C(0)OR5, or -S(0)2R5; n is an integer from 0-4, as permitted by valence.
70. The compound of claim 69, wherein the compound is represented by formula (Illk) or (IVk):wherein X, Y, and Z each independently represent CH, N, NH, O, S, or SO2.
71. The compound of claim 70, wherein the compound is represented by formula (Illk') or (IVk'):
72. The compound of claim 70, wherein the compound is represented by formula (Illk") or (IVk"):wherein at least one of X and Z is selected from the group consisting of O, N, NH, and S.
73. The compound of claim 72, wherein one of X and Z is selected from the group consisting of O, H, and S; and the other of X and Z is CH.
74. The compound of claim 72 or 73, wherein X is selected from the group consisting of O, NH, and S.
75. The compound of claim 72 or 73, wherein Z is selected from the group consisting of O, NH, and S.
76. The compound of claim 72, wherein each of X and Z are selected from the group consisting of O, N, NH, and S.
77. The compound of claim 76, wherein one of X and Z is N and the other of X and Z is NH.
78. The compound of claim 70, wherein the compound is represented by formula (Illn) or (IVn):wherein each of Y and Z are selected from the group consisting of O, N, NH, and S.
79. The compound of claim 78, wherein Y is N and Z is NH.
80. The compound of claim 69, wherein the compound is represented by formula (Illm) or (IVm):wherein X, Y, and Z each independently represent CH2, CO, H, O, S, or SO2.
81. The compound of claim 80, wherein each of X, Y, and Z is CH2.
82. The compound of claim 80, wherein one of X, Y, and Z is N or O.
83. The compound of any one of claims 69-82, wherein n is 0 or 1.
84. The compound of any one of claims 58-83, wherein R4, if present, is selected from the group consisting of optionally substituted alkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, and (heterocycloalkyl)alkyl.
85. The compound of any one of claims 58-84, wherein Rais H.
86. The compound of any one of claims 58-85, wherein R1is a nitrogen-containingheteroarylene.
87. The compound of any one of claims 58-86, wherein R1is a 5-membered nitrogen- containing heteroarylene.
88. The compound of any one of claims 58-87, wherein R1is imidazolene.I N-R1 a89. The compound of any one of claims 58-88, wherein -R^R13represents90. The compound of any one of claims 58-89, wherein Rlais H.
91. The compound of any one of claims 58-89, wherein Rlais optionally substitutedphenyl.
92. The compound of any one of claims 58-89, wherein Rlais phenyl, substituted by one or more occurrences of halo, hydroxyl, cyano, -C(0) H2, hydroxylalkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, -C(0)alkyl, -C(0)0-alkyl, heterocycloalkyl, - C(0) H(alkyl), -C(0)N(alkyl)2, -C(0)heterocycloalkyl, -C(0)(prolinol), - C(0) H((cycloalkyl)alkyl), or -C(0) H(cycloalkyl).
93. The compound of any one of claims 58-89, wherein Rlais phenyl, substituted by two or more occurrences of alkoxy.
94. The compound of claim 93, wherein Rlais 3,4,5-trimethoxyphenyl.
95. The compound of any one of claims 58-89, wherein Rlais substituted phenyl, wherein two adjacent substituents on the phenyl, taken together with the intervening atoms, form an optionally substituted cycloalkyl or heterocycloalkyl ring.
96. The compound of any one of claims 58-89, wherein Rlais optionally substituted heteroaryl, such as quinoline.
97. The compound of any one of claims 58-96, wherein J is aryl, optionally substituted by one or more occurrences of R2a.
98. The compound of any one of claims 58-96, wherein J is -NR2R3.
99. The compound of claim 98, wherein R2and R3, taken together, form aheterocycloalkyl ring, optionally substituted by one or more occurrences of R2a.
100. The compound of claim 99, wherein R2and R3, taken together, form a pyrrolidine ring, optionally substituted by one or more occurrences of R2a.
101. The compound of any one of claims 97-100, wherein R2a, independently for each occurrence, represents -C(0) H2, -C(0)R5, hydroxyalkyl, heteroaryl, or aryl.
102. The compound of any one of claims 97-101, wherein R2ais -C(0) H2.
103. The compound of any one of claims 97-101, wherein R2ais hydroxyalkyl.
104. The compound of claim 58, selected from the following table:A compound, or a pharmaceutically acceptable salt thereof, selected from the following table:
106. A pharmaceutical composition, comprising a compound of any one of claims 1-105, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
107. A method of inhibiting ALK2 kinase, comprising administering to a subject in need thereof an effective amount of a compound of any one of claims 1-105, or a pharmaceutically acceptable salt thereof.
108. A method of treating fibrodysplasia ossificans progressiva, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-105, or a pharmaceutically acceptable salt thereof.
109. A method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-105, or a pharmaceutically acceptable salt thereof.
110. The method of claim 109, wherein the cancer is a glioma.
111. The method of claim 110, wherein the glioma is diffuse intrinsic pontine glioma.
